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1  
Abstract 
 
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of metabolic syndrome in 
the liver. It is the most common chronic liver disease with fast-growing prevalence 
worldwide that parallels the obesity epidemic and type 2 diabetes (T2D). NAFLD 
ranges from simple hepatosteatosis to non-alcoholic steatohepatitis (NASH) and may 
finally leads to liver cirrhosis and failure. NASH is the critical stage in the progression 
from reversible and asymptomatic hepatosteatosis towards irreversible liver disease 
with significantly worsen prognosis. However, there is no effective drug for treatment 
of NASH.  
 
Matrine (Mtr) is a small molecule (MW: 248) originally isolated from plants and it has 
been used as a hepatoprotective drug in humans with few reported adverse effects. 
Several lines of evidence suggest that Mtr may be repurposed for the treatment of 
NASH, including a previous study of this laboratory showing its ability to reduce 
hepatosteatosis in high fat diet (HFD)-fed mice. However, a single HFD rodent model 
only replicates simple hepatosteatosis due to increased exogenous lipid overload. 
Therefore, the overall aim of this thesis was to characterise the therapeutic properties of 
Mtr for NASH treatment and investigate the underlying mechanism/s. The hypothesis 
addressed in this study was that Mtr has therapeutic properties for the treatment of 
NASH by ameliorating hepatic steatosis and inflammation as well as associated 
metabolic risk factors. These therapeutic effects were examined in three mouse models 
mimicking different characteristics of NASH.  
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The first aim was to examine the therapeutic effects of Mtr on hepatosteatosis and 
glucose intolerance induced by an over consumption of carbohydrates. This was 
assessed in high fructose (HFru) fed mice, a well-characterised model of 
hepatosteatosis causing an increased in hepatic de novo lipogenesis (DNL) pathway. 
This study (Chapter 3) showed that treatment with Mtr markedly ameliorates 
hepatosteatosis (reduced triglyceride content) and glucose intolerance in HFru-fed 
mice. Further studies revealed that the reduced hepatosteatosis by Mtr is due to its 
inhibition of hepatic DNL involving the blocking of the endoplasmic reticulum (ER) 
stress pathway. These effects are associated with an upregulation of heat shock protein 
72 (HSP72), the chaperone protein which is known to be protective against metabolic 
diseases and inflammation.  A separate aim was to evaluate the potential efficacy of 
Mtr in the treatment for hyperglycaemia as hepatosteatosis is an important contributor 
to hepatic insulin resistance leading to hyperglycaemia. In this study, the antisteatotic 
effects of Mtr on hyperglycaemia were investigated in a mouse model where type 2 
diabetes is induced by HFD in combination with low doses of streptozotocin (HFD-
STZ). The results showed that oral administration of Mtr to HFD-STZ mice reverses 
hyperglycaemia and hepatosteatosis. These findings support the use of Mtr to treat 
hepatosteatosis and associated disorders in glucose homeostasis. 
 
The second aim of this thesis (Chapter 4) was to examine the therapeutic efficacy of 
Mtr for hepatic inflammation and fibrosis. This was investigated in mice fed a 
methionine choline-deficient (MCD) diet, a well-established mouse model which shares 
pathologic features of severe NASH in humans, in particular hepatic inflammation and 
fibrosis. The study showed that Mtr treatment suppresses the increases in TNFα, CD68, 
MCP-1, NLRP3, and hepatic fibrosis markers (TGFβ and Smad3) induced by MCD 
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diet.  Along with these effects, Mtr inhibits mTOR activation and upregulates HSP72 
expression, suggesting a likely role of mTOR-HSP72 pathway in coordinating the 
therapeutic effects of Mtr for NASH.     
 
The final aim further investigated cellular mechanisms underlying the effects of Mtr on 
the inflammatory pathway. This was conducted using cultured J774A cells, a 
macrophage cell line rused here as a model for Kupffer cells believed to be a major 
source of inflammatory cytokines in the liver. Incubation of J774A cells with LPS 
stimulated the production of TNFα and increased NLRP3, CD68 and TGFβ expression. 
Treatment with Mtr also upregulated HSP72, inhibiting inflammation and fibrosis 
induced by LPS (Chapter 5). Additionally, Mtr suppressed the level of mTOR. These 
results provide further evidence that Mtr may exert its effect against NASH through the 
mTOR-HSP72 pathway. 
 
In summary, this thesis employed three different animal models to characterise a wide 
range of therapeutic effects of Mtr on NASH. Findings from these studies led to the 
following conclusions. Firstly, Mtr is a promising therapy for hepatosteatosis and 
associated glucose disorders. Secondly, Mtr can attenuate NASH-associated 
inflammation and fibrosis. Finally, mTOR-HSP72 may play an important role in 
mediating the therapeutic effects of Mtr on NASH. Overall, these findings provide 
strong pre-clinical evidence to support the repurposing of Mtr as a promising new drug 
for the treatment of NAFLD, particularly on the progression towards NASH. 
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1.1 Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of lipid in the liver that 
is not due to alcoholic consumption or viral liver infection. Development of NAFLD is 
generally associated with metabolic disease, and is identified as a hepatic manifestation 
of the metabolic syndrome. Globally, NAFLD is the most common chronic liver 
disease. NAFLD includes simple steatosis, non-alcoholic steatohepatitis (NASH), 
NASH-related cirrhosis and end-stage liver disease. NASH is considered a critical stage 
in the transition of simple steatosis to life-threatening cirrhosis. In addition to obstacles 
in understanding NASH pathogenesis, no effective treatment has yet been approved for 
the treatment of NASH with existing hepatic inflammation and fibrosis. This literature 
review focuses on relevant research to provide (1) the general background of NAFLD, 
including its stages and complications; (2) current treatments and newly developed 
drugs for NAFLD; (3) the rationale behind repurposing matrine (Mtr) for the treatment 
of advanced NAFLD; and (4) cellular targets, pathways and animal models for the 
investigation of new therapeutics for NAFLD. From this review of the literature, gaps 
in the current knowledge are identified and hypotheses/approaches are developed to 
guide the research presented in this thesis. 
 
1.2 Fatty liver disease 
 
Fatty liver is the accumulation of triglycerides (TG) in the liver and within liver cells 
(hepatocytes). Although the liver normally contains fat, when the percentage of this fat 
deposition exceeds 5% of liver tissue weight, it is characterised as fatty liver disease 
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[1]. This generally occurs when the amount of synthesis and delivery of fatty acids 
(FAs) exceeds the amount that is excreted and eliminated [2].  
 
FAs are derived from diet, lipolysis in adipose tissue de novo lipogenesis (DNL) and 
through the uptake of intestinally derived chylomicron remnants. Increase FAs the 
major cause of hepatic lipid accumulation, where saturated FAs (SFA), such as palmitic 
and stearic acids, are the most abundant circulating free FAs [3]. In contrast, 
supplementation with polyunsaturated FAs (PUFA) can improve lipid metabolism in 
NAFLD patients [4]. In addition, an imbalance between energy intake and consumption 
may cause a defect in FA metabolism and eventually fatty liver. 
 
Fatty liver disease may be broadly classified into two types: alcoholic and non-
alcoholic [5]. Alcoholic fatty liver (AFL) is hepatic steatosis caused by the excessive 
consumption of alcohol. NAFLD is a spectrum of diseases that ranges from steatosis to 
steatohepatitis. Conversely, AFL is caused by the production of toxic metabolites 
following excessive alcohol intake and is primarily treated by stopping alcohol 
consumption. The root cause of NAFLD remains unclear and an effective cure has yet 
to be developed. Less common causes of fatty liver disease include medications—for 
example, amiodarone, methotrexate and tamoxifen [6]—and chronic diseases such as 
HIV, hepatitis C virus (HCV) and autoimmune conditions [7]. Fatty liver disease may 
also occasionally occur during pregnancy and is associated with significant morbidity 
and mortality rates [8]. 
 
Because NAFLD has long been a serious health concern worldwide, it is of great 
interest in a broad range of medical fields. The past 30 years have seen increasingly 
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rapid advances in the field of NAFLD research. However, there remains insufficient 
understanding of NAFLD molecular mechanisms and treatments. Although the 
underlying mechanisms of NAFLD have been explored in depth in several studies [6, 
9], there remains an urgent need to address effective treatment modalities for NAFLD. 
To date, no reliable drug has been developed towards this end. Hence, this thesis will 
focus on NAFLD rather than other types of fatty liver disease and intends to explore an 
appropriate drug for treatment. 
 
1.3 Non-alcoholic fatty liver disease (NAFLD) 
 
NAFLD is a metabolic disease characterised by the accumulation of lipid in the liver in 
the absence of alcohol abuse or hepatic infectious disease [6, 10]. It ranges from simple 
hepatosteatosis to steatohepatitis and cirrhosis. In humans, an NAFLD patient is 
diagnosed when deposition of fat exceeds 5% of liver weight based on clinical history, 
clinical examination and non-invasive laboratory tests [1]. It is now globally recognised 
as the most common chronic liver disease in developed countries including Australia, 
the United Kingdom and the United States [6, 11]. 
 
NAFLD prevalence has doubled over the past two decades compared with other 
chronic liver diseases, which have remained relatively stable [12]. NAFLD is closely 
associated with metabolic disorders and abnormal liver physiology. According to the 
American Association for the Study of Liver Diseases (AASLD), even though NAFLD 
presents as hepatosteatosis correlated with dyslipidaemia, obesity and type 2 diabetes 
(T2D), its underlying mechanisms are still not fully understood [10, 13]. 
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There are two forms of NAFLD: simple fatty liver and NASH. Simple fatty liver 
(hepatosteatosis) is defined as an accumulation of lipid unrelated to alcohol 
consumption or viral hepatitis [10]. It is chiefly caused by excessive deposition of fat in 
liver cells (hepatocytes) in the absence of inflammation, fibrosis and hepatocyte injury 
[6]. It has been observed that hepatosteatosis usually presents with high serum TG level 
without any indication of inflammation, hepatocellular injury or liver injury in NAFLD 
patients and mice [14]. 
 
NASH is a critical and severe stage of NAFLD, defined as the presence of 
hepatosteatosis and inflammation with or without fibrosis [15]. Unlike liver disease due 
to viral infections such as hepatitis C, NASH is characterised by steatosis, hepatocyte 
damage, hepatic inflammation and fibrosis [6, 10]. As shown in Table 1.1, NAFLD can 
be classified into two major stages: hepatosteatosis and NASH, where NASH is the 
critical form of the disease because of its potential for progressing to cirrhosis, 
hepatocellular carcinoma (HCC) and liver failure. 
 
Table ‎1.1 Classifications and grades of NAFLD 
NAFLD stages Grades Remarks 
Hepatosteatosis Mild Increased TG 
NASH without fibrosis Moderate Increased TG + inflammation 
NASH with fibrosis Severe Increased TG + inflammation  
(varying degrees of fibrosis) 
NASH-related cirrhosis End stage 
(irreversible) 
Scar tissue (fibrotic connective 
tissue) + liver failure 
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As shown in Figure 1.1, NAFLD usually starts with simple fat accumulation within 
hepatocytes. Under certain conditions, this can progress to hepatic tissue inflammation 
and fibrosis, causing NASH and finally cirrhosis and even liver cancer (HCC). 
 
 
Figure ‎1.1 Schematic illustration of NAFLD progression presents a spectrum of 
liver disease.  
The progression of fatty liver from healthy liver to end-stage liver disease is illustrated. 
The first stage starts with excess fat deposits within hepatocytes causing 
hepatosteatosis. Then, an increase in inflammatory cytokines causing NASH with or 
without fibrosis occurs. This leads to an irreversible stage and scar tissue formation in 
cirrhosis, which leads to the end stage of liver disease. Histological sections are shown 
as the healthy normal liver progresses through these stages. Based on Cohen et al. [1]. 
 
Indeed, the pathogenic components of NAFLD are complex and a multitude of factors 
contribute to the development of this disease. Hepatosteatosis appears to be the first 
stage of NAFLD development, and the progression of NASH appears linked to hepatic 
inflammation. 
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1.3.1 Prevalence of NAFLD 
 
NAFLD is becoming increasingly widespread as a result of modern sedentary lifestyles 
and the increased incidence worldwide of related metabolic diseases including obesity, 
T2D and insulin resistance [16]. Obesity and T2D are the major risk factors for NAFLD 
as reviewed in detail in Section 1.3.2. In addition, NAFLD patients are highly 
vulnerable to other metabolic diseases and liver-related morbidity and mortality. The 
overall prevalence of NAFLD has risen significantly over the last two decades along 
with increased prevalences of T2D and obesity [17, 18]. 
 
Several studies have been conducted to estimate the prevalence of NAFLD. Generally, 
it has been reported that the prevalence of NAFLD is around 30% in the adult 
population, and that the prevalence of NASH is almost 3% in most Western populations 
[5]. The prevalence of NAFLD is markedly increased in obese individuals (more than 
25%) [5, 6]. In the United States, approximately 90% obese and 75% diabetic 
individuals have NAFLD, and this may explain the close relationship between NAFLD 
and metabolic diseases [5]. As shown in Table 1.2, metabolic diseases especially 
obesity and diabetes are major factors that seem to determine the prevalence of 
NAFLD. 
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Table ‎1.2 The prevalence of NAFLD in different countries 
Region/Country % in 
general 
population 
% in 
population 
with obesity 
% in 
population 
with T2D 
Reference 
Africa 9 10 5 [5] 
Australia 30 76 50 [19] 
China 25–31 70–78 20–32 [20, 21] 
Europe/Italy 20–25 80–90 95 [22] 
Iran 34 50–70 15–30 [23] 
India 9–32 61 25 [24] 
Japan 30 80 20–25 [5] 
Korea 38 50 40 [5] 
Northern Africa 17 30–83 60–98 [5] 
Middle East 30–60 68 34 [5] 
USA >30 80–90 45–75 [5, 25, 26] 
 
 
According to the Gastroenterological Society of Australia and the Australian Liver 
Association, NAFLD was the most common liver disease, affecting an estimated 5.5 
million Australians, in 2012. The number of estimated deaths from NAFLD correlated 
to the prevalence rate of NAFLD was 2,264 deaths. In 2008, the Australian Bureau of 
Statistics expected that the prevalence and mortality rates could increase to 7.7 and 4.5, 
respectively [19] (Table 1.3). Further, in the United States, NASH is expected to be the 
leading cause of liver transplant procedures by 2020 [27]. 
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Table ‎1.3 Prevalence of NAFLD and mortality in Australia in 2012 
 Male Female Total 
Prevalence  2,713,372 2,825,305 5,538,677 
Mortality 1,154 1,110 2,264 
Data adapted from the Gastroenterological Society of Australia and the Australian 
Liver Association in 2012 [19]. 
 
Multiple confounding factors affect the prevalence estimation of NAFLD in the general 
population. These factors include the rapid development of NAFLD and the rather 
vague classification of the disease stages; in addition, the lack of specific NAFLD 
markers is an important factor that can lead to further variations. Despite a lack of 
standard diagnostic tools, and diversity in sample population culture, age, ethnicity and 
gender, an abundance of studies have reported the incidence of NAFLD linked to these 
factors [28]. For example, the incidence of simple hepatosteatosis differs in gender and 
culture and is significantly higher in Hispanic, male and aged populations [5]. It also 
seems that high prevalence of NAFLD in developed countries may be at least in part 
due to dietary factors. 
 
The significance of obesity and T2D in the prevalence of NAFLD has been globally 
recognised [5], and these are strong predictors for this pathological condition in the 
liver. It has been reported that the incidences of NAFLD in patients with obesity (BMI 
>30) and T2D are about 90% and 75%, respectively [5, 25]. Further, the increased 
incidence of progression from hepatosteatosis to NASH is associated with the ongoing 
epidemic of obesity and diabetes [6]. In addition, the different degrees of NAFLD 
associated with metabolic syndrome can affect the estimate of NASH. Numbers of 
patients with mild hepatosteatosis associated with the metabolic syndrome are 
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significantly high compared with patients without the metabolic syndrome. Moreover, 
the selection between stages of NASH and different diagnostic criteria between 
countries affects the estimated prevalence of NAFLD. 
 
1.3.2 Relationship between non-alcoholic fatty liver disease and the 
metabolic syndrome 
 
NAFLD is regarded as a manifestation of the metabolic syndrome in the liver [29], and 
is highly prevalent in patients with the metabolic syndrome [30]. This is clearly seen in 
NAFLD patients with hepatic insulin resistance despite the presence of 
normoglycaemia and mild increased body weight [31]. Further, NAFLD has been 
associated with not only poor glycaemic control but also hypertriglyceridaemia, low 
plasma high-density lipoprotein (HDL)-cholesterol levels, increased waist 
circumference and high blood pressure (Figure 1.2). 
 
The presence of NAFLD is associated with increased risk of obesity, insulin resistance 
and cardiovascular diseases [29, 32], and its development is accompanied by lipid 
metabolism alterations [6, 29]. In addition, the ailment goes beyond mere liver disease 
to become an underlying cause of metabolic syndrome related to failure of other organs 
in the body. It has been discussed that insulin can inhibit lipolysis and increase TG 
synthesis in adipocytes and hepatocytes, respectively [33]. Accordingly, excess hepatic 
fat can induce impairment of glucose and lipid metabolism [31, 34]. This indicates that 
obesity and insulin resistance are associated with abnormalities in lipid metabolism 
associated with NAFLD. It has also been reported that the metabolic syndrome is 
associated with a higher risk of NASH developing in patients [29]. 
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Mechanisms of NAFLD development can be seen by dissecting the metabolic and 
nutritional pathways involving FAs and glucose sensors [6]. In humans, NAFLD is 
significantly increased among patients with T2D or hyperlipidaemia compared with 
non-diabetic or non-obese patients [25, 29]. It has been reported that NAFLD patients 
have high fasting plasma glucose levels with early metabolic derangement compared 
with healthy populations [35]. Conversely, the reversal of hepatosteatosis by reduction 
in hepatic TG content increases insulin sensitivity and glucose metabolism [36]. In 
further studies, various animal models often exhibit similar pathological features of 
NAFLD and associated metabolic diseases [37, 38]. Therefore, animal species and 
strains may be a major factor that influences the development of NAFLD and its 
association with metabolic syndrome in non-human models [39]. 
 
NAFLD is also linked to increased cardiovascular disease, which is a leading cause of 
death worldwide [40]. Progression of NASH increases the risk of cardiovascular 
complications and may be related to increased mortality [15]. A recent study has 
revealed that patients with NAFLD are more likely to have greater myocardial 
dysfunction than are those without NAFLD [41]. Higher incidences of metabolic 
syndrome complications including hypertension, hypertriglyceridaemia, 
hypercholesterolaemia and atherosclerosis have been seen in NAFLD patients with 
higher BMI [32]. Further, individuals with NAFLD are generally accepted as surrogates 
for the risk of developing nephropathy and retinopathy [42]. Therefore, NAFLD is 
increasingly found associated with a more severe adverse outcome and the reversal of 
NAFLD in the early stages can often alleviate these chronic conditions. 
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Figure ‎1.2 NAFLD and NAFLD-associated metabolic syndrome.  
NAFLD is likely a key indicator of chronic diseases associated with obesity, T2D and 
insulin resistance. Further, NAFLD is usually associated with increased risk of 
cardiovascular complications including hypertension, hypertriglyceridaemia and 
hypercholesterolaemia. 
                                                                           
The impact of dietary factors and nutritional differences in NAFLD-associated 
metabolic syndrome has been widely studied using animal studies. An increase in free 
FAs due to dietary overconsumption can result in TG accumulation in the liver and 
therapeutic hepatosteatosis [2]. A study conducted in rats has clearly indicated that 
there is a strong relationship between NAFLD and metabolic syndrome [43]. Rats fed a 
high-fat diet (HFD), high-fructose (HFru) diet or both have induced hyperglycaemia, 
hyperinsulinaemia and hypertriglyceridaemia associated with hepatosteatosis. The 
impact of diet on hepatosteatosis and insulin resistance has been demonstrated by Ren 
and colleagues [44], who have shown that mice fed a HFD or HFru diet have increased 
hepatosteatosis-induced glucose intolerance. Dietary fructose is almost entirely 
metabolised via the liver in its first pass, mainly as a substrate for DNL in both animals 
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[45-47] and humans [48-51]. In contrast, dietary fat directly provides FAs to produce 
hepatosteatosis. 
 
1.3.3 Pathogenesis of NAFLD 
 
The study of pathogenesis of NAFLD is complicated due to the spectrum of diseases 
arising from various cellular interactions within the disorder [6]. The first stage is a 
hepatic manifestation of the metabolic syndrome represented by hepatosteatosis. NASH 
is a critical and advanced form of NAFLD characterised by hepatocyte damage, release 
of inflammatory cytokines, and various degrees of fibrosis secondary to hepatosteatosis 
[1]. Due to the multiple pathways involved in this disease, there are no approved and 
effective treatments for patients with NAFLD.  A better understanding of the complex 
pathogenesis of NAFLD will help to identify an effective treatment that prevents or 
helps to delay the development of NAFLD and the progression of NASH.  
 
NASH pathogenesis has been established in literature by the two hit hypothesis [52]. 
According to Day et al, the first hit primarily manifests as an excessive TG 
accumulation in the hepatocytes and promotion of hepatosteatosis. As shown in Figure 
1.3, the second hit has been suggested to be the main reason for the progression from 
hepatosteatosis to steatohepatitis. This hit may be caused by inflammatory, 
endoplasmic reticulum (ER) and cell injury mediators directly related to activation of 
inflammation, oxidative stress and apoptosis, respectively.  Progression of NASH could 
irreversible depending on the severity of the disease [6, 52]. The exact mechanism 
behind NASH causation is multifactorial and its understanding is still incomplete [53]. 
During the progression of NAFLD, interaction of different pathways such as oxidative 
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stress, inflammatory cytokines, lipid peroxidation and mitochondrial dysfunction may 
be able to induce steatohepatitis [15, 44]. It has been claimed that the activation of 
inflammatory cytokines in hepatic kupffer cells (KCs) plays an important role in NASH 
development [6].  
 
 
 
Figure ‎1.3 The hallmark of NASH and the two-hit hypothesis.  
The first hit is caused by TG accumulation in the hepatocytes and promotion of 
hepatosteatosis. The second hit has been suggested to result from the activation of 
distinct pathways leading to simple steatosis and NASH, respectively [1]. 
 
In current literature, different pathways potentially involved in the pathogenesis of 
NASH have been investigated. One of the proposed mechanisms is the chronic 
stimulation of inflammatory cytokines, mainly tumour necrosis factor-α (TNFα) and 
interleukin 6 (IL-6). The activation of inflammatory mediators aggravates liver cell 
injury via pro-fibrogenic transforming growth factor beta (TGFβ), IL-6, intercellular 
adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein 1 (MCP-1) and 
TNFα [54] (Figure 1.4). From this pathway, it appears that inflammation is a dominant 
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factor involved in the process of the progression of NASH; this will be discussed in 
detail in Section 1.6.4. 
 
Another important factor claimed to be involved in the pathogenesis of NAFLD is 
oxidative stress [54]. In general, excessive TG accumulation in the liver causes 
metabolic stress on the mitochondria and ER and the release of reactive oxygen species 
(ROS). It has been reported that there is a significant increase in the products of lipid 
peroxidation among NAFLD patients compared with healthy controls [55]. Increased 
hepatic oxidative stress markers have also been found in severe inflammation in NASH 
induced in mice by feeding them methionine and choline-deficient (MCD) diet [56]. 
Further, several studies have reported that ER stress may be an essential factor in both 
the development of hepatosteatosis and the progression to NASH [57-59]. Indeed, it has 
been shown that attenuation of ER stress prevents the development of hepatosteatosis 
and progression of NASH in vivo and in vitro [60, 61]. 
 
 
Figure ‎1.4 Proposed ‘multiple hits’ in the pathogenesis of NASH.  
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The initial hit is through increased production of free FAs and hepatic fat deposition, 
usually due to the metabolic syndrome, resulting in hepatosteatosis. Second hits such as 
inflammation, oxidative stress and ER stress are involved in the progression of steatosis 
to NASH. Such multiple factors may include oxidative damage, increased inflammation 
and fibrosis leading to NASH [62]. 
 
To date, several studies have highlighted the multiple-hit theory that is associated with 
the development of NAFLD. Recent evidence suggests that gut-derived bacterial 
lipopolysaccharide (LPS) plays a key role in the development and progression of 
NASH [63]. It has been observed that there is an increase in the growth of LPS bacteria 
in patients with NASH compared with controls. Several studies in rodents have shown 
that LPS/toll-like receptor 4 (LPS/TLR4) and LPS-induced TNFα production are 
involved in the progression of NASH in rats and mice, respectively [64, 65]. Further, 
LPS stimulation with high caloric intake leads to hepatic inflammation and progression 
of NASH in C57BL/6 mice [66]. Interestingly, therapeutics that target LPS elevation 
such as Mtr might ameliorate diet-induced steatohepatitis, particularly fibrosis 
progression [67]. Gut microbiota-triggered LPS-induced hepatic inflammation and 
NASH are vital regulators of NAFLD pathogenesis. 
 
Understanding these NAFLD progression mechanisms will help to develop drugs that 
target hepatosteatosis and NASH that arise along these pathogenesis pathways. Further 
studies may be beneficial to not only dissect these pathways but also present potential 
new therapeutic agents that resolve NAFLD. New approaches have been explored to 
develop appropriate therapeutics that target various elements in the pathogenesis of 
NAFLD and progression of NASH [68]. There is great interest in identifying molecular 
targets for the treatment of this condition, making the outlook of NASH therapy more 
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optimistic. The use of treatments that target predictive risk factors such as obesity and 
T2D has become prominent, but is insufficient [68]. Current medications targeting 
these pathways will be discussed in detail in Section 1.9. 
 
1.4 Economic burden of NAFLD 
 
The burden of NAFLD is associated with tremendous clinical, economic and health-
related quality-of-life costs. The increased prevalence of this disease has led to greater 
analysis of the quantifications of clinical and economic burdens of this condition [69]. 
NAFLD has a high financial cost, which affects the patient’s health and treatment 
system, and the overall economy, and needs to be addressed through healthcare and 
prevention policies. The disease’s progression and related illnesses put a strain on 
national medical services. Hence, estimating economic costs and health burden of fatty 
liver disease is extremely important in monitoring the incidence of NAFLD and other 
related health problems. It is also essential to provide standard classifications in 
outlining the burden of fatty liver, morbidity and deaths affecting individuals and the 
society. This is aggravated by the limited availability of non-invasive and accurate 
diagnostic tools—one of the greatest challenges in NAFLD diagnosis [6]. 
 
There are currently insufficient data available on the cost-effectiveness of prevention 
and treatment of this disease [70]. Data reveal that pharmacological treatments in 
addition to standard lifestyle modifications in NASH patients with advanced fibrosis is 
likely more cost-effective than in NASH patients without advanced fibrosis. Another 
study has reported a total cost of 2,521 purchasing power parity (PPP) for each urban 
NAFLD patient per year including health services, diagnosis and drug treatment [5]. 
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Despite the short-term follow-up, including minimum cost and narrow spectrum of 
healthcare cost, the study reports that the total cost of NAFLD in Iran is 1 billion PPP 
yearly. 
 
The economic burden of NAFLD including diagnosis and treatment is extremely high 
worldwide. Statistics show that NAFLD is the most prevalent liver disease in Australia, 
with an estimated 5.5 million people affected, including 40% of all adults aged 50 years 
and over [19]. NAFLD is also associated with the highest number of deaths, with an 
estimated 2,264 in 2012. According to the same report by the Gastroenterological 
Society of Australia, the Australian government has spent around $5.44 billion on 
patients with liver diseases [19]. The prevalence rate of NAFLD continues to rise 
significantly worldwide including Australia. It is projected that NAFLD will affect 
more than 7 million Australians in 2030 [19]. A recent study has shown that the high 
prevalence of NAFLD has a marked effect on the economy of both the United States 
and Europe, outlining a comprehensive model estimating the clinical and economic 
burdens of NAFLD [69]. From the data reported in the study, the number of NAFLD 
patients in the United States and Europe is 60 million and 50 million patients with an 
annual cost of about $103 billion and €35 billion, respectively. 
 
The enormous economic burdens associated with NAFLD will continue to increase as 
its prevalence rises. Indeed, it is time to improve awareness of NAFLD at a social level 
and give more consideration to NAFLD in health policies worldwide to secure a better 
future for coming generations. Formal cost–benefit analyses in the context of NAFLD 
are needed for better management and treatment. Clearly, defining the natural history of 
NAFLD would be beneficial for the early detection and prevention of NAFLD 
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progression and complications. In turn, the effect of novel treatments on decision-
making may be beneficial to avoid high future healthcare costs related to progression of 
NAFLD. 
 
It is worthwhile to note that lack of awareness of the economic burden of NAFLD 
among hepatologists and non-hepatologists is putting individuals and society at 
elevated risk. This is likely due to underestimated prevalence of NAFLD and its 
implications. One of the most effective ways to monitor development and progression 
of NAFLD is to estimate the economic burden of this disease. Undertaking a study of 
the economic burden of NAFLD has been highly recommended by hepatologists and 
hepatic clinical practitioners to develop a comprehensive understanding of the liability 
of this disease. 
 
1.5 Hepatosteatosis  
 
Hepatosteatosis (also called fatty liver) is defined as the accumulation of TG in the 
liver, where the risk of progression to fibrosis and liver failure in the absence of 
additional insults is relatively small [10]. It is considered a benign stage of NAFLD but 
a primary mediator of most common fatty liver diseases [6] because of excessive lipid 
accumulation in the liver both directly and indirectly through liver-related diseases such 
as obesity and T2D. Simple hepatosteatosis is characterised by a hepatic TG content 
greater than 5% of liver weight in the absence of liver injury, inflammation and fibrosis 
(Figure 1.6). When left untreated, hepatosteatosis may progress to NASH, where the 
risk of fibrosis and cirrhosis is dramatically increased [69]. 
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There are four major causes of hepatosteatosis, including increased dietary fat 
(exogenous fat), increased DNL (endogenous fat synthesised in the liver), reduced fat 
oxidation and impaired fat export out of the liver [2, 71]. Indeed, dysfunction of the 
liver may cause improper trafficking of lipids, resulting in a higher rate of TG synthesis 
than TG secretion [6]. This prolonged impairment of hepatic TG secretion promotes 
inflammation, oxidative stress and fibrosis in the liver to form NASH. 
 
Table ‎1.4 Major features differences between simple hepatosteatosis and NASH 
Feature Hepatosteatosis NASH 
Lipid accumulation   
Liver injury   
Hepatic inflammation   
Hepatic fibrosis   
Risk of cirrhosis Minimal risk 
(cirrhosis <0.7%) 
High risk 
(cirrhosis >12%) 
Mortality Lower mortality 
(20%) 
Higher mortality 
(42%) 
FAs can also be generated from carbohydrates through DNL, a process initiated by the 
carboxylation of actyl-CoA that is catalysed by acetyl-coA carboxylase (ACC) [6]. It 
has been shown that DNL is promoted by hyperinsulinemia or high consumption of 
carbohydrates [72, 73]. Previous studies also showed DNL is increased in the liver of 
high-fructose fed mice [45]. 
 
FAs are the precursor of TG and play an important role in the development of 
hepatosteatosis. Several mechanisms contribute to increased FAs subsequently causing 
hepatosteatosis. It has been shown that several putative signalling mechanisms, 
including inflammatory cytokines, ER stress and oxidative stress, are activated as a 
result of excessive FAs supply [6]. Regulation of FAs pathways in both adipose tissue 
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and the liver are essential to maintain TG synthesis and secretion, which is essential for 
lipid metabolism in relation to hepatosteatosis [9]. 
 
1.5.1 Hepatic lipid metabolism 
 
Liver TG is formed from FAs and glycerol via hepatocellular long-chain FAs bound to 
coenzyme A to form fatty acyl coenzyme A (acyl-CoA) [35]. FAs are generally derived 
from circulating free FAs, DNL, lipoprotein uptake and TG breakdown [6]. Of the TG 
present in the liver, approximately 59% comes from circulating free FAs, 26% from 
DNL and 15% from the diet [2]. Thus, hepatosteatosis can be considered a 
heterogeneous condition. Our laboratory and others have found that excessive DNL 
represents a key feature of fatty liver from high-carbohydrate diet [6]. These sources 
contribute towards TG synthesis, which is stored and metabolised within the liver then 
exported and stored in adipose tissue. 
 
Dysregulation of lipid metabolism in the liver is strongly correlated with TG 
accumulation within hepatocytes, causing hepatosteatosis [15]. As indicated previously, 
an imbalance between free FA formation and utilisation (lipid synthesis and oxidation) 
can lead to an increase in hepatic free FA concentration, resulting in hepatosteatosis 
[35]. 
 
One important cause of increased fat uptake is excess FA intake, such as with a 
Western diet or HFD, directly leading to excessive accumulation of fat in the liver and 
eventually hepatosteatosis [44, 74]. A possible explanation for this connection may be 
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that circulating FAs mainly derive from digested dietary fat and adipose tissue lipolysis, 
leading to increased lipid deposits in the liver [6]. 
 
Another possibility is that insulin resistance in muscle due to impaired insulin-mediated 
glucose uptake leads to deviation of glucose to the liver for DNL [75]. Conversely, 
increased synthesis of TG through non-esterified FAs (NEFAs) and DNL promotes 
lipid droplets in circulation and in the liver, respectively [6]. During TG lipolysis, 
NEFAs are transported from adipose tissue to the liver and re-esterified with glycerol to 
form TG. The other cause of increased fat synthesis through the highly regulated DNL 
pathway will be discussed in Section 1.5.2. 
 
Dysregulation of FA metabolism is likely caused by FA oxidation-reduction [76]. In 
this pathway, mitochondrial regulated FA oxidation through carnitine 
palmitoyltransferase 1 (CPT1), which is the key enzyme in FA β-oxidation, facilitates 
the transport of acyl-CoA into mitochondria. It has been shown that an increase in 
CPT1 alleviates HFD-induced lipid metabolism disorders in a genetic obesity rat model 
[77]. Indeed, prevention of free FA-induced hepatosteatosis increased mitochondrial β-
oxidation in HepG2 cells and in MCD rats with a carnitine-supplemented diet [78]. In 
contrast, it has been suggested that overexpression of enzymes such as CPT1 increases 
FA oxidation and alleviates HFD-induced hepatosteatosis and inflammation [76]. 
 
Another factor that contributes to the aggravation of NAFLD is mitochondrial 
dysfunction. For example, a decrease in the regulator of mitochondrial biogenesis, 
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α), results 
in impaired lipid metabolism and hepatosteatosis development [79]. Dysregulated 
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mitochondrial metabolism involved in oxidative stress, ER stress and inflammation 
constitutes risk factors that progress NASH in humans and rodents [80, 81]. Hence, 
developing drugs that increase mitochondrial function could ameliorate NASH [82]. 
This indicates that mitochondrial dysfunction has an essential contribution to the 
development of NASH. 
 
Very low density lipoprotein (VLDL) secretion, which is a mechanism of TG removal 
from the liver, is another mechanism of hepatosteatosis [83]. Inhibition of VLDL 
secretion induces hepatosteatosis, suggesting that VLDL production plays a significant 
role in hepatic lipid metabolism and hyperlipidaemia [83]. It has been suggested that 
VLDL secretion deficiency can promote NAFLD progression [6]. Impaired VLDL 
export in a genetic NASH mice model exhibits excessive hepatic TG and increased 
expression of inflammatory markers [84]. In Zucker rats, increased TG secretion from 
the liver by circulation has been shown to prevent the development of hepatosteatosis 
[85]. Impairment of TG export and deficiency in VLDL synthesis leads to TG 
accumulation in liver cells, which may lead to hepatosteatosis. The TG exported from 
the liver is packed into VLDL and released into the blood stream, which is a 
mechanism of hyperlipidaemia [6]. The main cause of reduction in VLDL secretion in 
the liver is lack of microsomal TG transfer protein (MTTP), which plays a vital role in 
the synthesis of apolipoprotein B in VLDL formation. Deficiency of these proteins 
results in hepatosteatosis and NASH exacerbation in mice [86] and humans [87]. 
 
Hyperinsulinaemia has been associated with an increase in lipid synthesis to result in 
hepatosteatosis. Forkhead box protein O1 (FoxO1) is a key mediator in the insulin 
signalling pathway, and acts as a master transcription factor regulating hepatic DNL 
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and gluconeogenesis [88]. Prolonged insulin stimulation restores FoxO1 expression, 
while insulin receptor substrate 2 (IRS-2) is involved in the inhibitory effects of insulin 
on FoxO1 [89, 90]. The expression of FoxO1 regulates lipid metabolism through 
reduced transcriptional activity of sterol regulatory element-binding protein 1c 
(SREBP1c) in vivo and in vitro [91]. 
 
Mitochondria play an essential role in hepatic lipid metabolism and are affected by 
upstream signalling pathways involved in hepatosteatosis [92]. FA oxidation is a 
process to shorten FAs into acetyl-CoA and plays a vital role in hepatosteatosis and 
lipid metabolism. Impairment in FA oxidation and lipid export can increase hepatic 
DNL and thereby trigger hepatosteatosis. It has been suggested that stimulation of 
mitochondrial FA oxidation in the liver may ameliorate hepatosteatosis, inflammation 
and fibrosis and protect against hepatosteatosis [81, 93]. It seems that mild reduction in 
the rate of FA oxidation induces hepatosteatosis and significant reduction of FA 
oxidation exacerbates NASH. 
 
1.5.2 De novo lipogenesis 
 
The liver is a major metabolic organ responsible for the homeostasis of lipids in the 
whole body. DNL is a metabolic process for the conversion of an excess of 
carbohydrates into FAs, which are ultimately esterified with glycerol 3-phosphate to 
form TG [89]. DNL is thought to contribute to the development of NAFLD and related 
metabolic diseases [2]. Excess intake of carbohydrates especially fructose that exceeds 
liver utilisation capacity stimulates the lipogenic pathways and the production of DNL, 
lipids by disposing of glucose and calories [94]. The conversion of excess 
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carbohydrates regulated by the DNL pathway is a critical mechanism involved in lipid 
homeostasis in the liver [1]. Elevated DNL is one important source of hepatic lipid 
accumulation and the development of hepatosteatosis [6]. 
 
Fructose contributes to lipid synthesis via the influx of fructose carbons into lipogenic 
precursors. The role of dietary fructose has been implicated as an important risk factor 
for DNL promotion and NAFLD progression [95]. SREBP1c expression in rodents 
caused by fructose feeding promotes hepatic lipid synthesis [96]. Hepatic lipogenesis is 
affected by multiple factors including liver X receptor (LXR) and peroxisome 
proliferator-activated receptor-α (PPARα) [97, 98]. These elements play a vital role in 
regulating lipid metabolism by reducing the clearance of FAs through oxidation, 
consequently further increasing fat accumulation in hepatocytes [6]. The major 
transcriptional regulators and enzymes involved in hepatic DNL, including SREBP1c, 
carbohydrate-responsive element-binding protein (ChREBP), fatty acid synthase (FAS), 
ACC and stearoyl-coenzyme A desaturase-1 (SCD1), have garnered significant 
attention over recent years [95]. 
 
SREBP1c and ChREBP are two master transcriptional regulators that are widely 
expressed in the liver and drive DNL [89, 99]. Both these DNL transcriptional 
regulators are elevated in the liver during over consumption of fructose [100, 101]. 
Consumption of fructose has distinct effects on the expression of these lipogenic 
transcription factors (ChREBP and SREBP1c) and has been associated with poor 
metabolic outcomes, compared with glucose-fed mice [102]. 
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ChREBP is one of the major regulators of DNL in adipose tissue implicated in 
hepatosteatosis and insulin resistance [103]. It can be activated by high glucose levels 
and inhibited by cAMP [71]. It is a key determinant of lipid synthesis as a glucose-
responsive transcription factor in the liver [103]. Deficiency of ChREBP in the liver of 
genetically obese ob/ob mice markedly improves insulin resistance and hepatosteatosis 
[99]. Rodents fed HFru diet display a significant increase in ChREBP expression [104]. 
 
SREBP1c regulates the expression of genes encoding enzymes responsible for DNL, 
such as FAS [89]. A strong relation between the increased levels of nuclear SREBP1c 
and the elevation rates of hepatic FA synthesis has been previously reported [105]. In 
other words, elevated levels of hepatic SREBP1c lead to increased expression of genes 
for the synthesis of FAs, which in turn is associated with the development of 
hepatosteatosis. 
 
It has been shown that increased SREBP1c expression contributes to the development 
of hyperglycaemia and hepatic steatosis in diabetic mice [105]. As the activation of 
SREBP1c expression is not accompanied by lipogenic gene upregulation in adipocytes 
[106], this transcriptional factor seems to be a dominant regulator of DNL particularly 
in the liver. The expression of SREBP1c can be stimulated by fructose, glucose, insulin 
and ER stress [89]. Inhibition of SREBP1c levels by reducing ER stress decreases 
hepatic lipogenesis and markedly improves hepatosteatosis and insulin sensitivity in 
obese rodents [107]. 
 
Downstream of the enzymes SREBP1c and ChREBP in the lipogenic pathway for 
hepatic lipogenesis are ACC, SCD1 and FAS [71, 108]. These key lipogenic enzymes 
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can be targeted for the treatment of NAFLD. For example, mutant mice lacking ACC1 
are protected against hepatosteatosis [109]. Additionally, ACC inhibitors reverse 
hepatosteatosis in rats with diet-induced NAFLD [110]. Further, mice with liver-
specific SCD1 knockout are protected against hepatosteatosis induced by high-
carbohydrate diet [111], and FAS inhibition leads to a significant reduction in liver TG 
levels and improved insulin sensitivity in db/db mice fed HFru diet [112]. 
 
 
                                                                     
The activity of the lipogenic pathway is dependent upon nutritional conditions [95]. A 
diet rich in carbohydrates, mainly fructose, stimulates the lipogenic pathway in the 
liver, where fructose is cleared from the blood [101]. Several studies have suggested 
that HFru diet may increase DNL, which contributes to the pathogenesis of NAFLD 
Figure ‎1.5 Effect of carbohydrate 
overfeeding on DNL-induced 
hepatosteatosis.  
The conversion of glucose into FAs through 
DNL is nutritionally regulated by glucose and 
insulin signalling pathways, which induce 
lipogenic gene expression. Glucose activates 
the transcription factor ChREBP, which is 
required for the transcriptional induction of 
FAS and ACC. Insulin activates the 
transcription factor SREBP1c, which is 
required for the transcriptional induction of 
FAS and SCD1. Activation of lipogenic 
enzyme causes dysregulation of lipid 
metabolism, leading to hepatosteatosis and 
ultimately NAFLD development. 
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[100-102]. The transcription of lipogenic enzymes is regulated by insulin and glucose. 
Carbohydrate feeding promotes DNL, as summarised in Figure 1.5. 
 
Hepatic ER stress pathways have been implicated in the development of hepatosteatosis 
during HFru feeding in mice [46]. It has been reported that ER stress can lead to 
hepatosteatosis associated with glucose homeostasis by upregulation of SREBP1c, 
ACC, FAS and SCD1 [45]. Alleviating ER stress and inhibiting DNL has a significant 
impact on improving hepatosteatosis involved in NAFLD [57]. Studies in rodents 
suggest that alleviating ER stress protects against an increase in hepatic lipogenesis and 
hepatosteatosis [57, 107]. Thus, targeting ER stress might be a good candidate for 
NAFLD or NASH treatment. 
 
1.5.3 Non-alcoholic fatty liver disease and hyperglycaemia 
 
Data from several human studies suggest that the presence of NAFLD promotes the 
consecutive development of T2D and is a strong predictor of the metabolic syndrome 
[35]. T2D and obesity are closely associated with increased delivery of FAs to the liver 
and hence are the most common risk factors for the development of NAFLD. They 
have been proposed as major risk factors in T2D with a twofold to fivefold increased 
risk of developing NAFLD [113]. Factors associated with hepatosteatosis, including 
glucose intolerance and insulin resistance, can aggravate to severe NASH [6]. 
 
The liver is largely involved in whole-body insulin resistance and fasting 
hyperglycaemia in T2D [35]. Excessive TG accumulation in the liver may be associated 
with hyperinsulinaemia and dyslipidaemia and can contribute to elevated lipogenesis in 
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obesity and NAFLD [6]. In addition to the liver, adipose tissue plays an important role 
in NAFLD development and is associated with higher risk of mortality. A link between 
intestinal microbiota and development of obesity with its metabolic consequences 
including T2D has been suggested to be involved in NAFLD progression [63]. 
 
Dietary factors significantly contribute to hepatic TG accumulation and hyperglycaemia 
associated with NAFLD. In NAFLD patients with or without obesity or insulin 
resistance, roughly 15% of hepatic FAs originate from diet. During dietary over 
consumption of fructose, hepatosteatosis and insulin resistance occur at a very early 
stage [48, 114]. Dietary fructose in particular has been shown to have a distinct 
tendency to induce hepatosteatosis and insulin resistance in experimental animals. For 
instance, HFru feeding results in hepatosteatosis and insulin resistance induced by 
excessive DNL [44]. The study also suggested that activation of ER stress pathways 
may play an important role in DNL and subsequent hepatosteatosis. 
 
Interestingly, reduction of hepatosteatosis in diabetic patients has been shown to 
markedly improve glycaemia control and insulin sensitivity [36]. The reversal of 
hepatosteatosis and hyperglycaemia via lifestyle modification may be beneficial for the 
prevention of NAFLD and its associated metabolic diseases. For example, a study in 
experimental animals has indicated that improvement in hypertriglyceridaemia and 
insulin resistance induced by fructose protects against developing NAFLD [115]. It has 
been reported that PUFAs ameliorate many of the adverse changes in lipid and glucose 
metabolism responsible for NAFLD development [4]. 
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As previously mentioned, hepatic lipogenesis represents a critical mechanism for 
hepatosteatosis associated with glucose homeostasis [44]. An important reason for the 
activation of this lipogenic pathway in the liver is a diet rich in carbohydrates. Post-
translational and transcriptional mechanisms control the activities of hepatic lipogenic 
enzymes. The transcription of lipogenic enzymes is regulated by insulin and glucose as 
shown in Figure 1.5. 
 
There is clear evidence suggesting a strong relationship between hepatosteatosis and 
insulin resistance in the presence or absence of obesity. Because NAFLD and T2D 
share some common pathological features, most therapeutic approaches for NAFLD 
target the major pathways thought to be essential in the metabolic syndrome [35]. 
Among various stages in the progression of NAFLD, there is increasing interest in the 
prevention of NASH development as it is crucial for the control of fibrosis and disease 
prognosis. 
 
There are many different anti-diabetic drugs that act on the same mechanism in 
increasing insulin sensitivity and decreasing hepatic glucose production. Although 
metformin is one of these drugs because of its efficacy in T2D [116], it is necessary to 
develop an efficient therapy for fighting or preventing NAFLD. 
 
1.6 Non-alcoholic steatohepatitis (NASH) 
 
NASH is a severe and progressive stage of NAFLD, in which hepatocyte damage, 
inflammation and fibrosis are present [10]. Unlike simple hepatosteatosis, NASH may 
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become a more prominent public health issue in the near future with the potential of 
becoming the second most common indication for liver transplantation [6]. 
The pathogenesis of the transition from hepatosteatosis to NASH is complicated and, 
although it has been extensively studied in humans and animals, it remains unclear. It 
has been proposed that inflammation, ER stress, oxidative stress and mitochondrial 
dysfunction may be the dominant mechanisms in this disease [6]. Histologically, 
prolonged inflammation associated with ballooning degeneration of hepatocytes is a 
strong feature for defining NASH [54]. Other signs such as collagen deposition 
contribute to the severity of the disease. 
 
Numerous indications characterise the pathogenesis of NASH but these signs may vary 
considerably in most cases. For example, TG level and plasma levels of liver enzymes 
(aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) have been used 
as markers for diagnosis of NASH [117]. Other markers proposed by Walenbergh et al. 
indicate that oxidised low-density lipoprotein (oxLDL) is a substantial risk factor for 
NASH [118]. It seems that dysfunctional hepatic lipid metabolism may be a key factor 
in progression to NASH [119]. However, it is generally agreed that abnormal lipid 
metabolism alone is insufficient to cause liver injury and NASH [10, 80]. 
 
On the basis of the two-hit hypothesis of NAFLD pathogenesis, hepatosteatosis is 
classified as a first hit but a second hit is required to advance it to NASH [52]. 
Although it is not well understood how NASH occurs, several factors that seem to 
contribute to the progression of NASH have been reported in a number of studies [6]. 
These factors—cell injury, inflammation, ER stress, oxidative stress and mitochondrial 
dysfunction—are associated with the severity of NASH and progression to NASH with 
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fibrosis, while other factors yet to be identified contribute to the progression to severe 
fibrosis. Despite the difficulty in determining NASH due to the lack of definite 
pathogenesis, animal studies have been used to identify the factors critically involved in 
the progression of NASH [120, 121]. NASH characterisations according to the AASLD 
will be discussed in the following sections. 
 
1.6.1 Steatosis 
 
Hepatosteatosis is the hallmark of NAFLD resulting from excessive accumulation of 
lipids in hepatocytes, which can result from increased DNL, reduced utilisation of 
lipids or inhibited export of lipids from hepatocytes [6]. The amount of TG 
accumulated in the liver and other lipids such as FAs, diacylglycerols, phospholipids, 
sphingolipids and cholesterol is influenced by diet, physical activity, age and ethnicity. 
Thus, hepatosteatosis has heterogeneous causes, which are obvious risk factors for 
NASH [122, 123]. 
 
The two-hit hypothesis considers steatosis a first hit to the liver in NASH pathogenesis; 
however, not all patients with steatosis develop NASH: approximately only one-third 
will develop NASH [6]. In animals, a diet rich in fat, carbohydrate or both has been 
shown to cause simple hepatosteatosis [120]. Animal models and diets will be 
discussed in Section 1.8. 
 
Understanding the mechanism involved in the progression of hepatosteatosis to NASH 
is important for the prevention of NASH that can lead to cirrhosis or cancer. According 
to AASLD guidelines, hepatosteatosis does not require pharmacological treatments 
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[10]. However, hepatosteatosis should not be neglected because it is a risk in the 
pathogenesis of NASH. 
 
1.6.2 Cell damage 
 
Hepatocytes are the most predominant cells in the liver and account for 70–80% of 
healthy liver mass. Hepatocytes are the major storage site for excessive TG 
accumulation in the highly metabolised liver cell [124]. Hepatocyte injury is a key 
feature that distinguishes hepatosteatosis from NASH [6]. It is strongly linked to the 
pathogenesis of NASH because of the ability of hepatocytes to release factors that 
promote inflammation and fibrosis in the liver (Figure 1.6). 
 
It has been suggested that repetitive or chronic liver injury may cause dysregulation in 
wound-healing response, promoting progressive hepatic cell damage, which leads to 
cirrhosis [6]. In humans, there exist highly significant correlations between the 
hepatocyte damage and the severity of NASH [125]. Mice fed with special diets such as 
choline-deficient L-amino acid-deficient (CDAA) or MCD show liver injury and 
display more pronounced features of NASH [120]. 
 
Hepatocyte damage induces several factors that activate signalling cascades that result 
in cell death and aggravate NASH development. Fat deposition, ER stress, apoptosis 
and inflammation in the liver are directly or indirectly caused by cell injury. These 
factors associated with cell damage induce signalling pathways that contribute to the 
pathogenesis of NASH. It has been shown that excess lipid in mouse and human 
hepatocytes induces liver injury, inflammation and fibrosis with NASH [126]. 
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Increased lipid droplets cause hepatic inflammation via cholesterol loading of 
macrophages in the liver [127]. 
 
 
 
Figure ‎1.6 Major cell types involved in the pathogenesis of NASH.  
Hepatocytes are the most predominant cells in the liver and play a vital role in liver 
injury. KCs are macrophages present in liver responsible for the release of 
inflammatory cytokines. HSCs are considered a major source of liver fibrogenic cells. 
 
1.6.3 Macrophages activation and infiltration 
 
Macrophages are a main component of the innate and adaptive immune systems present 
in all living tissues. It has been shown that KCs in NASH are associated with 
stimulation of the immune and inflammatory systems to detect and protect against the 
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disease [6, 128]. Activation of KCs and infiltration of macrophages from the blood 
circulation have been proposed to be essential in NASH and NASH with fibrosis [129]. 
 
Activation of KCs has been identified as a critical factor in NASH pathogenesis, 
mediating inflammation and exacerbating fibrosis (Figure 1.7). It has been found to be 
increased in both humans and animals with NASH [129]. Secretion of inflammatory 
cytokines by activated KCs is a key event in the initiation of NASH [130, 131]. It also 
plays a pivotal role in activation of hepatic stellate cells (HSCs) towards hepatic 
fibrosis and NASH-related fibrosis. It has been reported that targeted deletion of KCs 
completely prevents TNFα production and TGFβ mRNA expression in MCD diet-fed 
mice [131]. 
 
Polarisation of KCs has been demonstrated in prevention of the progression of NASH 
[130]. KCs are classified as M1 when responsible for releasing inflammatory properties 
and M2 when releasing anti-inflammatory properties. Chronic HFD feeding increases 
KCs with M1 phenotype, hence increasing inflammatory cytokines, while KCs 
polarisation switch from M1 to M2 leads to prevention of the development of NAFLD 
in HFD mice [132]. These studies suggest that pharmacological interventions targeting 
M2 KCs polarisation may provide an effective therapy in the prevention of 
inflammatory hepatic injury and hepatic fibrosis in NASH. 
 
1.6.4 Inflammation 
 
Hepatic inflammation plays a critical role in the development of NAFLD and a crucial 
aspect in NASH pathogenesis [15, 133]. It has been reported that macrophage 
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activation causing inflammation leads to NASH in mice [134]. LPS has been shown to 
promote the progression of NASH because of stimulation of inflammatory gene 
expression [135]. Alternatively, inhibition of inflammation by drugs may improve diet-
induced NASH [136, 137]. 
 
Activation of KCs induces the production of inflammatory cytokines generated by LPS-
induced signalling that is dependent on macrophage activation [138]. Inflammatory 
cytokines have two roles: first, to increase the recruitment of inflammatory cells and, 
second, to exacerbate the progression of NASH. The balance between pro- and anti-
inflammatory acting cytokines is an acknowledged regulator of liver diseases including 
NASH [54]. 
 
The major inflammatory cytokine TNFα plays diverse roles in the pathogenesis of 
NASH [15]. The expression levels of TNFα and IL-6, two important inflammatory 
cytokines, are hugely increased in the liver of NASH subjects [139, 140]. Crespo et al. 
report increased hepatic expression of TNFα and tumour necrosis factor receptor 2 
(TNFR2) in patients with NASH compared with healthy people [139]. In NASH 
patients, more advanced fibrosis is also accompanied by increased hepatic expression 
of TNFα. In line with these results, TNFα plasma levels have been shown to correlate 
positively with the grade of liver fibrosis assessed by ultrasound-guided liver biopsy in 
patients with advanced stages of NAFLD. 
 
The release of numerous inflammatory cytokines, including TNFα, mediates 
inflammatory production and liver cell death—inflammation and cell damage are 
known to be involved in the pathogenesis of NASH. An earlier study has revealed that 
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overexpression of TNFα induces elevation of inflammatory and fibrotic signalling 
pathways in patients with more advanced NASH [139]. On the contrary, there are no 
significant differences in the levels of TNFα in NASH patients compared with simple 
hepatosteatosis [141]. However, it is generally agreed that inflammation plays a major 
role in the progression of this disease [133]. 
 
Recently, reduction of TNFα has been shown as an independent predictor for positive 
NASH prognosis [139]. Anti-inflammatory drugs can decrease the activity of this 
cytokine, and thus prevent NASH [67, 142]. In humans, such therapies represent an 
improvement in histological features of this disease through reduction in 
hepatosteatosis and inflammation [143, 144]. The anti-inflammatory effects of 
pentoxifylline reduce the increase in TNFα-induced NASH-like phenotype in mice fed 
HFD with cholesterol or MCD diet [145]. 
 
Activation of inflammatory cytokines also drives activation of inflammasome, which 
contributes to steatohepatitis [146]. Inflammasome and interleukin 1 beta (IL-1β) 
activation are required for the pathogenesis of NASH [147, 148]. Identification of the 
inhibitors of NOD-like receptor family pyrin domain-containing 3 (NLRP3) 
inflammasome is an important step in the process of developing effective drugs for the 
treatment of NASH in which inflammation is a known component [149, 150]. It has 
been reported that the inhibition of NLRP3 inflammasome activation reduces liver 
injury, inflammation and fibrosis in MCD diet-induced steatohepatitis and in foz/foz 
mice with NASH [149]. 
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Another factor contributing to inflammation of the liver involved in the progression of 
this disease is iron accumulation. Hepatic iron deposition is strongly associated with 
hepatocyte injury and inflammation in NASH patients [151]. It has been found in one-
third to half of patients with NAFLD and ranges from mild elevations to about 1000–
1500 ng/mL accumulated within hepatocytes. Accumulation of iron has been also seen 
in KCs, which increases inflammatory and fibrotic cytokines [152]. The mild degree of 
body iron excess compared with markedly raised serum ferritin concentrations suggests 
that iron overload in patients with NAFLD results from a combination of alimentary 
and inflammatory-driven iron loading and retention [153, 154]. This is in line with the 
current evidence that NAFLD is both a metabolic and an inflammatory disease. Indeed, 
iron depletion is effective in the treatment of NASH, including improving hepatic 
enzymes and steatosis and reducing inflammation and oxidative stress [154]. 
 
1.6.5 Fibrosis 
 
Liver fibrosis is a complicated pathological process that leads to the destruction of 
hepatocytes and impairment of liver functions, and it is strongly associated with all-
cause or liver-related mortality in NASH [155]. It is another hallmark of advanced 
NASH where KCs induce inflammatory responses for the subsequent steps towards 
fibrosis. It has been shown that inflammatory cytokines secreted by KCs play a key role 
in fibrogenesis [156]. In fact, several drugs targeting ER stress, inflammation, oxidative 
stress and apoptosis may cause activated HSCs [6, 157]. 
 
At the cellular level, progression to NASH is associated with activated HSCs, the 
primary cells that drive the fibrogenic process [15]. Activation of HSCs leads to 
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increased secretion of fibrotic proteins, including TGFβ, collagen 1, alpha smooth 
muscle actin (α-SMA) and Smad signalling, and other extracellular matrix proteins 
causing the formation of scar tissue and fibrosis in the liver [158]. Several studies have 
shown that diet-induced HSCs activation increases these fibrotic cytokines, promoting 
the development of NASH fibrosis [159, 160]. 
 
The most commonly used model of liver fibrosis in experimental rodents is MCD diet 
[161]. The MCD mouse model represents the progression of NASH and the 
development of liver fibrosis. Rodents fed an MCD diet have significantly increased 
TG and ALT levels, indicators of steatosis and liver injury, respectively [120, 162]. 
TGFβ-1, α-SMA and type 1 collagen expression levels also increase among mice fed 
MCD diet for 8 weeks [14, 159]. 
 
Advanced fibrosis has become a central focus in clinical studies that address fibrosis 
and liver-related clinical endpoints in NASH, but the treatment remains the main 
challenge for scientists [155]. The only treatment available for NASH patients with 
fibrosis is liver transplantation—commonly used but unsatisfactory because of 
increased risk of disease recurrence after transplantation [163]. An antifibrotic drug that 
is safe, potent, bioavailable and specific to the liver is not yet available. Currently, 
several therapies are being scanned for their efficacy in the treatment of liver fibrosis 
via regulation of the activity of collagen deposition and HSCs in humans and animals 
[67, 157, 164]. 
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1.7 Cirrhosis and liver cancer 
 
NASH is a complex pattern of fatty liver disease in the absence of alcohol intake. It is 
one of the highest liver morbidity and mortality diseases worldwide with poor 
prognosis and progression of irreversible diseases such as HCC [165]. NASH is now 
recognised as the most common cause of cirrhosis and may progress to liver cancer 
[166]. Cirrhosis and liver cancer are characterised by the replacement of healthy liver 
tissue by scar tissue or cancer cells, respectively. The severity of the disease in humans 
differs depending on the liver biopsy and clinical and pathological severity. The recent 
increase in NASH and its impact on liver cirrhosis incidence highlight the need for 
effective screening and the development of drugs to halt liver disease progression in 
persons with NASH. A statistical study has revealed that approximately 10% to 29% of 
NASH advances to cirrhosis within 10 years [1]. In addition, it has been suggested that 
NASH significantly increases the incidence rate of HCC. A previous report has shown 
that patients with NASH cirrhosis are at roughly 2.6% increased risk of HCC [167]. 
 
NASH is significantly involved in the progression of cirrhosis and primary liver cancer 
[6]. Some patients suffer NASH-related cirrhosis and liver-related death [168]. Mice 
fed CDAA with carbon tetrachloride (CCl4) have been developed to help understand 
mechanisms of carcinogenesis in NASH [169]. It has been suggested that cirrhosis and 
cancer represent a late complication of NASH-related fibrosis because progressive 
fibrosis increases the risk of cirrhosis and HCC [6]. 
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1.8 Non-alcoholic steatohepatitis animal models 
 
Animal models of NASH have been used extensively and discussed in several reviews 
[120]. The ideal model of NASH should mimic the aetiology and histopathology of 
NASH in humans. However, there is no single animal model that can completely 
replicate this disease in humans. It is important to develop an animal model that mimics 
human disease with respect to disease pathogenesis. It has been recommended that at 
least two individual NASH models should be used for the assessment of anti-NASH 
drugs [170]. 
 
Hepatosteatosis and NASH stages have distinct histopathological features that differ 
from each other. For example, the hallmark of hepatosteatosis is an increase in fat 
droplets within hepatocytes without any damage to hepatocytes. The degree of steatosis 
varies, with mild (≤30%), moderate (31–60%) and severe (≥61%) in humans [10]. 
Conversely, liver NASH shows hepatocellular ballooning, with or without Mallory-
Denk bodies, accompanied by inflammation in the presence of macrosteatosis [6]. 
 
An NAFLD animal model has been a hot topic for scientists interested in NAFLD 
pathogenesis and treatment. Each of the NAFLD stages has distinctive 
histopathological features [6]. As mentioned earlier, hepatosteatosis is characterised 
histologically by excessive fat droplets within hepatocytes. As steatosis progresses to 
NASH, hepatocyte injury (ballooning and Mallory bodies), inflammation and collagen 
depositions develop. Thus, metabolic with inflammatory NASH models are highly 
applicable for preclinical drug testing in NASH [120]. 
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These two features are not always present in one animal model of NASH—that is, the 
presence of the metabolic syndrome features, including central obesity, 
hyperglycaemia, insulin resistance and hypertriglyceridaemia, together with the 
features of hepatic inflammation with or without fibrosis. Apparently, the selection of 
appropriate animal models is challenging because no rodent displays these features 
[120]. 
Some animal models currently used for NAFLD/NASH present only one stage, either 
hepatosteatosis or NASH. For example, HFD, high-fat high-carbohydrate (HFHC) and 
HFru-fed animal models are widely used to produce steatosis, as they have the hallmark 
features observed in humans with NAFLD, including obesity and insulin resistance. 
Other animal models have been developed for studying NASH pathogenesis, such as 
the MCD, CDAA and CCl4 models. 
 
The following section summarises currently used and recently developed animal 
models for NASH. 
 
HFD represents the modern Western diets, which directly lead to NAFLD and obesity. 
This can be replicated in animals fed HFD (containing approximately 45–75% fat, 47% 
carbohydrates and 18% protein) ad libitum. In HFD rat models, a diet of increased FAs 
(composed of more than 71% fat) caused hepatosteatosis-associated increased insulin 
level [121]. However, these animals do not usually show a significant increase in 
plasma level of ALT [80]. Hepatosteatosis, obesity, hyperglycaemia, insulin resistance 
and mitochondrial changes are also present in C57BL/6 mice fed HFD [171]. Similarly, 
male C57BL/6 mice fed HFD (45% fat, 35% carbohydrates and 20% protein) for 10 
weeks develop steatosis with minimal increases in gene expression levels of 
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inflammatory cytokines [172]. However, the degree of NASH appears to depend on the 
rodent strain and duration of HFD. Overall, HFD animal models represent 
hepatosteatosis related to the metabolic syndrome and hepatosteatosis. However, the 
inflammatory and fibrotic features are not displayed in most HFD animals; therefore, 
they are not considered a typical model of NASH. 
 
Food containing high levels of cholesterol is a major risk factor in the development of 
hepatic inflammation and progression of NASH in animals and humans. Several studies 
have suggested that dietary cholesterol increases lipid accumulation and inflammation 
in the liver of HFD-fed mice [80]. It has been suggested that addition of cholesterol 
(0.2%; #C75209, Sigma-Aldrich) to HFD can produce the NASH phenotype [173]. 
Similarly, rats fed the same diet do not show severe inflammation and fibrosis [174]. 
Atherogenic HFD accelerates the development of steatosis and inflammation after 
chronic feeding for 24 weeks [62]. Hepatosteatosis and liver injury (minimal fibrosis) 
may develop in mice fed a diet enriched with high-fructose corn syrup (HFHC-fed 
mice) [175]. 
 
One animal model of T2D has been fed HFD with a low dose of streptozotocin (STZ) 
injections for 5 consecutive days to partially damage the pancreatic β-cells [176-178]. 
T2D (HFD-STZ) mice display a significant increase in hyperglycaemia and TG content 
in the liver [88]. However, the HFD-STZ model of T2D only develops metabolic-
related NAFLD, not full-blown NASH. Most rodents fed HFD, HFru and HFHC 
represent hepatosteatosis [120]. However, inflammatory and fibrotic features are not 
displayed in most HFD animals; therefore, they are not considered typical models of 
NASH. 
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MCD diet is commonly used to produce NASH in animals. The diet is deficient in 
methionine and choline, which are essential proteins in regulating lipid secretion in the 
liver [162]. Mice fed MCD diet mimic the pathophysiology of NASH in humans but 
without the phenotype of metabolic syndrome [161]. The development of fibrosis may 
occur within 3 weeks of MCD feeding. MCD-induced inflammation is usually 
associated with an elevated plasma level of ALT [162]. Importantly, animals fed MCD 
diet do not develop obesity or insulin resistance, as in the metabolic profile of NASH in 
humans. However, it has been reported that mice lacking either leptin (ob/ob) or the 
long form of the leptin receptor (db/db) fed MCD exhibit NASH associated with 
metabolic abnormalities [123], and that HFD promotes NASH in these genetic animal 
models [120]. 
 
Genetic animal models have been widely used in the study of NAFLD/NASH and to 
identify novel drugs. Genetic models are associated with minor or major contexts of the 
metabolic syndrome. Animals with a spontaneous truncating mutation, such as acyl-
CoA oxidase null (ACOX−/−), methionine adenosyltransferase (MAT)-1A knockout 
(MATO mice) and liver-specific pten deletion, exhibit severe steatosis associated with 
inflammatory infiltration. However, these mice do not show features of the metabolic 
syndrome. Conversely, ob/ob or db/db mice are steatotic and morbidly obese because 
of hyperphagia but do not display typical characteristics of NASH. Secondary insults 
such as LPS and MCD may induce steatohepatitis with severe fibrosis, but this depends 
on mice strain. The liver of HFD-fed foz/foz C57BL6/J mice shows severe 
inflammation and fibrosis compared with non-diabetic foz/foz BALB/c mice [179]. 
Another genetic model used for lipodystrophy-associated steatohepatitis is called 
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SREBP1c transgenic mouse [120]. This model develops steatosis, inflammation and 
fibrosis where serum leptin levels are usually increased. 
 
A number of environmental factors promote the pathogenesis of NASH. As mentioned 
earlier, excess exogenous fat, increased endogenous fat and decreased lipid secretion 
are the main sources of hepatic lipid accumulation. Animal models produced by these 
three components generally resemble human NAFLD. Firstly, mice fed HFD represent 
hepatosteatosis related to obesity. Secondly, increased endogenous fat defined as DNL 
is observed in mice fed HFru diet, as previously explained in Section 1.6.2. However, 
these two models do not exhibit severe inflammation, hepatocyte injury and fibrosis, as 
occur in humans. Finally, mice fed MCD diet exhibit decreased lipid secretion and 
impaired TG excretion. These mice have become the most commonly used model for 
NASH despite the lack of the phenotype of the metabolic syndrome. 
 
Prevention or treatment of NASH in humans remains a big challenge. Dedicated efforts 
are necessary to develop an appropriate treatment that is able to improve NASH with 
hepatoprotective and metabolically favourable advantages. Animal models that 
recapitulate NASH in humans are important for the evaluation of potential therapeutic 
agents for the treatment of NASH. 
 
In summary, there is no optimal NASH animal model at present. To determine 
pathogenic mechanisms of the transition from hepatosteatosis to steatohepatitis, 
different animal models are required. The table summarises rodent models for NAFLD 
and NASH reported in the literature (Table 1.5). 
  
 Chapter One - Introduction and Literature Review  
49 
Table ‎1.5  Current rodent models of NASH 
Manipulation Model Metabolic 
syndrome 
Steatosis NASH Fibrosis Characteristics 
Dietary High-fat diet (HFD) Yes  Yes  Yes  No Modern Western diet, depends on rodent 
strain and feeding duration, long-term 
feeding, not considered a NASH model 
 HF + cholesterol Yes Yes  Yes  No Atherogenic diet, depends on the amount of 
cholesterol and cholate, insulin sensitive, no 
significant fibrosis 
 HFD + streptozotocin 
(HFD-STZ) 
Yes Yes No No Type 2 diabetes model, does not induce 
inflammatory NASH 
 High-fructose (HFru) 
diet 
Yes Yes No No Liver injury may develop, no inflammation, 
not good model for NASH 
 Methionine- and 
choline-deficient 
(MCD) diet 
No Yes Yes Yes Mimics pathological NASH in humans, 
appropriate model for studying inflammation 
and fibrosis in NASH, no metabolic profile of 
NASH in humans 
 Choline-deficient diet 
(CDD) 
No No Yes Yes Depends on time of feeding, metabolic 
alterations in Wistar rats 
 Carbon tetrachloride 
(CCl4) 
No Yes Yes Yes Short-term fibrosis, toxic and high mortality 
Genetic ob/ob, db/db mice Yes Yes Yes No db/db mice have a defect in leptin signalling, 
ob/ob mice have a non-functional leptin gene, 
good models for NAFLD, human metabolic 
syndrome features, poor models for NASH 
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Manipulation Model Metabolic 
Syndrome 
Steatosis NASH Fibrosis Characteristics 
 foz/foz mice Yes Yes  Yes  No Alms1 gene mutation, metabolic syndrome 
profile, poor model for NASH 
 SREBP1c transgenic 
mice 
Yes Yes  Yes Yes Congenital lipodystrophy mouse model, long-
term feeding to develop NASH, severe IR, 
decreased adiposity 
 KK-A
y
 mice Yes Yes No No Loss of melanocortin, MCD diet is a second 
hit required to develop NASH 
 PPARα knockout 
mice 
No  Yes  No No PPARα gene homozygous mutation, steatosis 
in starved state 
 ACOX null mice No Yes Yes No Defective peroxisomal β-oxidation of LCFAs, 
mice develop HCC 
 Zucker fatty rats Yes Yes Yes  No Do not spontaneously develop steatohepatitis, 
resistant to liver fibrosis 
 Otsuka Long-Evans 
Tokushima fatty rats 
Yes Yes No No A model for the metabolic syndrome with 
diabetes, not a suitable model for NASH 
 Prague hereditary 
hypercholesterolaemic 
rats 
Yes Yes No No A model for polygenic 
hypercholesterolaemia, comparable to human 
disease 
 MAT-1A null 
(MATO) mice 
No Yes Yes Yes Methionine adenosyltransferase-1A mutation, 
no metabolic syndrome (rare IR) 
NASH, non-alcoholic steatohepatitis; IR, insulin resistance; HCC, hepatocellular carcinoma. Based on Lau JK. et al, Journal of Pathology, 
2017 [179]. Santhekadur PK. et al, Journal of Hepatology, 2018 [120]. 
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1.9 Current treatments of NASH 
 
NAFLD is the most common liver disease in developed countries, leading to an 
emerging public health crisis that may progress to a more serious situation. Persistent 
NASH leads to cirrhosis or HCC and is a leading cause of liver transplantation. While 
NASH is reversible, untreated NASH and transition to advanced stages of cirrhosis are 
difficult to reverse in most cases. Therefore, NASH is a critical stage in NAFLD broad 
spectrum of diseases and effective treatment that may halt its transition will be of great 
benefit for the control of fatty liver disease. 
 
To date, there is no approved specific drug for NAFLD or NASH. There is rapid 
progress in identification of new therapies, and the development of NASH repurposing 
of currently available drugs is an effective means for the development of new drugs for 
NASH. Treatment of NAFLD is especially important because this can prevent the 
progression to NASH. 
 
Patients with NAFLD and NASH need an effective treatment that can reverse 
hepatosteatosis development and prevent the progression of NASH. Unfortunately, 
treatments of the metabolic syndrome are not effective for the treatment of NASH [67]. 
The lack of non-invasive markers to assess steatosis, liver damage, inflammation and 
fibrosis is also a barrier for developing effective treatments [180]. As NASH results 
from complex pathophysiological processes, therapeutic treatments are likely to include 
a wide array of drugs targeting different mechanisms. Figure 1.7 illustrates the major 
approaches for these mechanisms. Current treatments for NAFLD include reducing the 
risk factors that may cause the disease, such as obesity, prediabetes or diabetes and high 
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cholesterol or TG. Multiple pharmacological agents have been investigated in several 
studies for the treatment of this disease. 
 
 
 
Figure ‎1.7 Pathways representing possible targets for the treatment of NAFLD.  
Understanding the pathogenesis of NAFLD and progression of NASH helps develop 
effective treatments that target different pathological pathways leading to different 
stages of NAFLD. 
 
The current management of NAFLD includes lifestyle interventions and drug therapy. 
Introduction of lifestyle changes including dietary intervention, increased physical 
activity and reduced weight is usually recommended first for the management of 
NAFLD. However, it is intended to support the treatment of not only NAFLD but also 
diseases associated with obesity, insulin resistance, diabetes and dyslipidaemia. 
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Apart from the above-mentioned lifestyle interventions, some drugs have been 
considered, including those listed in Table 1.6. These include insulin sensitisers 
(metformin, troglitazone, rosiglitazone and pioglitazone), lipid-lowering agents 
(statins), antioxidants (Vitamin E and C), hepatoprotective agents (betaine, 
ursodeoxycholic acid and pentoxifylline) and angiotensin-converting enzyme 
inhibitors. However, none of these drugs is effective for NASH. Therefore, this thesis 
aims to investigate the potential use of Mtr for the treatment of NASH. 
 
 Chapter One - Introduction and Literature Review  
54 
Table ‎1.6 Summary of currently drugs used for the treatments of NAFLD/NASH 
Target/Mode of action Example of drugs Hepatosteatosis  Inflammation Fibrosis  Adverse events and concerns 
Weight loss therapies Loss of body weight  Yes  No No 
 
 Hard to achieve and poor compliance 
Liver histology remains unknown 
Anti-metabolic Metformin Yes No No  No effect on liver histology 
Rosiglitazone and 
Pioglitazone 
Yes No No  Weight gain, heart disease 
No effect on inflammation and fibrosis 
Ursodeoxycholic Acid Yes No No  No effect on inflammation and fibrosis 
Antioxidant Vitamin E Yes Yes No  No effect on hepatic fibrosis 
Prostate cancer 
Anti-inflammatory Pentoxifylline No Yes No  No effect on lipid profile 
Amlexanox No Yes No  Safety but require more data 
Cenicriviroc No Yes No  Insufficient data for safety and efficacy 
Antifibrotic Galectin-3 inhibitor  No Yes Yes  Require long-term outcomes 
Simtuzumab No Yes Yes  Ineffective in reducing fibrosis 
Selonsertib No Yes Yes  Require long-term outcomes 
Based on Sanyal, A. J. et al, The New England Journal of Medicine, 2010 [181] and Sumida, Y. et al, Journal of Gastroenterology, 2018 [67]. 
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Despite increasing development of new drugs to keep up with the increasing incidence 
of NAFLD, there remains an urgent need to identify novel drugs with improved 
efficacy and fewer side effects for the treatment of NASH. 
 
1.10 Identification of matrine as a potential new drug for 
non-alcoholic steatohepatitis 
 
In searching for a new therapeutic treatment for NASH, we have taken the approach of 
repurposing existing drugs for this condition [182]. The main advantage of drug 
repurposing is safety in humans because these existing drugs have been used without 
major side effects [182]. A second important advantage is reduction of the duration, 
risk and cost involved in the drug development pipeline to the clinic and the drug 
regimens [183]. 
 
Several lines of evidence suggest that Mtr may be repurposed for the treatment of 
NASH. Mtr is a small molecule (Figure 1.8), easy to absorb orally and can be scaled 
up. As reviewed by Liu et al., Mtr is a safe drug for the treatment of chronic viral 
infections and tumours in the liver [184]. Another study has shown that high 
concentrations of Mtr may lead to cytotoxicity of human hepatocytes; however, low 
concentrations of Mtr have no severe side effects [185]. Moreover, Mtr may prevent 
progression of HCC via inhibiting overexpression of MMP-9 by reduction of the 
nuclear factor kappa beta (NF-κB) signalling pathways [186]. Mtr has a different 
chemical structure and plasma protein binding from other drugs including metformin, 
which has no effects on TG level, glucose tolerance, lipogenic protein levels (ACC and 
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FAS), and protein expression or activity of energy metabolism markers. Recently, Zeng 
and colleagues have found that Mtr is able to reduce hepatosteatosis and glucose 
intolerance in HFD-fed mice. This study has also revealed that the antisteatotic effect of 
Mtr is associated with upregulation of HSP72 in the liver, suggesting a unique 
mechanism underlying Mtr’s effect [172]. 
 
Figure ‎1.8 The chemical structure of matrine.  
Mtr is likely to work at different mechanistic levels to reduce 
hepatosteatosis and reverse metabolic dysfunction. It is 
noteworthy to study the benefits of Mtr in the reversal of 
hepatic fibrosis and reduction in the progression of NASH. 
 
1.10.1 Reported effects of matrine on inflammation 
 
As reviewed previously, hepatic inflammation is one of the major hallmarks of NASH. 
An early study has shown that Mtr suppresses LPS-induced production of inflammatory 
cytokines, suggesting Mtr might be an anti-inflammatory drug [187]. Mtr has been 
shown to inhibit TNFα, IL-6 and NF-κB activation in vivo and in vitro. Consistent with 
the anti-inflammatory effects of Mtr in BALB/c mice, Mtr significantly reduces the 
inflammatory gene expression levels in the liver of HFD C57BL/6J mice [172]. Mtr 
treatment has also been shown to decrease virus-induced TNFα expression and the 
nuclear translocation of p65 NFκB [188]. 
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1.10.2 Reported effects of matrine on fibrosis 
 
Liver fibrosis leads to the destruction of hepatocytes and impairment of liver functions 
and is strongly associated with all-cause or liver-related mortality in NASH [155]. Mtr 
has been shown to inhibit the activation of HSCs, which play a central role in liver 
fibrogenesis [189]. The antifibrotic effect of Mtr has been proven in CCL4-induced 
fibrosis in a rat model by attenuating TGFβ and collagen synthesis. 
 
1.10.3 Heat shock protein as putative targets for matrine 
 
Heat shock proteins (HSPs) are chaperone proteins modified by heat shock response 
(HSR) to protect the organism against physiological and environmental stresses [190]. 
HSPs are known to prevent protein aggregation and refolding of damaged proteins 
through proteasomes, autophagy or protein degradation [191]. HSP90 HSF1 and 
HSP70 (stress inducible form is HSP72) have been suggested to modulate inflammation 
[192]. Physiological stress and heat shock activate HSF1 by dissociating it from HSP90 
[193]. This allows HSF1 to translocate into the nucleus and transactivate the expression 
of HSP72. HSP72 is highly inducible and its upregulation has been shown to correlate 
with attenuation of diabetes, obesity and NAFLD [194]. We have chosen to focus on 
HSPs because they are ubiquitous chaperone proteins existing in prokaryotes and 
eukaryotes and they play a major role in inflammatory diseases. 
 
HSP72 is abundantly expressed in the liver under normal conditions [195]. A reduction 
in HSP72 has been seen in the muscle of T2D patients [192]. It has also been 
demonstrated that loss of function of anti-inflammatory HSP70 may increase the 
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progressive liver inflammation influence of NASH [194]. It is possible that HSP72 
expression has a critical role in blocking hepatic inflammation and KCs activation. 
 
The correlation between the progression of NASH and expression of HSPs in the liver 
has been clearly demonstrated [194]. It has been revealed that activation of KCs and 
production of inflammatory cytokines may result in downregulated expression of 
HSP72. In contrast, upregulation of HSP72 improves insulin sensitivity and 
inflammation contributing to insulin resistance and obesity [196]. In humans, there is a 
significant reduction in HSP72 in the liver paralleled by inflammatory cells that 
promote NAFLD development and the progression of NASH [194]. Overexpression of 
HSP72 in mice prevents HFD-induced JNK phosphorylation and impaired insulin 
signalling [196]. Consistent with this, another study has suggested that increased 
hepatic HSP72 results in reductions in glucose intolerance and plasma insulin level, 
hepatic TG content and adiposity in HFD-induced hepatosteatosis mice [172]. 
 
The anti-inflammatory HSP72 pathway has been revealed in many cellular activities 
and is expressed at low level under metabolic disease states [197]. Overexpression of 
HSPs is sufficient to inhibit LPS-induced TNFα, IL-1β, IL-6 and IL-12 response in the 
liver [198]. Overexpression of HSP90, a negative regulator of HSP72, increases the 
activity of hepatitis B virus [192]. Interestingly, HSP72 is involved in the pathogenesis 
of NASH. Reduction of HSP72 paralleled by similar reductions in HSF1 in KCs may 
contribute to NAFLD progression and associated ballooned hepatocytes in NASH [194, 
199]. Studying the link between compounds and HSP72 is essential to understand how 
this association can prevent inflammation. Importantly, docking simulation technique 
has confirmed that there is a strong association between Mtr and HSP72. Further study 
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suggests that Mtr treatment improves HFD-induced hepatosteatosis in mice, at least in 
part by upregulating the expression of HSP72 in the liver [172]. 
 
As discussed in Section 1.6.4, Mtr is one of the oldest drugs used to treat inflammation, 
and has been proposed as a possible anti-inflammatory drug [182]. This proof-of-
principle study reports the potential efficacy of Mtr for the treatment of hepatic 
inflammation [200] via HSP72 [172, 201]. 
 
1.11 Summary, study aims and hypothesis 
 
This review was conducted to identify gaps in the current literature and the aims of this 
thesis were suggested. Subsequent studies were dedicated to investigate the therapeutic 
efficacy and underlying molecular mechanisms of Mtr in this disease. 
 
NAFLD is the most common chronic liver disease, affecting one-third of people 
globally (Section 1.3.1) with a high rate of progression to NASH (Section 1.6) and 
serious complications (Section 1.7). Although in vitro and animal models have been 
developed, and may be appropriate as preclinical models of NASH, there is no single 
animal model that can fully resemble metabolic NASH in humans (Section 1.8). 
Different animal models are therefore needed for the proper evaluation of new 
therapeutics for NASH. While several drugs have been considered for the control of 
NAFLD and the progression of NASH (Section 1.9), none of them satisfy the 
requirements for the treatment of this serious condition. In the quest to find an effective 
and safe treatment for NAFLD and its progressive form, Mtr was selected for the 
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investigation in this thesis on the basis of its reported pharmacological properties and 
safety. 
 
Therefore, the overall purpose of this thesis was to investigate the therapeutic effects 
and mechanisms of Mtr for the treatment of NAFLD and NASH. To address this 
objective, three specific aims were designed as follows: 
 
Aim 1: To investigate the effects of Mtr on lipogenesis-induced hepatosteatosis and 
associated disorders in glucose homeostasis (Chapter 3). 
 
Aim 2: To investigate the effects of Mtr on NASH associated with inflammation and 
fibrosis in MCD-fed mice (Chapter 4). 
 
Aim 3: To investigate the mechanisms involved in the therapeutic effect of Mtr in 
NAFLD/NASH (Chapters 3 and 4) including HSP72 and the role of macrophages in 
LPS-stimulated inflammation (Chapter 5). 
 
The working hypothesis was as follows: Mtr can alleviate hepatic steatosis, 
inflammation, injury and fibrosis by mechanisms involving HSP72 and the inhibition of 
inflammation. 
 
The overall design of the studies for these aims is illustrated below. The results from 
these studies are likely to provide new insight into the therapeutic effects of Mtr in the 
development of NAFLD and progression of NASH. The findings may help decide 
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whether Mtr is a promising new drug for the treatment of NAFLD, particularly of 
NASH. 
 
 
Figure ‎1.9 Schematic view of the research aims. 
 
 
  
Chapter 2 Research Design and 
Methodology
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2.1 Introduction 
 
This section presents all the common methods and techniques used for the studies presented 
in Chapters 3, 4 and5. Special methods and techniques for a particular study are described 
separately in corresponding Chapters.  
 
2.2 Rodent models 
 
The Animal Ethics Committee of RMIT University approved all experimental procedures 
(AEC #1012 and #1415) in accordance with the National Health and Medical Research 
Council of Australia Guidelines on Animal Experimentation [202, 203]. 
 
All animal studies were conducted in male C57BL/6J mice (10 week old and weight 22-25 g) 
that were purchased from the Animal Resources Centre (Perth, Australia). The animals were 
kept in a temperature-controlled room (22 ± 1°C) on a 12-h light/dark cycle. Before any 
procedure was performed, mice were first allowed to acclimatize for at least one week while 
they were fed ad libitum with a standard normal chow diet. The standard chow diet (CH; 
Meat Mouse Diet) was purchased from Specialty Feeds, Western Australia. It contains 12% 
calories from fat, 23% from protein, and 65% from carbohydrate. The digestible energy in 
this diet is 3.34 kcal/kg. 
 
The study animal models were undertaken separately for each animal model Chapter. The 
number, group and statistical analysis were determined for each model to address the specific 
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research questions on the hypotheses. Three animal models design including high fructose, 
HFD-STZ and MCD mice models were demonstrated in Chapter 3 and 4 respectively. 
 
2.3 Measurement of plasma and tissue parameters 
 
Blood samples were collected using heparinized capillary tubes (SteriHealth Laboratory 
Products, Australia) to prevent clotting. Blood samples were collected from the tail tip and 
then immediately mixed with the same volume of saline and stored on ice. Plasma separated 
by centrifugation (13,000 RPM for 1 min) was transferred to a new Eppendorf tube and 
stored at -80°C for subsequent measurements. 
 
Mice were killed by cervical dislocation and liver samples were immediately freeze-clamped 
and stored in -80°C. Next, freeze-clamped liver tissue were weighed and placed in different 
sets of Eppendorf tubes depend on the experimental requirements; such as western blotting 
set for 30 and 20 mg of liver tissue for western blotting and RT-PCR technique, respectively.  
 
2.4 Glucose determination 
 
The body weight of mice was measured in the afternoon one day before the glucose tolerance 
test (GTT) for the calculation of glucose loads. On the day of GTT, food removed from mice 
cages for 5-7 hours before glucose was injected i.p. at a dose indicated in each study. Blood 
glucose levels were analysed at described time (0, 15, 30, 60 and 90 min) points for the 
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measurement of blood glucose using an Accu-Chek glucometer (Roche Diagnostics, 
Australia). The absolute volumes used were depended on the experimental requirements. 
 
2.5 Extraction and determination of tissue triglyceride  
 
The triglyceride level in plasma and liver extracts were determined by a Peridochrom 
triglyceride GPO-PAP kit (Roche Diagnostics), according to the manufacturer’s instructions 
(Roche Diagnostic, Australia). Triglyceride reagent (300 μl) added to all plasma samples (5 
μl), and then incubated at 37°C for 10 min. A FlexStation microplate reader (Molecular 
Devices, USA) was used for reading the absorbance on microtiter plate at 485 nm. A standard 
curve was created using internal standards (glycerol solution, 0.21 mg/ml, Roche, Catalogue 
No.166588). 
 
With regard to measuring liver triglyceride, liver samples were immediately freeze-clamped 
and stored in -80°C after mice were killed by cervical dislocation. Triglyceride extraction 
started with a pre-weighed sample of tissue (30 mg liver). Liver tissue was homogenised in 2 
ml of chloroform/methanol (2:1) using a glass homogeniser. After transferring the 
homogenate to a clean 15 ml tube, the homogeniser was rinsed with another 2 ml of 
chloroform/methanol (2:1) and added to the homogenate. To ensure the complete 
solubilisation of the triglyceride, the tubes were tightly capped and rotated at room 
temperature overnight. A sodium chloride (0.6% NaCl, 2 ml) was added to the tubes followed 
by centrifugation at 2,000 RPM for 10 min to separate the aqueous from the organic phases. 
The lower chloroform layer contained triglycerides was carefully extracted and then 
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transferred into a glass vial and dried completely under air at 45°C. An absolute ethanol (500 
μl) dissolved in the extract and then triglyceride concentration was determined by a 
Peridochrom triglyceride GPO-PAP reagent (Roche Diagnostics, Catalogue No. 11730711). 
 
2.6 Protein quantification 
 
Protein concentrations were determined through use of commercially available colorimetric 
bicinchoninic acid (BCA) protein kit (Sigma-Aldrich, #B9643). Usually, 1 µl tissue lysate 
was added to 19 µl dH2O to dilute lysate, then 200 µl BCA reagent mix (50 parts reagent A 
to 1 parts reagent B) was added to detect concentration of protein in the each sample. 
Solutions were mixed and incubated at 37°C for 30 mins prior to the determination of 
absorbance by spectrophotometry at 562 nm using a Polarstar Optima microplate reader 
(BMG Lab Technologies, Germany). In every BCA assay, varying dilutions of BSA protein 
were included to create a standard curve between the ranges of 0 µg/ml to 2.0 µg/ml
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2.7 Western Blotting 
 
2.7.1 Reagents / Buffers  
 
The table below showed the main buffers and solution used in western blotting technique. 
 
Table ‎2.1 The preparation of western blotting reagents and buffers  
Name Preparation 
RIPA buffer 65 mM Trizma® base (Tris, Sigma-Aldrich, #T1503), 150 mM NaCl, 5mM EDTA, 1% Nonide-P 40 Substitute (NP-
40, Sigma-Aldrich, #74385), 0.05% Sodium-deoxycholate (Sigma-Aldrich, #D6750), 0.1% (w/v) Sodium dodecyl 
sulphate (SDS, Sigma-Aldrich, #L4390), 10% Glycerol (Sigma-Aldrich, #49770), pH 7.5 and stored at 4°C 
Lysis buffer 10 mM Sodium fluoride (NaF, Sigma-Aldrich, #S7920), 1 mM Sodium orthovanadate (Na3VO4, Sigma-Aldrich, 
#S6508), 1 mM Phenylmethanesulfonyl fluoride (PMSF, dissolved in 100% Ethanol, Sigma-Aldrich, #78830), and 
10 µl/ml Protease/Phosphatase inhibitor (Sigma-Aldrich, #P5726) in RIPA buffer 
4xLaemmli’s 
buffer (100ml) 
8.2 g SDS, 40ml Glycerol, 50 ml 0.5 M Tris, 500 µl 1% Bromo-phenol blue (Sigma-Aldrich, #114391) in dH2O, pH 
6.8 and stored at -20°C. Before use, added 6.2 mg DL-Dithiothreitol (DTT, Sigma-Aldrich, #D9779)  
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Name Preparation 
Running gel 1.5 M Tris Buffer (pH 8.8), 30% Acrylamide/Bis-acrylamide (Sigma-Aldrich, #A3574), 10% (w/v) SDS, dH2O, 
10% Ammonium persulfate (APS, Sigma-Aldrich, #A9164), Tetramethylethylene diamine (TEMED, Sigma-
Aldrich, #T9281) 
Stacking gel 0.5 M Tris Buffer (pH 6.8), 30% Acrylamide/Bis-acrylamide, 10% (w/v) SDS, dH2O, 10% APS and TEMED 
10x Running 
buffer (1L) 
30 g Tris, 144 g Glycine (Sigma-Aldrich, #G8898) and 10 g SDS in dH2O, pH 8.8 and stored at room temperature 
10x Transfer 
buffer (1L) 
30 g Tris, 144 g Glycine in dH2O and stored at room temperature 
10x TBS (1L) 24.2 g Tris and 80 g NaCl in dH2O, pH 7.6 and stored at room temperature 
1x TBS-Tween 
(TBST, 1L) 
100 ml 10x TBS buffer and 500 µl Tween® 20 (Sigma-Aldrich, #P9416) in 900 ml dH2O and stored at room 
temperature 
Blocking buffer 3% (g/100ml) Bovine Serum Albumin (BSA, Sigma-Aldrich, #A9418) in 1x TBST and stored at 4°C 
Stripping buffer 
(1L) 
6.25% 1 M Tris-HCl (pH 6.7), 10% (w/v) 20% SDS in dH2O and stored at room temperature. Added 100 mM 2-
Mercaptoethanol (Sigma-Aldrich, #M7154) before use 
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2.7.2 Sample preparation 
 
Tissue samples were homogenized with a pestle mixer in an ice-cold RIPA buffer 
containing 10 μL/mL protease inhibitor cocktail (Sigma-Aldrich, #9599), 10 μL/mL 
phosphatase inhibitor cocktail (Sigma-Aldrich, #P5726), 10 mM NaF (Sigma-Aldrich, 
#S7920), 1 mM Na3VO4 (Sigma-Aldrich, #450243) and 1 mM phenylmethanesulfonyl 
fluoride (Sigma-Aldrich, #78830). Tissue lysates were then centrifuged at a speed of 
20,000 × g for 15 minutes at 4°C. The protein concentrations in the supernatant were 
determined by bicinchoninic acid assay (Sigma-Aldrich, #B9643). Protein samples 
were then diluted with water and mixed with 4× Laemmli buffer together with 1 mM 
DTT. Finally, samples were boiled at 95°C for 5 minutes to denature the protein.  
 
2.7.3 PAGE gels preparation 
 
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) is a 
standard technique used for separating proteins according to their molecular weight. 
 
Table ‎2.2 Recommended Polyacrylamide % for Separation in Denaturing Gels 
Protein size (kDa) Gel percentage (%) 
25-200 8% 
15-100 10% 
10-70 12% 
4-50 14% 
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Table ‎2.3 Composition of running gel and stacking gel 
          Running Gel (in ml) (for two gels)                                 
   # Solution 8% 10% 12% 14% 
1 1.5M Tris Buffer, pH 8.8 5 5 5 5 
2 30% Acrylamide/Bis-acrylamide 5.3 6.7 8.0 9.3 
3 10% SDS 0.2 0.2 0.2 0.2 
4 dH2O 9.5 8.1 6.8 5.5 
5 10% APS 0.2 0.2 0.2 0.2 
6 TEMED 0.02 0.02 0.02 0.02 
 
           Stacking Gel (for two gels)                       ml             
1 0.5M Tris Buffer, pH 6.8 1.25 
2 30% Acrylamide/Bis-acrylamide 1.7 
3 10% SDS 0.1 
4 dH2O 7.0 
5 10% APS 0.1 
6 TEMED 0.02 
 
 
2.7.4 Immunoblotting 
 
Following the gel preparation, the denatured protein samples (20 μg/well) and standard 
protein ladders (5 μL/well, Bio-Rad, #161-0374) were loaded to the gel and separated 
at 120 V until the protein ladder above or below the protein of interest were well 
separated. Subsequently, proteins in the gel were transferred to the PVDF membrane 
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(Bio-Rad, #162-0177) in a transfer buffer at 100 V for 2 h. The PVDF membrane was 
incubated in 3% BSA (in TBST buffer, Sigma-Aldrich, #A9418) at room temperature 
for 1 h to block the non-specific binding and then incubated with the primary antibody 
overnight at 4ºC. After 1 h of wash in TBST, the membrane was incubated in the 
horseradish peroxidase conjugate secondary antibody (Santa Cruz, #sc-2004 for rabbit, 
#sc-2005 for mouse) and followed by 1 h of wash in TBST. Enhanced chemilumescent 
(Perkin Elmer, #NEL113001EA) was used for the detection. Densitometric analysis 
was performed using Image Lab software 5.0 (Bio-Rad Laboratories). The primary 
antibodies are listed in Table 2.4. Antibodies from Cell Signaling and Abcam were 
diluted 1:1000 and these from Santa Cruz were diluted 1:500, with a TBST buffer 
containing 1% BSA, 0.02% sodium azide (Sigma-Aldrich, #71289) and 0.0025% 
phenol red (Sigma-Aldrich, #32661). The bound antibody was detected using a 
chemiluminescence system with western lighting ultra solution (Perkin Elmer, 
#NEL113001EA). The membranes were exposed in a ChemiDoc (Bio-Rad 
LaboratoriesInc., USA) for images capturing for a sufficient time. Densitometry 
analysis was performed using Image Lab (version 4.1; Bio-Rad Laboratories, Hercules, 
CA, USA) [45, 88]. 
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2.7.5 Antibody list 
 
Table ‎2.4 list of common antibodies 
Pathway Name Supplier Catalogue No. 
Lipolysis SREBP1c   
ChEBP   
ACC Cell signaling  3662 
SCD1   
FAS   
ER stress eIF2α Cell signaling 9722 
CHOP Santa cruz  sc-793 
IRE1 Abcam  ab37073 
Inflammation NLRP3 
MCP-1 
AdipoGen 
Cell signaling 
20B-0006-C100 
2027 
Fibrosi TGFβ   
Cell signaling 
Santa cruz 
3709 
Smad3 
Caspase-1 
5678 
G2914 
Loading control GAPDH Cell signaling  2118 
Tubulin 3873 
 
2.8 Real-time quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) 
 
2.8.1 Isolation of RNA from mice  
 
Liver tissues (20-30mg) were homogenised in 1 ml TRIZOL® reagent (Invitrogen, 
Catalogue No.15596026). The homogenate was mixed with 200 μl of Chloroform 
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(VWR, Catalogue No.22711324) by inverting several times, and incubated at room 
temperature for 5 min. The homogenates were subsequently centrifuged at 13,000 rpm 
for 15 min at 4°C. The upper aqueous phase containing RNA was collected and mixed 
with 500 μl of isopropanol (Sigma-Aldrich, Catalogue No.I9516). After another 
centrifugation at 13,000 rpm for 20 min at 4°C, the supernatant was removed. The 
remaining RNA precipitate was washed twice with 500 μl 75% ethanol with vortex. 
The ethanol was removed by centrifugation at 13,000 rpm for 5 min at 4°C. The air-
dried RNA pellet was dissolved in 100 μl of DEPC-treated water (Invitrogen, 
Catalogue No.AM9916) for the measurement of RNA concentration. 
 
2.8.2 Measurement of RNA concentration  
 
The liver RNA purity and concentrations were assessed using a NanoDrop 
Spectrophotometer (Eppendorf Thermo Scientific, Australia) at the absorbance of 260 
and 280 nm, with DEPC water as a blank. Each RNA sample (1.0 µl) was loaded onto 
the sampling platform for the measurement of RNA concentration. The absorption ratio 
of 260/280 nm is used to assess the purity of RNA samples (Ratio should be between 
1.8 and 2.0).  
 
2.8.3 Complimentary DNA synthesis by reverse transcription 
 
Complimentary DNA synthesis by reverse transcription Purified RNA with known 
concentrations was used to generate the complementary DNA (cDNA) using a Reverse 
Transcription System (Bio-Rad Laboratories Inc., USA) with random primers 
according to the manufacturer’s instructions. The RNA concentration of each sample 
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was normalised to 1 μg/8 μl with DEPC water on ice. To remove DNA contamination, 
1 μg of RNA was mixed with 2 μl of DNase I (Invitrogen, Catalogue No.18068-015), 
and incubated at room temperature for 15 min. After the removal of DNA, 1 μl of 25 
mM EDTA was added and incubated for 10 min at 65°C to inactivate DNase I. The 
purified RNA (2 μl) was reverse transcribed using a high capacity cDNA reverse 
transcription kit (Life Technologies, Catalogue No. 4374967) (2 μl of reverse 
transcription buffer, 0.8 μl of dNTP mix, 2 μl of random primers, 1 μl of reverse 
transcriptase and 12.2 μl of DEPC water). Reverse transcription polymerase chain 
reaction was carried out using the following steps: equilibrated at 25°C for 10 min, 
37°C for 2 hr, 85°C for 5 sec, and finally maintained at 4°C. The cDNA products from 
reverse transcription reactions were stored at 4°C to use for RT-PCR analysis. 
 
2.8.4 Real-time polymerase chain reaction  
 
The cDNA samples were analysed for genes of interest by RT-PCR using the SYBR 
Green RT-PCR system (Bio-Rad Laboratories Inc., USA). A reaction master mixture 
(1x IQ SYBR Green Supermix (Bio-Rad Laboratories Inc., USA; Catalogue No.170-
8882), 500 nM forward primers and 500 nM reverse primers, DEPC water to a final 
volume of 24 μl) for each gene of interest was prepared and added to each 1 μl cDNA 
sample in a sterile 96-well plate. The plate was placed in a controlled-temperature heat 
block equilibrated at 50°C for 2 min, 95°C for 3 min and 40-50 cycles of 95°C for 15 
seconds, 72°C for 30 seconds. The gene expression from each sample was analysed in 
duplicates and normalised against the ribosomal housekeeper gene 18S (GeneWorks, 
Australia). All reactions were performed on the iQTM 5 RT-PCR Detection System 
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(Bio-Rad Laboratories Inc., USA). The results are expressed as relative gene expression 
using the ΔCt method. Primers used for specific genes are in Table 2.5. 
 
Table ‎2.5 Primer sequences for measurements of gene expressions 
Gene Primer Sequences 
18S Forward: 5’-CGCCGCTAGAGGTGAAATTCT-3’ 
Reversed: 5’-CGAACCTCCGACTTTCGTTCT-3’ 
TNFα Forward: 5’-CACAAGATGCTGGGACAGTGA-3’ 
Reversed: 5’-TCCTTGATGGTGGTGCATGA-3’ 
IL1β Forward: 5’-GACGGCACACCCACCCT-3’ 
Reversed: 5’-AAACCGTTTTTCCATCTTCTTT-3’ 
IL6 Forward: 5’-ATTCCAGAAACCGCTATGAAGTTC-3’ 
Reversed: 5’-GTCACCAGCATCAGTCCCAA-3’ 
CD68 Forward: 5’-TGACCTGCTCTCTCTAAGGCTACA-3’ 
Reversed: 5’-TCACGGTTGCAAGAGAAACAT G-3’ 
Collagen 1 Forward: 5’-CTGCTGGTGAGAGAGGTGAAC-3 
Reversed: 5’-ACCAAGGTCTCCAGGAACAC-3 
Each Chapter has designed with measuring specific and interest gene for diagnosis. 
 
2.9 Statistical analysis 
 
Throughout the thesis, results are presented as means ± SEM. For the comparison of 
only two groups, a Student’s t test was used. One-way analysis of variance was used to 
assess the statistical significance across all groups. When significant differences were 
found, the Tukey-Kramer multiple comparisons post-hoc test was used to establish 
differences between groups. Differences at P ≤ 0.05 were considered to be statistically 
significant and P ≤ 0.01 were considered to be highly significant. 
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3.1 Introduction 
 
The liver plays an important role in regulating whole-body lipid metabolism and 
glucose homeostasis. Excess accumulation of lipids (namely hepatosteatosis), either 
from endogenous DNL and/or influx of exogenous FAs, can disturb glucose 
homeostasis, increasing the risk of type 2 diabetes (T2D) [16, 113]. Although the 
degree of hepatosteatosis and T2D are not necessarily tightly coupled [204], inhibition 
of excess hepatic DNL has been shown to ameliorate hepatosteatosis and associated 
glucose intolerance [112]. Shulman and colleagues have also demonstrated that 
correction of hepatosteatosis in patients with T2D is important for hyperglycaemia 
control [36]. In a search for new therapeutic agents for the treatment of hepatic steatosis 
from DNL, we have taken the approach of repurposing existing drugs for these 
conditions [182, 205]. One main advantage of this approach is most existing drugs are 
well-known safety and pharmacokinetic profiles.  
 
Mtr is a small molecule (MW: 248) found in Sophora and is structurally different from 
the drugs currently used to treat T2D [7, 172, 184]. Mtr has been used clinically as a 
hepatoprotective drug for the treatment of tumors and viral hepatitis [184], where DNL 
is often increased [206]. A recent study from our laboratory found that Mtr is able to 
reduce hepatosteatosis, fasting blood glucose and glucose intolerance in high fat (HF)-
fed mice [172]. However, the HF model does not exhibit the characteristics of DNL-
induced hepatosteatosis and glucose intolerance because the accumulation of 
triglyceride (TG) in the liver is due to a direct influx of lipids into the liver from the HF 
diet [44, 45].  
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The liver is a major site of DNL production from carbohydrates [44] and interestingly 
the inhibition of hepatic DNL reduces hepatosteatosis and hyperglycaemia [112, 207]. 
It has been suggested that an increase in DNL is the second major source of lipid 
accumulation in the liver after circulating FFAs and contributes about 26% of patients 
with hepatosteatosis [2]. In mice, a high-fructose (HFru) diet induces hepatosteatosis as 
early as one day [46] prior to the development of glucose intolerance [44, 48, 114]. 
Dietary fructose is almost entirely metabolised in the liver in its first pass, and serves 
mainly as a substrate for DNL in both animals [46, 47] and humans [48-51] . HFru diets 
increase the expression of lipogenic transcription factors, sterol regulatory element 
binding protein (SREBP1c) and carbohydrate response element binding protein 
(ChREBP) which upregulate lipogenic genes. Upregulation of these lipogenic 
transcription factors can result in hepatosteatosis and glucose intolerance via promoting 
DNL [99, 105]. Notably, HFru-stimulated hepatic DNL via SREBP1c is dependent on 
the activation of the ER stress pathway [44]. 
 
The primary aim of the present study was to investigate whether the hepatoprotective 
drug Mtr can limit hepatosteatosis and the associated glucose intolerance that usually 
results from increased DNL in HFru-fed mice. If established, the second aim was to 
investigate whether the action of Mtr is mediated via the ER stress pathway. Finally, we 
also evaluated whether Mtr assists glycemic control in a T2D mouse model generated 
by a combination of HF and streptozotocin (STZ) where an increased DNL via 
SREBP1c is also involved [88, 176]. 
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3.2 Materials and methods 
 
3.2.1 Animals and diets 
 
The experiments described in this study were approved by the Animal Ethics 
Committee of RMIT University (Application ID: 1012) and conducted in compliance 
with the guidelines of the National Health and Medical Research Council of Australia 
for Animal Experimentation. C57BL/6J mice aged 10-12 weeks and weighing 21-24 g 
were obtained from the Animal Resource Centre Pty. Ltd. (Perth, Australia). The 
animals were housed in a temperature-controlled room (22 ± 1˚C) on a 12-h light/dark 
cycle with free access to food and water. Mice were fed ad libitum for 1 week on a 
normal chow diet (~70% calories from starch, ~10% calories from fat, and ~20% 
calories from protein; Gordon's Specialty Stock Feeds, Yanderra, Australia). Mtr (≥ 
98% by HPLC) was purchased from Sigma Aldrich.  
 
Two sets of animal experiments were performed. In the first set of experiments, mice 
were fed a HFru diet (35% fructose, 35% starch, ~10% fat and ~20% protein) to 
generate hepatosteatosis. Mice were fed for 8 weeks with or without Mtr at a dose of 
100 mg/kg every day as a food additive in the last 4 weeks as described previously [7, 
172]. Body weight gain and food intake were measured twice a week. For blood 
glucose levels, blood samples were collected from the tail tip and measured using a 
glucometer (AccuCheck II; Roche, New South Wales, Castle Hill, Australia) after 2 
weeks of Mtr treatment. In the second set of experiments, the effects of Mtr on 
hepatosteatosis and hyperglycaemia were examined in a T2D model induced by HF 
feeding in combination with low doses of STZ as previously reported [88, 208, 209]. 
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Briefly, mice were fed a HF diet (45% calorie from lard, 20% calories from protein and 
35% calories from carbohydrate) for 14 weeks to induce insulin resistance. After 8 
weeks of HF feeding, mice were injected with STZ at a low dose (40 mg/kg per day, ip) 
for 5 consecutive days to reduce the level of plasma insulin by ~50% [88, 208, 209]. 
One week after the last injection of STZ, fasting blood glucose was usually increased 
by 50-100% (Hyperglycaemia, defined as T2D). The T2D mice were then divided into 
2 groups: one group receiving Mtr added in the HF diet (100 mg/kg/day) for 4 weeks 
(T2D-Mtr) whereas the other group was fed HF alone (T2D-Con) for the same period 
of time. During the period of Mtr treatment, fasting blood glucose was monitored once 
a week. A normal control group of mice (CH-Con) was included for the same period. 
At the end of both sets of experiments, mice were killed by cervical dislocation and 
liver tissues were collected and freeze-clamped immediately for further analysis. 
 
3.2.2 Assessment of the effect on hepatosteatosis 
 
Hepatosteatosis was assessed by measuring TG content in the liver. Mice were fasted 
for 5-7 h before being killed; the liver was collected and freeze-clamped immediately. 
As described previously [45, 88] plasma and liver TG levels were determined with a 
Peridochrom triglyceride GPO-PAP biochemical kit (Roche diagnostics). The method 
of lipid extraction from liver with chloroform/methanol has been described previously 
[46]. 
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3.2.3 Assessment of the effect on hepatic FA oxidation  
 
FA oxidation was assessed in fresh liver tissue ex vivo as described [44, 45]. Briefly, 
fresh liver samples were homogenised in an isolating medium which contained 100 
mM sucrose, 50 mM Tris, 100 mM KCl, 1 mM KH2PO4 and 0.1 mM EGTA, 0.2% FA-
free BSA at pH 7.0. The liver homogenate was incubated with [
14
C]-palmitate and 
[
14
C]-CO2 produced from the incubation was collected in 1 M sodium hydroxide. 
Palmitate oxidation rates were determined by counting the 
14
C radioactivity of captured 
CO2 and acid-soluble metabolites and oxidation rate were expressed as nanomoles of 
CO2 per gram of wet weight per hour [44].  
 
3.2.4 Assessment of the effects on DNL and ER stress  
 
DNL and ER stress were assessed by immunoblotting with specific anti-bodies for the 
key proteins in the DNL, ER stress and heat shock protein (HSP) pathways based on 
our recent work [7, 44-46, 172]. Briefly, freeze-clamped liver was homogenized in ice-
cold lysis buffer supplemented with fresh protease inhibitor and phosphatase inhibitor 
(Sigma Aldrich). The key proteins in the DNL pathway included SREBP-1 (Santa 
Cruz), ChREBP (Abcam), acetyl-CoA carboxylase (ACC, Upstate), fatty acid synthase 
(FAS, Abcam) and stearoyl-CoA desaturase 1 (SCD-1, Cell Signaling). The key 
proteins measured in the ER stress pathway included inositol-requiring kinase 1 (IRE1, 
Abcam), eukaryotic translation initiation factor 2α (eIF2α, Cell Signaling) and CHOP 
(Santa Cruz). The effect on the HSP pathway was assessed by heat shock protein 72 
(HSP72, Abcam) based on our recent work [7, 172]. Proteins were quantified using a 
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ChemiDoc and densitometry analysis was performed using Image Lab software (Bio-
Rad Laboratories, USA).  
 
3.2.5 Statistical analysis  
As described in Chapter 2 Section 2.9. 
 
3.3 Results 
 
3.3.1 Effects on body weight, adiposity, hepatosteatosis and glucose 
tolerance in HFru-fed mice  
 
HFru feeding is a well-defined model of hepatosteatosis, visceral adiposity and glucose 
intolerance resulting from increased DNL in the liver [44]. As expected, HFru feeding 
moderately increased the mass of epididymal fat (by 40%, P < 0.01) without altering 
body weight or food intake (P > 0.05) (Figure 3.1A-C). The TG content (indicative of 
hepatosteatosis) was increased dramatically in the liver (by 3 fold) but only moderately 
in muscle (~35%) (Both P < 0.01; Figure 1D). As shown in Figure 3.1E, HFru-fed mice 
also showed moderate in glucose intolerance.    
  
Administration of Mtr prevented the moderate body weight gain (8-10%) in HFru-fed 
mice during this period of time (Figure 1A). It corrected HFru-induced increases in 
epididymal fat, liver TG content and glucose intolerance (all, P < 0.01 vs untreated 
HFru-fed mice) to the levels similar to CH-fed normal mice (Figure 1B-E). Although 
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not significantly reduced, muscle TG content in Mtr-treated HFru-fed mice was no 
longer different from the value of CH-fed normal mice (Figure 3.1D).  
 
 
 
Figure ‎3.1 Effects of Mtr on body weight gain, visceral adiposity, hepatosteatosis 
and glucose tolerance in HFru-fed mice.  
Mice were fed a high-fructose (HFru) diet for 8 weeks and matrine (Mtr, 100 mg/kg per 
day in diet) was administered in the last 4 weeks. A glucose tolerance test (GTT at 3g 
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glucose/kg BW, ip) was conducted after 2 weeks of treatment with Mtr. Epididymal 
(Epi) fat weight and liver TG content were determined at the end of the study. (A) Body 
weight gain, (B) Epididymal fat weight as a percentage of body weight, (C) Caloric 
intake, (D) Glucose tolerance and (E) TG content in liver and muscle. **P < 0.01 vs 
CH; †P < 0.05, ††P < 0.01 vs HFru (n=7-8 mice/group). 
 
3.3.2 Effects on FA oxidation and DNL in the liver of HFru-fed mice.  
 
We first examined whether Mtr treatment may promote FA oxidation in the liver of 
HFru-fed mice. As shown in Figure 3.2A, palmitate oxidation by the liver 
homogenates was not affected by the treatment with Mtr, suggesting that the reduced 
hepatosteatosis by Mtr is not likely to be due to an increased FA oxidation in the liver. 
We next examined the DNL pathway because HFru-induced hepatosteatosis is believed 
to result from the stimulation to this pathway in the liver [45-47]. As expected, HFru-
fed mice exhibited dramatic increases in DNL proteins in the liver (Figure 3.2B-E), 
including SREBP-1c (by 2-fold), ChREBP (by 33%) ACC (by 3-fold), FAS (by 3.4 
fold) and SCD-1 (by 4-fold) (all P < 0.05). Interestingly, these lipogenic proteins 
except for ACC were significantly reduced by the treatment with Mtr, including 
SREBP-1c (by 45%, P < 0.01), ChREBP (by 33%, P < 0.05), SCD-1 (by 32%, P < 
0.01) and FAS (by 24%, P < 0.05). These results suggest that the reduced TG content in 
the liver by Mtr can be attributed to its inhibitory effect on HFru-induced increase in 
hepatic DNL. 
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Figure ‎3.2 Effects of Mtr on FA oxidation and DNL pathways in the liver of HFru-
fed mice.  
FA oxidation was detected by incubating fresh liver homogenates with [14C]–palmitate 
and DNL was assessed by the protein expression of palmitate in this pathway. (A). 
Liver lyzates from mice were immunoblotted with the mature form of SREBP-1c and 
ChREBP (B), SCD-1 (C), FAS (D) and ACC (E) and then quantified for statistical 
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analysis. *P < 0.05, **P < 0.01 versus CH-Con; †P < 0.05, ††P < 0.01 versus HFru-
Con, n = 7-8 mice per group. 
 
3.3.3 Effects on ER stress and HSP72 in the liver of HFru-fed mice 
 
By promoting DNL in the liver, the activation of ER stress represents a key step in the 
pathogenesis of hepatosteatosis [44, 59, 210]. As shown in Figure 3.3A, HFru-fed mice 
exhibited significant increases of the mature form of eIF2α (by 2-fold), CHOP (by 2.3-
fold) and IRE1 (by 2-fold) along with the upregulation of the DNL pathway in the liver. 
Treatment with Mtr markedly reduced the protein levels of these hepatic ER markers 
towards the levels seen in CH fed mice. These results indicate that Mtr induced-
suppression of ER markers may be associated with the improvement in lipogenesis, 
which could account for its beneficial effects on hepatosteatosis. Recent studies 
indicate that HSP72 is likely to mediate the effect of Mtr on hepatosteatosis and 
glucose intolerance [172, 192, 196]. As shown in Figure 3B, there was ~50% 
suppression of HSP72 (P < 0.05 vs CH fed mice) in the liver of HFru-fed mice and this 
reduction was reversed following treatment with Mtr (P < 0.05 vs untreated HFru-fed 
mice). 
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Figure ‎3.3 Effects on ER stress and HSP72 in the liver of HFru-fed mice.  
Liver lyzates from mice were immunoblotted for (A) eIF2α, CHOP and IRE1 and (B) 
HSP72 and quantified for statistical analysis. *P < 0.05, **P < 0.01 versus CH-Con; †P 
< 0.05, ††P < 0.01 versus HFru-Con, n = 7-8 mice per group.  
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3.3.4 Effects on hyperglycaemia in T2D mice  
 
To investigate the relationship of the effect on hepatosteatosis with glycemic control, 
we examined the metabolic effects of Mtr in T2D mice generated by a HF diet in 
combination with low doses of STZ [88, 172, 176]. The body weight was reduced in 
HFD-STZ-induced T2D mice (by ~15%) and treatment with Mtr had no effect on the 
body weight (Figure 3.4A), while visceral adiposity remained unchanged in T2D-Con 
mice compared to CH-fed mice Mtr significantly reduced epididymal fat in T2D mice 
(P < 0.05, Figure 3.4B). T2D-Con mice displayed typical fasting hyperglycaemia and 
Mtr treatment significantly reduced the degree of the hyperglycaemia over the period of 
4 weeks (by 20-30%, Figure 3.4C). As expected, HFD-STZ-induced T2D showed 
severe glucose intolerance but this was not attenuated by the treatment with Mtr (Figure 
AD). 
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Figure ‎3.4 Effects of Mtr on body weight, visceral adiposity, blood glucose and 
glucose tolerance in T2D mice.  
T2D was generated by a high-fat (HF) diet plus low-dose of STZ injections. After the 
development of hyperglycaemia, Mtr (100mg/kg per day in diet) was administered to 
diabetic mice for 4 weeks. Body weight at the end of the study (A).Epididymal (Epi) fat 
weight (B). Blood glucose levels (after 5-7 h of fasting) (C) were monitored once a 
week. An ipGTT (1.0g glucose/g body weight) was performed after 2 weeks of 
treatment with Mtr (D). **P < 0.01 vs CH-Con; ††P < 0.01 vs T2D-Con (n=7-8 
mice/group).  
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3.3.5 Effect on TG levels in T2D mice  
 
Recent studies indicate that hepatosteatosis can contribute to hyperglycaemia and 
hepatic insulin resistance [30, 44]. To determine whether the reduced hepatosteatosis by 
resulting from Mtr treatment is associated with the control of hyperglycaemia in T2D 
mice, we measured the TG content in the liver. As shown in Figure 3.5A and B, T2D 
mice exhibited hypertriglyceridemia and hepatosteatosis; however Mtr significantly 
reduced these conditions (P < 0.05). Together, these results clearly indicate that Mtr 
reduces the T2D-induced hepatosteatosis that is associated with hyperglycaemia and 
this could account for its beneficial effects on the regulation of lipid metabolism. 
 
 
 
Figure ‎3.5 Effects of Mtr on TG level in the plasma and livers of T2D mice.  
Plasma levels of TG were measured from blood samples collected in week 2 of the 
treatment (A). Liver TG content was determined from freeze-clamped samples obtained 
at the end of the study (B). **P < 0.01 vs CH-Con; ††P < 0.01 vs T2D-Con (n=7-8 
mice/group). 
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3.4 Discussion   
 
The present study investigated whether the hepatoprotective drug Mtr can treat the 
hepatosteatosis and associated glucose intolerance in HFru-fed mice resulting from 
increased DNL. Consistent with previous studies from our laboratory [45, 46, 211], 
HFru-fed mice developed hepatosteatosis and glucose intolerance by promoting ER 
stress-associated DNL. Treatment of these mice with Mtr ameliorated hepatosteatosis 
and glucose intolerance. Within the liver, Mtr decreased the protein expression of DNL 
enzymes concomitant with reduced ER stress. This study further examined the effects 
of Mtr on hepatosteatosis in relation to glycemic control in T2D mice, which display a 
phenotype of hyperglycaemia and hepatosteatosis associated with increased DNL [88, 
176]. The results showed that Mtr treatment reduced hepatosteatosis and improved 
hyperglycaemia. Collectively, these findings suggest that Mtr has the potential to be 
repurposed for the treatment of hepatosteatosis resulting from increased DNL and 
associated disorders in glucose metabolism.  
 
Overconsumption of dietary fructose can lead to DNL and hepatosteatosis [44, 95], 
which in turn can result in glucose intolerance and contribute to hyperglycaemia [48, 
75]. Therefore, correction of hepatosteatosis is beneficial for improving glucose 
homeostasis in the metabolic syndrome. For example, in obese patients with T2D, a 
reversal of hepatosteatosis can improve hepatic insulin action and glycemic control 
[36]. This study has investigated drugs that have previously been used for the treatment 
of liver conditions, in order to determine whether they can be repurposed to treat 
hepatosteatosis [182]. One such candidate is Mtr chosen because liver has been shown 
to be the major target site of Mtr [212, 213]. Indeed, the study from our laboratory has 
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demonstrated that Mtr is able to attenuate the increased fasting blood glucose and 
improve glucose tolerance in insulin resistant mice induced by a HF diet [172]. The 
same study found that these anti-diabetic effects of Mtr appears to result from its effect 
in reducing hepatosteatosis without affecting HF diet induced lipid accumulation in 
muscle.   
 
Mtr is clinically used for treatment of chronic liver conditions including hepatocellular 
carcinoma and viral hepatitis with minimal adverse effects [172, 182, 184]. 
Interestingly, both hepatocellular carcinoma and viral hepatitis are associated with an 
increase in DNL [7, 214, 215]. Indeed, previous findings in 3T3L1 adipocytes have 
shown that Mtr can reduce DNL and lipid accumulation within the cells [216]. 
Although recent results from our group [172] have shown that Mtr is able to reduce 
hepatosteatosis and glucose intolerance in mice that have been fed a HF diet, the source 
of hepatosteatosis in this mouse model is from the exogenous FA due to the intake of 
dietary fat rather than endogenous FA from an increased DNL. Therefore, it is not clear 
yet whether Mtr is effective for metabolic disorders by that involve an increased hepatic 
DNL [44]. 
 
Several studies have demonstrated that DNL enzymes are over-expressed during the 
development of hepatosteatosis [71, 105]. HFru-fed mice are a well-defined animal 
model of DNL-induced hepatosteatosis and insulin resistance [44, 45], and DNL-
induced hepatosteatosis can be observed as early as one day after HFru feeding [211]. 
Indeed, the present study showed that chronic HFru feeding resulted in hepatosteatosis 
(increased TG level) by promoting DNL (indicated by SREBP1c, ChREBP, acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (FAS) and stearoyl-CoA desaturase-1 
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(SCD-1)) without affecting FA oxidation, as indicated by unchanged levels of [
14
C]–
palmitate in the liver. However, reduced hepatic FA oxidation and mitochondrial 
enzyme activity has been demonstrated to occur prior to the appearance of 
hepatosteatosis, it has been shown that DNL is a primary cause of the development of 
hepatosteatosis [44, 77]. As expected, treatment with Mtr significantly reduced steatosis 
in the liver but not in muscle because of the high distribution of Mtr in the liver after 
oral administration [213]) and the associated glucose intolerance in these mice. Levels 
of key lipogenic enzymes were then measured and it was found that SREBP1c, 
ChREBP, SCD-1 and FAS in the liver were all reduced in HFru-fed mice treated with 
Mtr. These results suggest that Mtr is likely to reduce hepatosteatosis via inhibition of 
the DNL pathway. 
 
As an increase in FA oxidation can also attenuate hepatosteatosis [217], this study next 
examined whether the reduction of hepatosteatosis caused by Mtr in HFru-fed mice 
results from an increase in liver FA oxidation. However, Mtr did not increase oxidation 
of 14C-palmitate in the liver, indicating that the FA oxidation pathway was not activated 
in HFru-fed mice. These findings add further support to our interpretation that Mtr 
reduces hepatosteatosis and glucose intolerance in HFru-fed mice by inhibiting DNL 
rather than by stimulating FA oxidation in the liver.  
 
It has been shown that the ER stress pathway plays a critical role in HFru-induced DNL 
and hepatosteatosis [59, 211]. For example, in ob/ob mice hepatosteatosis is largely due 
to increased DNL as a result of hyperphagia in an ER stress-dependent manner [107]. 
The same study also showed that alleviation of hepatic ER stress by overexpression of 
GRP78 reduces hepatosteatosis and insulin resistance by inhibiting DNL. Similarly, in 
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HFru-fed mice, inhibition of ER stress by tauroursodeoxycholic acid (TUDCA) and 
Betulin suppress DNL and improve insulin signalling in the liver [45-47]. To 
investigate whether the inhibition of hepatic DNL by Mtr involves the ER stress 
pathway, the major ER stress markers in response to HFru-induced DNL was 
examined. Interestingly, the results showed that HFru-induced ER stress (indicated by 
eIF2α, CHOP and IRE1) were all inhibited by Mtr. These findings suggest that 
attenuation of ER stress may be a novel mode of action for the inhibitory effect of Mtr 
on DNL and the resultant hepatosteatosis. 
 
In terms of the possible cellular target of Mtr, published studies from our laboratory 
suggested that a downregulation of HSP72 contributes to lipid accumulation in vivo 
[172], and in vitro [216]. Indeed, Mtr is able to increase HSP72 expression and protect 
against lipid accumulation and glucose intolerance in the liver. Consistent with this 
observation, the present study found that liver tissue from HFru-fed mice had 
significantly lower concentrations of HSP72 protein, and this reduction was prevented 
by Mtr treatment. HSPs have been implicated in the regulation of diverse metabolic 
disorders including hepatosteatosis (the major metabolic defect of non-alcoholic fatty 
liver disease) and insulin resistance (the major metabolic defect of T2D) [194, 196, 
218]. It has been reported that an enhanced expression of HSP72 can block the 
activation of the stress kinase JNK by TNFα [219]. Collectively, the data from this 
study suggest that Mtr may inhibit the ER-DNL axis by up-regulating HSP72 to reduce 
hepatosteatosis and the associated glucose intolerance. 
 
Hepatic DNL and hepatosteatosis also occur in transgenic diabetic mice such as db/db 
[105]. Therefore, the present study explored whether Mtr is able to reduce 
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hepatosteatosis in a mouse model of T2D induced by HFD-STZ [88, 176]. Results from 
previous studies showed that Mtr reduced epididymal fat and lowered hyperglycaemia, 
indicating that Mtr may have the potential to control hyperglycaemia in T2D. Although 
Mtr showed no effect on normal fasting blood glucose, glucose tolerance or liver TG 
content in chow-fed mice [172], the anti-diabetic effects of Mtr could be attributed to 
its effect in reducing hepatosteatosis. 
 
In summary, this thesis reports a potential novel application of the hepatoprotective 
drug Mtr for the treatment of hepatosteatosis and associated abnormal glucose 
homeostasis. This study is the first to evaluate the effect of Mtr on hepatosteatosis 
induced by the ER stress-DNL signalling pathway in HFru-fed mice. As suppression of 
ER stress can reduce hepatosteatosis by inhibiting DNL [2, 211], it is likely that Mtr 
may exert these beneficial effects by suppressing ER stress-induced increase in hepatic 
DNL. This study hypothesises that the upregulation of the chaperon protein HSP72 may 
play a critical role in suppressing ER stress (as illustrated in Figure 3.6) but this 
hypothesis requires validation by further studies using HSP72 knock-down animal 
model. Together with recent findings in HFD-fed mice [172], results from this Chapter 
suggest that Mtr may be repurposed for the treatment of hepatosteatosis and associated 
disorders in glucose homeostasis including T2D.  
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Figure ‎3.6 Proposed mechanisms underlying the therapeutic effects of Mtr for 
hepatosteatosis and associated disorders in glucose homeostasis. 
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4.1 Introduction 
 
As described in Section 1.9, treatments for NASH fail to improve all aspects of this 
disease because of its diversity and the risks of available drugs. Alternatively, with its 
predictable efficacy in hepatosteatosis-associated disorders in glucose homeostasis 
(Chapter 3) and safety profile raises an attractive possibility that this hepatoprotective 
drug may have therapeutic potential for NASH. 
 
NASH is a severe condition of NAFLD, the most common chronic liver disease. It is 
characterised by liver damage, inflammation and variable degrees of fibrosis, which 
may lead to cirrhosis and HCC [6]. The inflammatory component of NASH may induce 
hepatic fibrosis, which aggravates the progression of this disease [15]. To date, there is 
no drug approved specifically for the treatment of NASH [220]. 
 
As described in Chapters 1 and 3, Mtr has several well-recognised pharmacological 
effects targeting the liver, including anti-inflammatory, anti-tumour and antiviral 
activities [184, 221]. One of the well-characterised anti-inflammatory effects of Mtr is 
inhibition of the inflammatory cytokine production such as  TNFα; a key player in the 
pathogenesis of NASH [143]. Moreover, Mtr treatment significantly inhibits 
inflammation upon challenge with LPS in vivo and in vitro [187, 222] and improves 
liver damage due to reperfusion injury in rats [200]. Recently, it has been found that 
treatment with Mtr attenuates hepatosteatosis and glucose intolerance induced by HFD 
in mice [172]. Further, the results in Chapter 3 show that Mtr is therapeutically 
effective in reducing HFru-induced hepatosteatosis. 
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However, mice fed with either HFD or HFru diet do not exhibit the inflammation and 
fibrosis in characteristic of NASH. Although MCD diet does not induce the metabolic 
syndrome as commonly seen in humans, this diet is still considered the most reliable 
candidate for diet-induced model of NASH in rodents, with liver damage, inflammation 
and fibrosis—a spectrum of changes that mimic the hepatic pathology of NASH [220, 
223]. 
 
The results presented in this Chapter demonstrate the therapeutic efficacy of Mtr in the 
treatment of NASH, which was accompanied by a significant improvement in 
inflammation and fibrosis—major NASH components. In this study, we investigated 
the effect of treatment with Mtr on MCD diet-induced NASH in mice. In addition, 
metformin which has been suggested to be useful for the treatment of NASH [136, 
224], was used in this study for comparison. 
 
4.2 Materials and methods  
 
4.2.1 Animal care, diets and experimental design  
 
Male C57BL/6J mice (10 weeks old) were purchased and acclimatised for at least 1 
week. Mice were randomly assigned to four groups: feeding ad libitum with a standard 
chow diet (CH-Con; Gordon’s Specialty Stock Feeds, Yanderra, NSW, Australia); 
MCD alone (MCD-Con); MCD with Mtr treatment as a food additive (MCD-Mtr; Mtr: 
100 mg/kg/day); and MCD with metformin treatment as a food additive (MCD-Met; 
Met: 250 mg/kg/day) for 6 weeks, as indicated in Figure 4.1. Body weight and food 
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intake were monitored daily throughout the experiment. Before the start of the study 
and at 5 weeks, following 5–7 h of food removal, tail vein blood was collected for 
glucose measurement with a glucometer (AccuCheck II; Roche, Castle Hill, Perth, 
Australia). Before the start of the study and at the end of the study, plasma was 
collected and stored at −80°C for subsequent biochemical testing. Mice were 
anaesthetised with a ketamine/xylazine mixture (up to 100 mg/kg body weight 
ketamine and 20 mg/kg body weight xylazine) was administered via intraperitoneal 
injection. Mice fixation was then performed via transcardial perfusion with heparinised 
phosphate buffered saline (PBS; 10–20 mL/mouse) followed by 4% paraformaldehyde 
(PFA; 10–20 mL/mouse; #C007, ProSciTech). At the completion of the PFA perfusion, 
the right lobe of the liver was dissected and immersed in 4% PFA-filled glass 
scintillation vials for further analysis. 
 
All experiments were approved by the Animal Ethics Committee of RMIT University 
(#1415) in accordance with the guidelines of the National Health and Medical Research 
Council of Australia. Mtr (purity >99.5%) was a gift from Professor Li-Hong Hu from 
the Shanghai Institute of Materia Medica; metformin was purchased from Sigma-
Aldrich. 
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Figure ‎4.1 Schematic diagram of the experimental plan for studies in MCD diet-
fed mice.  
Male C57BL/6J mice were fed a chow (CH-Con) or MCD diet for 6 weeks. The MCD 
diet-fed mice were assigned into three groups: MCD diet-fed mice without treatment 
(MCD-Con); MCD diet-fed mice with Mtr (100 mg/kg/day) (MCD-Mtr); and MCD 
diet-fed mice with metformin (250 mg/kg/day) (MCD-Met). ipGTT: intraperitoneal 
glucose tolerance test; MRI: magnetic resonance imaging. 
 
4.2.2 Assessment of the effect on hepatic steatosis 
 
Hepatosteatosis was assessed by measuring TG contents in the liver using the method 
of Folch and a colorimetric assay kit (Triglyceride GPO-PAP; Roche, Castle Hill, 
NSW, Australia), as described previously [44]. 
 
4.2.3 Evaluation of total body fat content 
 
Total body fat content in mice was evaluated using the EchoMRI™-100H body 
composition analyser (EchoMRI). Mice were restrained live inside a tube during this 
harmless and non-invasive analysis. The principle of measuring the whole-body fat 
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composition using the EchoMRI™-100H was based on the magnetic resonance 
imaging (MRI) technique measuring live body composition such as fat tissue, lean 
tissue and free fluid. 
 
4.2.4 Assessment of the effect on liver damage 
 
To examine the effects of Mtr on liver damage, the second component of NASH, 
plasma ALT and AST were measured at baseline and at Week 6 using commercial kits 
(ALT/SGPT Liqui-UV; Australia) [80]. Food was removed from mice cages for 5–7 h, 
and blood was collected from the tail vein (50 μL blood + 50 μL saline; fast spin for 1 
min), and then mixed with 200 μL reagent (R1:R2 = 5:1, as described in the 
manufacturer instructions). The absorbance was measured at 340 nm using a 
FlexStation (Molecular Devices, Australia). 
 
4.2.5 Quantitation of total and non-heme iron 
 
The total iron, and heme and non-heme iron, contents of liver samples were determined 
colorimetrically [225] because iron deposition is also regarded as a characteristic of 
NASH [226, 227]. As described previously [228], the fixated liver tissue (50–60 mg) 
was homogenised with 50 mM NaOH (using suitable volume to provide uniform 
homogenisation). The sample was incubated overnight at 75–80°C, and then separated 
into two aliquots for determination of the total and non-heme iron contents. The total 
iron was determined by adding reagent A (a freshly mixed solution of equal volumes of 
1.4 M HCl, 4.5% (w/v) KMnO4 and 40% TCA in H2O), and the non-heme iron was 
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determined by adding reagent B (same as reagent A without KMnO4), to the sample 
[229]. 
 
The iron content of the sample was calculated by comparing its absorbance to that of a 
range of standard concentrations of equal volume. Standards (five diluted standards) 
were prepared as a mixture of FeCl3 in 10 mM HCl and 50 mM NaOH. The standard 
value was measured using lysis reagent that either contained or lacked permanganate 
[229]. The mixture was transferred into 96-well plates and its absorbance was measured 
at 550 nm. 
 
4.2.6 Real-time polymerase chain reaction of liver RNA 
 
Total RNA was isolated from mouse liver using TRIzol reagent (Invitrogen, 
#15596026) as previously described [88]. Reverse-transcription polymerase chain 
reaction (RT-PCR) was carried out using the IQ SYBR Green Supermix (Bio-Rad 
Laboratories, USA) for interest genes and analysed by real-time PCR using specific 
primer sets. Target gene expression levels were normalised to a housekeeping gene 
(18s). Primer sequences are listed in Table 4.1. 
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Table ‎4.1 Primers used in quantitative RT-PCR 
Gene Primer sequences 
18S Forward: 5′-CGCCGCTAGAGGTGAAATTCT-3′ 
Reverse: 5′-CGAACCTCCGACTTTCGTTCT-3′ 
TNFα Forward: 5′-CACAAGATGCTGGGACAGTGA-3′ 
Reverse: 5′-TCCTTGATGGTGGTGCATGA-3′ 
IL-1β Forward: 5′-GACGGCACACCCACCCT-3′ 
Reverse: 5′-AAACCGTTTTTCCATCTTCTTT-3′ 
CD68 Forward: 5′-TGACCTGCTCTCTCTAAGGCTACA-3′ 
Reverse: 5′-TCACGGTTGCAAGAGAAACATG-3′ 
Collagen 1 Forward: 5′-CTGCTGGTGAGAGAGGTGAAC-3′ 
Reverse: 5′-ACCAAGGTCTCCAGGAACAC-3′ 
 
 
4.2.7 Western blotting 
 
Liver lysates were resolved by SDS-PAGE and immunoblotted with specific antibodies 
[45]. Antibodies listed in Table 4.2 were diluted 1:1000 with a TBST buffer containing 
1% bovine serum albumin (BSA), 0.02% sodium azide (Sigma-Aldrich, #71289) and 
0.0025% phenol red (Sigma-Aldrich, #32661). Ponceau Red ensured equal loading of 
blots staining (Roth). Proteins were quantified using a ChemiDoc, and densitometry 
analysis of bands was performed using Image Lab software (Bio-Rad Laboratories, 
USA). 
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Table ‎4.2 List of antibodies used in western blotting 
Pathway Antibody Supplier Catalogue no. 
Inflammation MCP-1 Cell Signaling  2027 
NLRP3 AdipoGen 20B-0006-C100 
 HSF1 Cell Signaling  4356 
 HSP72 Enzo Life Sciences C92F3A-5 
 HSP90 Enzo Life Sciences ADI-SPA-840HRP 
Fibrosis TGFβ Cell Signaling  3709 
Smad3 Cell Signaling  9523 
Autophagy mTOR Cell Signaling  2983 
Loading control Tubulin Cell Signaling  3873 
 GAPDH Cell Signaling  2118 
Secondary antibody Goat anti-mouse  Santa Cruz sc-2005 
 Goat anti-rabbit  Santa Cruz sc-2004 
 Goat anti-rat Santa Cruz Sc-2065 
 
4.2.8 Histopathological examination 
 
The liver samples were perfused using PFA and sliced into 5 μm sections. Free-floating 
sections were stained with picrosirius red for liver fibrosis, and then quantified in five 
non-overlapping fields of view per animal by using an Olympus BX41 microscope with 
a 20× objective lens and an Olympus DP72 digital camera (Olympus, Australia) [80, 
230]. The mean value was calculated for each experimental group using the threshold 
function in the ImageJ software package (NIH, Bethesda, MD, USA). Data are 
represented as percentage (%) of positive area per field. To obtain statistical 
signiﬁcance, at least ﬁve random-ﬁeld images were taken per slide, and at least seven 
mice per group were scored (n = 7). 
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4.2.9 Statistical analysis 
 
The statistical analysis was carried out as described in Chapter 2, Section 2.9. 
 
4.3 Results  
 
4.3.1 Effects on adiposity, hepatosteatosis and plasma glucose  
 
MCD diet feeding is a common nutritional model of NASH despite lack of the 
metabolic phenotype [162]. As expected, MCD diet-fed mice showed reduced body 
weight and body weight gain but no significant changes in food intake, calorie intake 
and blood glucose level. As shown in Table 4.3, the TG content (indicative of 
hepatosteatosis) was increased dramatically in the liver of MCD-Con compared with 
CH-Con mice (by 1.5 fold, P < 0.01). The difference in weight gain between chow, 
MCD alone and MCD with treatments was maintained throughout the treatment period 
of 6 weeks. 
 
Mtr had no effect on body weight gain and calorie intake in MCD diet-fed mice. 
Consistent with previous studies [161, 231], MCD diet-fed mice did not show any 
glucose intolerance or metabolic abnormality. Glucose levels in Mtr-treated MCD diet-
fed mice did not differ from the value of CH-fed mice. Associated with these effects, 
Mtr had no effect in reducing hepatic TG content in MCD diet-fed mice (Table 4.3). 
Similarly, metformin did not show any effect on any of these parameters in MCD diet-
fed mice. 
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Table ‎4.3 Effects of Mtr and metformin on body weight, total food intake and liver 
triglyceride 
 CH-Con MCD-Con MCD-Mtr MCD-Met 
Body weight (g) 24.3 ± 0.2 23.5 ± 0.2** 22.6 ± 0.1†† 22.7 ± 0.1†† 
Body weight gain (g) 2.0 ± 0.2 0.4 ± 0.2** 0.3 ± 0.2 0.7 ± 0.1 
Food intake (g/kg/day) 80.5 ± 2.3 85.6 ± 2.3 86.5 ± 2.5 85.6 ± 3.0 
Caloric intake 
(kcal/kg/day) 268.2 ± 7.5  313.7 ± 9.0 319.7 ± 10.0 334.8 ± 18.4 
Fasting blood glucose 
(mM) 8.0 ± 0.5 7.4 ± 0.4 6.3 ± 0.4 6.4 ± 0.5 
Liver TG (mmol/g) 13.8 ± 4.2 31.6 ± 3.3** 28.2 ± 2.5 31.2 ± 3.1 
Mice were fed a chow (CH-Con), MCD alone (MCD-Con), MCD treated with matrine 
100 mg/kg/day (MCD-Mtr) or MCD treated with metformin 250 mg/kg/day (MCD-
Met). Body weight and food intake were measured twice a week. Blood glucose 
measurement was performed at Week 5. Plasma was collected before tissue collection 
at Week 6 for subsequent analysis of ALT and AST. **P < 0.01 vs. CH-Con; ††P < 
0.01 vs. MCD-Con (n = 8 mice/group). 
 
4.3.2 Effects on body composition using magnetic resonance imaging 
 
MCD diet feeding resulted in a lack of metabolic phenotype possibly because of 
signiﬁcantly decreased body weight (Figure 4.2A). Total body fat content using the 
EchoMRI analyser was measured in all mice. As illustrated in Figure 4.2B, in spite of 
the reduction in body weight by MCD diet feeding, there was a significant increase in 
fat mass in MCD diet-fed mice compared with the chow-fed group. MRI analysis also 
revealed that MCD diet-fed mice and mice treated with either Mtr or metformin had a 
significant decrease in lean mass compared with the chow group (Figure 4.2C). 
However, Mtr and metformin had no effect on fat mass. 
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Figure ‎4.2 Effects of Mtr on body composition in MCD mice.  
The body composition of CH-Con, MCD-Con, MCD-Mtr and MCD-Met was 
determined by EchoMRI analyser at Week 4. (A) Lean + fat mass; (B) Fat mass; (C) 
Lean mass. *P < 0.05, **P < 0.01 vs. CH-Con; †P < 0.05 vs. MCD-Con; ns: not 
significant (n = 8 mice/group). 
 
4.3.3 Effects on plasma levels of liver enzymes and iron deposition 
 
Liver damage has been suggested as an important factor that distinguishes NASH from 
hepatosteatosis [129]. The present study examined whether Mtr treatment might inhibit 
liver damage of MCD diet-fed mice. As shown in Figure 4.3A and B, along with the 
increase of hepatosteatosis in the liver, MCD-fed mice exhibited marked increases in 
ALT (by 68%, P < 0.01) and AST (by 40%, P < 0.05) levels, resulting from liver 
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damage. Treatment with Mtr or metformin markedly decreased ALT levels (±80% and 
25%, respectively). In addition, Mtr treatment but not metformin, further decreased 
AST levels (P < 0.05) in MCD diet-fed mice, indicating Mtr may reduce liver damage, 
a hallmark in the progression of NASH. We further examined the effects of Mtr on iron 
levels in the liver of MCD-fed mice. Neither Mtr nor metformin treatment altered the 
accumulation of heme and non-heme iron induced by MCD diet (Figure 4.3C and D). 
This was likely due to an excessive overload of iron in the liver among mice fed MCD 
diet. 
 
 
 
Figure ‎4.3 Effects of Mtr on liver damage and iron level.  
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After 6 weeks of feeding and drug treatment, blood samples were collected for the 
measurement of (A) ALT and (B) AST levels. Liver tissue was collected for iron 
measurement (C) heme iron and (D) non-heme iron. *P < 0.05, **P < 0.05 vs. CH-
Con; †P < 0.05, ††P < 0.01 vs. MCD-Con (n = 7–8 mice/group). 
 
4.3.4 Effects on hepatic inflammation  
 
An important pathological characteristic of NASH is hepatic inflammation, and MCD 
diet has previously been shown to cause marked hepatic inflammation [10, 120]. Key 
inflammatory proteins, including TNFα, IL-1β, MCP-1, cluster of differentiation 68 
(CD68) and NLRP3 inflammasome, are particularly associated with liver inflammation 
and the progression of NASH [53, 232]. To examine the anti-inflammatory effects of 
Mtr in MCD diet-fed mice, the protein expression levels of these inflammatory markers 
was measured. Consistent with other studies [56, 149, 162], MCD feeding resulted in a 
marked inflammatory response in the liver as evidenced by increased expression levels 
of TNFα and CD68 (±50% and 80%, respectively; both P < 0.05), an indicator of KCs 
activation [233]. Further, livers of MCD-Con mice with NASH exhibited a substantial 
increase in MCP-1 and NLRP3 expression (both 38% vs. CH-Con). Mtr treatment 
normalised the expression levels of TNFα, CD68 (both P < 0.05 vs. MCD-Con) and 
MCP-1 (P < 0.01 vs. MCD-Con), as shown in Figure 4.4A, B and D. However, no 
significant differences were detected in the expression of IL-1β among the experimental 
groups (Figure 4.4C). It has been suggested that NLRP3 blockade reverses advanced 
stage liver inflammation and fibrosis in MCD diet-induced NASH [149]. Consistent 
with the previous study, there was ±65% reduction in NLRP3 inflammasome 
expression (P < 0.05 vs. CH-Con) (Figure 4.4E). In contrast to Mtr, metformin had no 
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effect on the expression levels of inflammatory markers including TNFα, CD68, MCP-
1 and NLRP3 (Figures 4.4A-E). 
 
 
 
Figure ‎4.4 Effects of Mtr on hepatic inflammation in MCD diet-fed mice.  
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(A) TNFα mRNA, (B) CD68 mRNA, (C) IL1β mRNA, (D) MCP-1 (E) NLRP3 and (F) 
representative western blot images. *P < 0.05 vs. CH-Con; †P < 0.01, ††P < 0.01 vs. 
MCD-Con; ns: not significant (n = 7–8 mice/group). 
 
4.3.5 Effects on expression of genes involved in hepatic fibrosis 
 
Liver fibrosis is another hallmark of advanced NASH [15]. An ideal anti-inflammatory 
approach to NASH treatment would not only abolish inflammation but also reverse 
established liver fibrosis. Therefore, the effect of Mtr on hepatic fibrosis was examined. 
As shown in Figure 4.5A-C, MCD diet-fed mice exhibited marked increases in the 
expression of key proteins of the pro-fibrotic pathway in the liver, namely collagen 1, 
TGFβ and Smad3 (all P < 0.05 vs. CH-Con), and these results were consistent with 
others [14, 149]. Treatment of MCD diet-fed mice with Mtr inhibited hepatic 
expression of these proteins (±55%, 65% and 45%, respectively) towards the levels 
seen in CH-Con mice. In contrast, metformin treatment had no effect on MCD diet-
induced liver fibrosis. There were no significant changes in caspase-1 protein 
expression between groups (Figure 4.5D). These results revealed that treatment with 
Mtr attenuated MCD diet-induced fibrosis in the liver, which may support its beneficial 
effects in NASH with fibrosis. 
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Figure ‎4.5 Effects of Mtr on hepatic fibrosis in MCD-fed mice.  
(A) A hepatic fibrosis gene of collagen 1 was determined by quantitative RT-PCR 
analysis. Liver lysates from mice were immunoblotted for (B) TGFβ, (C) Smad3 and 
(D) caspase-1 and quantified for statistical analysis. *P < 0.05 vs. CH-Con; †P < 0.05, 
††P < 0.01 vs. MCD-Con; ns: not significant (n = 7–8 mice/group). 
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4.3.6 Effects on liver fibrosis using picrosirius red stained liver 
sections 
 
MCD diet caused extensive fibrosis at 6 weeks, evidenced by collagen accumulation 
combined with thickened hepatocytes cell membranes (Figure 4.6A). Picrosirius red 
staining of the liver sections for collagen confirmed the beneficial effects of Mtr 
treatment on hepatic fibrosis. In agreement with the gene expression and western blot 
data, treatment with Mtr resulted in a robust reduction in collagen accumulation As 
shown in Figure 4.6B, there was an increase in liver fibrosis of ±83% (P < 0.01 vs. 
CH-Con) in the liver of MCD-fed mice and this increase was reversed following 
treatment with Mtr (reduction of ±66%, P < 0.01 vs. MCD-Con). In comparison, no 
obvious hepatic fibrosis changes were observed in mice fed MCD diet with metformin 
treatment. 
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Figure ‎4.6 Effects on extent of liver fibrosis stained with picrosirius red.  
(A) Representative images showing collagen staining with picrosirius red in liver 
sections from CH-Con, MCD alone and MCD treated groups (scale bar = 200 µm (top 
set) and 50 µm (below set), 10× magnification). (B) Mtr-treated mice had significantly 
reduced fibrosis area compared with MCD diet-fed mice. **P < 0.01 vs. CH-Con; ††P 
< 0.01 vs. MCD-Con (n = 7–8 mice/group). 
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4.3.7 Effects on hepatic mTOR and heat shock protein expression 
 
Dysregulation of mTOR signalling has been implicated in fatty liver diseases [234]. 
Inhibition of mTOR has previously been shown to be efficacious in improvement of 
NASH-induced by MCD diet [235-237]. It has been reported that Mtr treatment inhibits 
autophagy in cell lines by impairing the activity of lysosomal proteases [238]. To 
elucidate the mechanism underlying mTOR inhibition-induced by Mtr, protein 
expression using western blotting was performed to evaluate whether mTOR 
contributes to hepatocyte damage, inflammation, and fibrosis in NASH. Interestingly, 
treatment with Mtr normalised the protein level of mTOR (P < 0.01 vs. MCD-Con) 
towards the levels seen in CH-Con mice (Figure 4.7A). These results revealed that 
treatment with Mtr inhibited MCD diet-induced hepatic mTOR expression. 
 
A recent study has examined the effects of Mtr on the expression of HSP72 [172]. This 
study has shown that the antisteatotic effect of Mtr is associated with the upregulation 
of HSP72 in the liver of HFD-fed mice. To determine whether Mtr treatment is 
associated with the upregulation of HSP-induced improvement in NASH, HSP90, 
HSF1 and HSP72 expression was measured in the liver. As shown in Figure 4.7B-D, 
HSP90 and HSP72 expression levels were blunted (50% reduction vs. CH-Con, P < 
0.05) by MCD diet feeding, but there was no significant effect on the protein levels of 
HSF1. Treatment with Mtr upregulated hepatic HSP72 and HSF1 expression levels (P 
< 0.01 vs. MCD-Con) in MCD diet-fed mice, but had no significant effect on HSP90 
expression. Therefore, these results indicated that the beneficial effect of Mtr on the 
development of MCD diet-induced NASH might be associated with its ability to limit 
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mTOR and upregulate HSPs. In comparison, metformin treatment significantly rescued 
HSF1 but had no significant effect on the expression of HSP72 and HSP90. 
 
 
 
Figure ‎4.7 Effects of Mtr on mTOR, HSF1, HSP90 and HSP72 in MCD-fed mice.  
Liver lysates from mice were immunoblotted for (A) mTOR, (B) HSP90, (C) HSF1 and 
(D) HSP72 and quantified for statistical analysis. *P < 0.05 vs. CH-Con; †P < 0.05, 
††P < 0.01 vs. MCD-Con (n = 7–8 mice/group). 
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4.4 Discussion 
 
This study found that Mtr markedly ameliorated MCD diet-induced NASH by 
suppressing key regulators of hepatic damage, inflammation and fibrosis. Results of 
this Chapter showed that Mtr treatment was therapeutically effective for the treatment 
of NASH compared with metformin in MCD diet-fed mice. These effects were 
associated with an inhibition of mTOR and upregulation of HSPs, suggesting Mtr 
might be repurposed for the treatment of NASH by a novel mechanism different from 
those recognised at the present time [67]. 
 
Previous studies have reported a potential effect of Mtr in ameliorating hepatosteatosis, 
fasting blood glucose and glucose intolerance in HFD-fed mice [172]. In addition, Mtr 
treatment is effective at reversing hepatosteatosis and glucose intolerance, probably via 
reduced ER stress associated with decreased hepatic lipogenesis in mice fed HFru diet. 
Despite the possible benefits of Mtr for the treatment of NAFLD-associated glucose 
intolerance, the therapeutic effects in NASH are not clear because of the absence of 
NASH features in these mouse models. Therefore, the studies described in Chapter 4 
particularly examined the protective effect of Mtr against MCD diet-induced NASH in 
mice. 
 
MCD diet feeding is a well-recognised model of NASH and rapidly induces 
steatohepatitis in mice [120, 161]. Although MCD-fed mice do not exhibit metabolic 
abnormalities such as insulin resistance and hyperglycaemia; MCD diet feeding is a 
frequently used dietary model because it causes severe NASH with hepatic steatosis, 
damage, inflammation and fibrosis [162]. This study showed that 6-week Mtr treatment 
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significantly ameliorated liver damage, inflammation and fibrosis, albeit not 
hepatosteatosis. 
 
The degree of hepatosteatosis may predict the severity of NAFLD and vary among 
NASH patients [28]. MCD diet has been shown to induce higher levels of TG in the 
liver compared with normal chow diet [145]. To investigate the antisteatotic effects of 
Mtr in the liver, hepatic TG content was measured in MCD diet-fed mice. Treatment of 
these mice with Mtr or metformin did not change hepatosteatosis in relation to body 
weight and glucose level in MCD mice. This might be due to the lack of metabolic 
abnormalities in MCD diet-induced NASH. Secondly, Mtr treatment exerts its 
beneficial effects on NASH independent of an improvement in hepatosteatosis. 
 
It is suggested that elevations of liver enzymes and hepatic iron levels are strongly 
associated with hepatocyte injury and liver damage [239]. ALT is used as a marker of 
liver damage in fatty liver including NASH [240]. Consistent with these reports, 
feeding mice MCD diet produces a significant increase in ALT levels in the mouse 
MCD diet model of NASH [241]. Mtr showed a beneficial effect in the inhibition of 
MCD diet-induced increases in plasma ALT and AST; this indicates that Mtr can 
attenuate the liver damage without changes in body composition in mice. Conversely, 
metformin had moderate effect on ALT levels, but did not change AST levels; 
therefore, it is not strongly recommended for NASH treatment [10, 242, 243]. 
 
The activation of inflammatory cytokines plays a vital role in the progression of NASH 
[244]. The increase in inflammatory cytokines production, in particular TNFα by KCs, 
resident hepatic macrophages, was suggested to be the key mediator of the progression 
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of NASH [245]. In line with increased TNFα production, increased CD68 and MCP-1 
are associated with the severity of NASH [80, 231]. Alternatively, inhibition of TNFα 
activity using anti-inflammatory drugs improves liver damage, inflammation and 
NASH [145, 246]. It is generally believed that the anti-inflammatory activities of Mtr 
are largely due to its ability to inhibit hepatic inflammation [200, 222]. 
 
Iron overload plays a role in liver damage where simple uncomplicated steatosis 
progresses to fibrotic NASH [153, 154]. It has been suggested that iron overload 
exacerbates inflammation and fibrosis-induced steatohepatitis in humans [151, 227] and 
in animals [226, 247]. Further, iron accumulation in tissue is positively correlated with 
the severity of NASH manifestations in the Tsumura Suzuki obese diabetes (TSOD) 
mouse model [248]. It appears that reduced iron overload may prevent development 
and progression of NASH. Despite the inhibitory effects of Mtr on liver enzymes, the 
elevation of heme and non-heme iron did not change during the treatment period with 
Mtr or metformin. These findings together raise the possibility that Mtr might offer 
additional therapeutic effects on manifestations of NASH through reduction of liver 
enzymes. 
 
Results in this Chapter revealed that Mtr prevented NASH-associated hepatic 
inflammation and fibrosis after 6 weeks of treatment. Mtr suppressed the increases in 
TNFα, CD68 and MCP-1, major inflammatory markers in NASH. Another central 
participator in the development of NASH is the activation of NLRP3 inflammasome 
[147, 249]. It has been recently reported that blockage of NLRP3 activation reduces 
liver inflammation and fibrosis in MCD-fed mice [149]. Consistent with the anti-
inflammatory effects, a similar reduction in NLRP3 expression in the liver was 
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observed compared with CH-Con mice. The results support Mtr may reduce NASH via 
inhibition of inflammatory pathways. 
 
Hepatic fibrosis is known as another hallmark feature of NASH after inflammation, 
which can cause scaring, resulting in liver cirrhosis and cancer [15, 240]. Because of its 
severe impact on the prognosis of NASH, the control of hepatic fibrosis is regarded as a 
key criterion in the treatment of NASH [6]. Although Mtr has been reported to prevent 
liver fibrosis (TGFβ and collagen synthesis) induced by CCl4 in rats [189], whether Mtr 
inhibits fibrosis in MCD-induced NASH remains unclear. To investigate whether the 
inhibition of hepatic inflammation by Mtr involves the inhibition of fibrosis pathways 
[147], this study examined the effect of Mtr on the major fibrotic markers in response 
to MCD diet-induced NASH. Consistent with the reduction in inflammation, our data 
indicated that Mtr inhibited the activation of fibrosis by suppression of TGFβ, Smad3 
and collagen synthesis in the liver of MCD diet-fed mice. These results provide further 
support for the idea that Mtr might provide a possible mechanism for the inhibition of 
fibrosis because of its antifibrotic effects. Indeed, this is the first experimental evidence 
that Mtr can prevent and ameliorate the progression of NASH of not only inflammation 
but also fibrosis in the liver of a NASH model. 
 
In terms of possible cellular targets of Mtr, a critical role of the activated mTOR 
pathway in the severity and progression of NASH has become a focus for research 
[234, 250, 251]. The involvement of the mTOR pathway in MCD-induced advanced 
NASH has been explored [237]. Recently, Mtr has shown beneficial effects in the 
inhibition of mTOR in cell lines and primary cells of acute myeloid leukaemia [252]. 
Mtr treatment decreased the expression of mTOR in the liver of MCD diet-fed mice. In 
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particular, Mtr may provide a protective effect against the progression of NASH 
through mTOR inhibition. 
 
Another interesting finding presented in this Chapter was that Mtr is able to modulate 
HSP expression levels. It has been reported that overexpression of HSP72 may 
attenuate inflammation and restore homeostasis even in the face of metabolic insult 
[196], which may likely be attributed to its ability to suppress the production of 
inflammatory cytokines [253]. A previous study from our laboratory has suggested that 
upregulation of HSP72 may contribute to hepatosteatosis induced by HFD or HFru 
feeding in mice [172]. Consistent with this observation, the present study found that 
liver tissue from MCD diet-fed mice had significantly lower levels of HSP72 and 
HSP90, and this reduction was rescued by Mtr treatment. It is noteworthy that 
upregulation of HSPs by Mtr treatment has been associated with the improvement of 
NASH. Importantly, Mtr exerts these effects through a distinct pathway different from 
that of metformin without any significant change in mTOR or HSP72. These data 
suggest that the therapeutic effects of Mtr in treating NASH may involve dysregulation 
of mTOR or HSPs. 
 
This studies reported in this chapter have provided direct support for our hypothesis 
that Mtr treatment markedly ameliorates NASH via inhibiting the inflammatory and 
fibrotic pathways. Therefore, Mtr has the potential to be a therapeutic drug for the 
treatment of NASH, possibly by inhibiting mTOR expression and upregulating HSP72. 
Importantly, anti-inflammatory and antifibrotic effects of Mtr are related to the 
inhibition of key aspects of NASH (Figure 4.8). 
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In summary, the study in this Chapter demonstrated that Mtr may be useful as an 
effective drug to prevent NASH-associated inflammation and fibrosis. It is possible that 
the improvement of inflammation and fibrosis by Mtr treatment occurs via the 
inhibition of mTOR, which appears associated with the upregulation of HSP72. 
Compared with metformin, Mtr demonstrates clear superiority for the treatment of 
NASH. Further works are needed to explore whether the anti-inflammatory and 
antifibrotic effects of Mtr result directly from its effects on the hepatic mTOR-HSP72 
pathway, given that previous studies from our laboratory have excluded the commonly 
recognised mechanisms. 
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Figure ‎4.8 Schematic diagram illustrating the proposed mechanism underlying the 
effects of Mtr against MCD diet-induced NASH. 
  
 
Chapter 5 Effects of Matrine on 
Lipopolysaccharide-
Stimulated 
Inflammation in 
Macrophage Cells  
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5.1 Introduction 
 
As reviewed in Chapter 1, macrophages including hepatic KCs play an important role 
in perpetuating the inflammatory phase of NASH by the release of inflammatory and 
fibrogenic mediators [130, 254]. It has been shown that LPS stimulates the 
inflammatory activation of KCs, which contributes to NASH [255]. Because 
macrophages are critical in initiating liver damage and inflammation, targeting 
macrophages activation may guide the development of effective treatment for the 
inflammation in NASH [129]. For example, mice with lack of hepatic TLR4 stimulated 
with LPS are protected from hepatosteatosis and inflammation via impaired 
hepatocytes and activated KCs [256]. J774A.1 is a macrophage-like cell line that is 
used as a model for KCs in the liver and the macrophages in the circulation. Activation 
of J774A.1 by LPS produces inflammatory cytokines and promotes the fibrogenic 
process [257]. 
 
LPS or endotoxin comprises a major portion of the cell wall of gram-negative bacteria 
and is a potent inducer of the inflammatory response in macrophages via its receptor 
the CD14/TLR4 complex [258]. It has been proposed that LPS may be a ‘second hit’, 
which contributes to the progression of simple hepatosteatosis to NASH [54]. 
Activation of macrophages by LPS induces the expression of TLR4, which mediates 
the secretion of inflammatory cytokines such as TNFα [138, 259]. The release of TNFα 
can cause severe liver inflammation and contribute to pro-fibrotic activity and 
eventually NASH [129]. An increase in the synthesis of inflammatory cytokines 
including TNFα has been reported in patients [129, 131, 139] and rodents [142, 245] 
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with NAFLD/NASH. Indeed, inhibition of LPS-induced TNFα production reduces 
inflammatory cytokine activation and decreases inflammation [260]. 
 
The studies reported in Chapter 4 revealed that Mtr treatment inhibits the elevated 
expression of TNFα and related inflammatory and fibrotic signals in the liver. Chapters 
3 and 4 have described the ability of Mtr to reduce lipid accumulation, inflammation 
and fibrosis in the liver. However, the underlying cellular mechanisms of the effects of 
Mtr in these conditions are not clear because of multiple interactions among different 
cells in the organ. As cell lines are homogenous, and are easily manipulated and 
propagated for the study of signalling pathways, they can be used to provide a clearer 
understanding of the cellular mechanisms of Mtr on specific cell types for NASH. This 
Chapter investigates the cellular mechanisms underlying the effects of Mtr on 
inflammatory and fibrogenic pathways in a cell line that represents the major cell type 
responsible for the inflammatory cytokines in NASH. 
 
5.2 Materials and Methods  
 
5.2.1 Cell Culture  
 
J774A.1 a murine reticulocyte sarcoma cell line derived from a female BALB/c mouse, 
was purchaesed ATCC
®
 TIB-67
™
 and maintained in RPMI (Gibco/Invitrogen, 
Carlsbad, CA, USA) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 
μg/mL streptomycin and 10% (v/v) heat-inactivated foetal bovine serum in a 
humidified 5% CO2 atmosphere at 37°C. Cell culture medium was changed every two 
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or three days and used at passages numbers 6–15 for all experiments. Briefly, cells 
were subcultured at 1 in 10 dilutions when cells reached 80–90% confluence. 
Subculture was formulated by rinsing the cells first with warm 1× PBS, and then 
adding 2–3 mL 1× trypsin-EDTA solution to detach the cells from the T75 flask. Cells 
were then centrifuged at 100 × g for 5 min and re-suspended in ±10 mL fresh growth 
medium, and the desired amount of cells was transferred into a new T75 flask 
containing fresh RPMI growth medium. 
 
5.2.2 Chemicals and drugs 
 
LPS was purchased from Sigma-Aldrich (O127:B8; Australia). It was dissolved in 
water to obtain a stock concentration of 10 mg/mL. Mtr (≥98% by high performance 
liquid chromatography) was purchased from Sigma-Aldrich. Mtr (purity >99.5%) was a 
gift from Professor Li-Hong Hu from the Shanghai Institute of Materia Medica. 
Quercetin was purchased from Sigma-Aldrich (Q4951; Australia), dissolved in 
dimethyl sulfoxide (0.1% DMSO) and stored at −20°C. Bay 11-7082 was purchased 
from Sigma-Aldrich (B5556; Australia). 
 
5.2.3 Treatments of J774A.1 macrophage cell line 
 
To induce inflammation in J774A.1 cells, a serial dilution of LPS was prepared and 
1 mg/mL stock LPS solution was kept at −80°C for further experiments. On the day 
before testing, the cultured cells were confirmed as having a confluence of >90% and 
cell viability of >90% by microscopic examination and LDH release cytotoxicity assay, 
respectively (Section 5.2.5). Medium was aspirated from the cell culture flask and 
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10 mL fresh RPMI medium added to the flask. Cells were removed using a cell scraper 
and 0.5 (× 2) mL was used to start a new passage, while the remaining 9 mL was placed 
into a 15-mL conical tube. Cells were counted using trypan blue at a 1:10 dilution. The 
desired volume of the cell-containing medium (at a density of 2 × 10
5
 cells per well) 
was transferred into a 24-well culture plate with fresh growth medium. Two hours prior 
to inflammatory stimulation, each prepared drug was added to the appropriate well at a 
indicated concentration. The plate was then returned to the incubator for the indicated 
periods of time. Then, LPS was added to appropriate wells to induce inflammation. 
After 2 h of incubation, the cell supernatant was collected in 1.5-mL Eppendorf tubes 
for enzyme‑linked immunosorbent assay (ELISA). Cell lysates were harvested after 
washing with cold PBS and kept at −80°C for further analysis. 
 
5.2.4 Determination of TNFα, IL-1β and IL-6 production 
 
The production of the inflammatory cytokines, TNFα, IL-1β and IL-6, in the culture 
medium of J774A.1 was determined using commercially available ELISA kits (BD 
Biosciences) according to the manufacturer protocol. The experimental design is 
illustrated in Figure 5.1. 
 
 
 
Figure ‎5.1 Schematic diagram of the in vitro experimental protocol.  
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Cells were harvested and seeded at 2 × 10
5
 cells/mL per well into 96-well plates. After 
cells were treated with selected compounds, followed by incubation with or without 
3 ng/mL LPS at 37°C for 2 h, the culture supernatants were collected into microfuge 
tubes and centrifuged at 10,000 rpm for 2–3 min at 4°C. J774A.1 cells were lysed after 
washing with ice-cold 1× PBS buffer. 
 
5.2.5 Determination of lactate dehydrogenase release 
 
The cytotoxicity was assessed by measuring the activity of released lactate 
dehydrogenase (LDH) in the medium. The enzyme activity in the whole cell lysate and 
medium was determined using a CytoTox 96
®
 Non-Radioactive Cytotoxicity Assay kit 
(#G1780; Promega) according to the manufacturer protocol. Briefly, 50 µL diluted cell 
medium (1:5) or cell lysate (1:10) was transferred into a 96-well plate before the 
addition of 50 µL reconstituted substrate mixture. The plate was then covered with foil 
and incubated at room temperature for 30 min; subsequently, 50 µL stop solution was 
added to each well before measuring absorbance. The absorbance was read at 490 nm 
using a POLARstar OPTIMA microplate reader (BMG Lab Technologies, Germany). 
The LDH released into the medium (a measure of cells viability) was expressed as a 
percentage of the total LDH activity (ratio of LDH in lysate and in the medium) [216]. 
 
5.2.6 Determination of protein concentration 
 
As described in Section 2.6, protein concentration in J774A.1 cells was measured 
through the use of a colorimetric bi-cinchoninic acid (BCA) protein kit (#B9643; 
Sigma-Aldrich). First, 1 µL diluted tissue lysate (1 part lysate to 9 µL dH2O) was added 
to 200 µL BCA reagent mix (50 parts reagent A to 1 part reagent B). Solutions were 
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then mixed and incubated at 37°C for 30 min prior to the determination of absorbance 
at 562 nm using a POLARstar OPTIMA microplate reader (BMG Lab Technologies, 
Germany). In each BCA assay, varying dilutions of BSA protein were included to 
create a standard curve in the range of 0–2.0 µg/mL. 
 
5.2.7 Other methods 
 
Other methods used in this study are as described in Chapter 2. 
 
5.3 Results 
 
5.3.1 Inflammatory response of J774A.1 cells to the stimulation of LPS  
 
We firstly determined the effective concentration of LPS (1–100 ng/mL) to induce 
inflammatory cytokines in J774A.1 cells. As shown by the inflammatory cytokines in 
cell culture media, at 1 ng/mL, LPS had no effect on the production of TNFα, whereas 
at 3–100 ng/mL LPS increased TNFα production in a concentration-dependent manner 
(Figure 5.2A). As shown in Figure 5.2B and C, however, there was no significant 
difference between vehicle and LPS-treated J774A.1 in the production of IL-1β and IL-
6 at this range of concentrations. On the basis of these results, 3 ng/mL LPS was used 
in further experiments and TNFα was used as the readout of cell inflammation. 
 
To determine the optimal Mtr concentration, cells were treated with different 
concentrations of Mtr in the absence of LPS. Mtr had no effect on the basal production 
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of TNFα (Figure 5.2D). In contrast, in the presence of LPS, Mtr (1–50 µM) 
significantly reduced LPS-induced increase in TNFα production in a concentration-
dependent manner (Figure 5.2E). The minimum inhibitory concentration of Mtr to 
suppress LPS-induced TNFα production in J774A.1 macrophages was 1 µM. Its 
efficacy was similar to that of the well-known inflammatory inhibitor Bay 11-7082 at 
its maximum concentration (15 µM). 
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Figure ‎5.2 Effects of Mtr on LPS-induced production of inflammatory cytokines in 
J774A.1 cells.  
J774A.1 cells (2 ×10
5
 cells/mL) were treated with 1–100 ng/mL LPS for 2 h to 
stimulate the production of inflammatory cytokines. Levels of (A) TNFα, (B) IL-1β and 
(C) IL-6 in culture media were determined by ELISA. Cells were pretreated with 
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different concentrations of Mtr (0.1, 1, 10 and 50 µM) and 15 µM Bay 11-7082 for 2 h, 
and then treated (D) without or (E) with 3 ng/mL LPS for 2 h. At the end of treatment, 
each cell culture medium was collected and the production of TNFα was determined by 
ELISA as described in Section 5.2.4. Results are expressed as ±SEM and represent at 
least three independent experiments. **P < 0.01 vs. Veh; ††P < 0.01 vs. LPS-untreated 
group; ns: not significant. Veh: vehicle. 
 
 
5.3.2 Effects on the viability of J774A.1 macrophages 
 
To exclude a possibility that the inhibition of inflammation by Mtr resulted from 
cytotoxic effects, we determined LDH activity in the culture medium as an indicator of 
cell damage. As shown in Figure 5.3A, LPS and Mtr caused no significant elevation in 
LDH level at 3 ng/mL and 1 µM, respectively, compared with the positive control 
causing elevation of LDH activity. Consistent with the negative results of LDH release, 
the cells displayed normal morphology in response to these treatments. Similarly, cells 
treated with Mtr or LPS remained similar to the vehicle without cell damage observed 
(Figure 5.3B). 
 
 
 
Chapter Five – Cellular Mechanism of Matrine’s effects 
135 
 
 
Figure ‎5.3 Effects of Mtr on cell viability and morphology in J774A.1 cells.  
(A) J774A.1 cells (2 × 10
5
 cells/mL) were treated with 3 ng/mL LPS or 1 μM Mtr for 2 
h, and cell viability was determined by LDH assay in the cultured medium. (B) Cells 
were examined under a light microscope (magnification, ×100). Results are expressed 
as ±SEM and represent at least three independent experiments. **P < 0.01 vs. Veh; ns: 
not significant. Veh: vehicle. 
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5.3.3 Changes in mTOR and heat shock proteins  
 
As shown in Chapters 3 and 4, the anti-inflammatory effects of Mtr are associated with 
the downregulation of mTOR and upregulation of HSP72. To assess the potential 
involvement of mTOR and HSPs in the effects of Mtr in LPS-activated J774A.1 
macrophages, we measured the mTOR, HSP72, HSF1 and HSP90 expression levels in 
the cell lysate using western blotting. Consistent with the results from the previous 
Chapters, treatment with Mtr reversed the increased protein level of mTOR (P < 0.01 
vs. LPS) to normal levels as seen in the vehicle (Figure 5.4A). 
 
Interestingly, HSP72 expression was significantly suppressed (40% reduction vs. 
vehicle, P < 0.01) following stimulation with LPS with a trend to reduce HSF1. 
However, HSP90 was not affected. Pretreatment with Mtr upregulated HSP72 and 
blocked the suppression of LPS on HSF1 protein expression with no significant effect 
on HSP90 expression (Figure 5.4B-D). 
 
To elucidate the potential mechanism by which Mtr upregulates HSP72 in LPS-
activated J774A.1 macrophages, the HSP72 inhibitor quercetin was examined for 
comparison in this Chapter. Cells were pretreated with quercetin (50 μM) for 2 h, and 
then treated with LPS (3 ng/mL) for 2 h. Interestingly, quercetin significantly increased 
mTOR expression in the presence of LPS compared with the vehicle (Figure 5.4A). As 
expected, quercetin significantly decreased HSP72 (P < 0.01 vs. vehicle) expression in 
the presence of LPS (Figure 5.4B), whereas there were no significant changes in HSF1 
and HSP90 expression levels (Figure 5.4C-D). These data suggest that the reversal of 
LPS-induced upregulation of mTOR may be dependent on an upregulation of HSP72. 
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Figure ‎5.4 Changes in mTOR, HSF1, HSP90 and HSP72 in J774A.1 macrophage 
cells. Cells (2 × 10
5
 cells/well) were pretreated with 1 μM Mtr or 50 μM quercetin for 
2 h, and then treated with 3 ng/mL LPS for 2 h. Cell lysates were immunoblotted for 
(A) mTOR, (B) HSP72, (C) HSF1 and (D) HSP90 and quantified for statistical 
analysis. Results are expressed as ±SEM and represent at least three independent 
experiments. *P < 0.05, **P < 0.01 vs. Veh; †P < 0.05, ††P < 0.01 vs. LPS; ns: not 
significant. Veh: vehicle; Q: quercetin. 
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5.3.4 Effects of matrine on lipopolysaccharide-induced changes in 
inflammatory markers 
 
The anti-inflammatory effect of Mtr was previously explored by measuring secretion of 
TNFα in the cell culture medium. In line with this, the effect of Mtr on CD68 mRNA 
expression was examined by quantitative RT-PCR and the protein expression levels of 
MCP-1 and NLRP3 inflammasome were detected by western blotting. As shown in 
Figure 5.5A-C, LPS at 3 ng/mL significantly increased the levels of these 
inflammatory markers in cell lysate (all P < 0.05 vs. vehicle). As expected, Mtr 
completely reversed all of these increases induced by LPS. In contrast, treatment with 
the HSP72 inhibitor quercetin in the presence of LPS did not show any significant 
reduction in any of these inflammatory markers. 
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Figure ‎5.5 Effects of Mtr in LPS-induced inflammatory markers in the lysate of 
J774A.1 macrophage. Cells were pretreated with 1 µM Mtr or 50 μM quercetin for 
2 h, and then treated with 3 ng/mL LPS. Quantitative RT-PCR results were normalised 
against 18s mRNA for (A) CD68 mRNA expression. Western blotting was analysed 
with densitometry for (B) MCP-1 and (C) NLRP3. Results are expressed as ±SEM and 
represent at least three independent experiments. *P < 0.05 vs. Veh; †P < 0.05, ††P < 
0.01 vs. LPS. Veh: vehicle; Q: quercetin. 
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5.3.5 Effects of matrine on lipopolysaccharide-induced fibrogenic 
markers 
 
The data presented in Chapter 4 showed that Mtr significantly inhibited MCD diet-
induced fibrosis in the liver. To determine the potential mechanisms, the effect of Mtr 
on LPS-induced fibrogenic protein expression in J774A.1 cells was determined. As 
shown in Figure 5.6A and B, exposure to LPS stimulated the expression of key 
proteins of the fibrogenic pathway, namely collagen 1 and TGFβ (all P < 0.01 vs. 
vehicle). Mtr inhibited the increased expression of these proteins in LPS-activated 
J774A.1 macrophages (±55% and 56%, respectively) towards levels seen in the vehicle 
control. In contrast, the HSP72 inhibitor quercetin showed no effect on the increased 
expression of both proteins induced by LPS (P < 0.05 vs. vehicle). There were no 
significant changes in Smad3 and caspase-1 protein expression levels between groups 
(Figure 5.6C and D) during the treatment with LPS, Mtr or quercetin. These results 
suggest that Mtr may attenuate LPS-stimulated fibrogenic pathways and that this effect 
is associated with an upregulation of HSP72 as previously shown. 
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Figure ‎5.6 Effects of Mtr on LPS-induced fibrogenic markers in J774A.1 
macrophages. Cells were pretreated with 1 µM Mtr or 50 μM quercetin for 2 h, and 
then treated with 3 ng/mL LPS. Quantitative RT-PCR results were normalised against 
18s mRNA for (A) collagen 1 mRNA expression. Western blotting was analysed with 
densitometry for (B) TGFβ, (C) Smad3 and (D) caspase-1. Results are expressed as 
±SEM and represent at least three independent experiments. *P < 0.05 vs. Veh; ††P < 
0.01 vs. LPS; ns: not significant. Veh: vehicle; Q: quercetin. 
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5.4 Discussion 
 
This Chapter investigated the effects of Mtr on LPS-induced activation of the pathways 
of inflammation and fibrogenesis at the cellular level in J774A.1 macrophages. The 
results showed that Mtr markedly ameliorated LPS-induced stimulation of cellular 
inflammatory and fibrotic activities in J774A.1 macrophages. The inhibitory effect of 
Mtr was associated with downregulation of mTOR and upregulation of HSP72. One 
consistent pattern of the effect of Mtr to inhibit LPS-induced increases in mTOR and 
markers of inflammatory and fibrogenic pathways was the upregulation of HSP72. 
 
Macrophages play a major role in both inflammation and fibrosis in NASH. The 
macrophages present within the liver come from the activation of KCs (resident 
macrophages within the liver) and circulating monocyte-derived macrophages [261]. 
Once activated, macrophages produce inflammatory and fibrogenic cytokines to cause 
liver inflammation and fibrosis [262]. The results from this Chapter show that a low 
LPS concentration level can activates TNFα production in J774A.1 after 2 h. This is 
consistent with the report that stimulation of J774A.1 murine macrophages with LPS 
markedly increases TNFα production [263]. It has been suggested that the presence of 
LPS in KCs accelerates liver injury and aggravates the progression of NASH [128, 
264]. The increase in TNFα production enhances inflammation and fibrogenesis in 
J774A.1 macrophages. Interestingly, the present study showed that low LPS 
concentration increased TNFα, but not IL-1β and IL-6, production. This suggests that 
TNFα is the major inflammatory cytokine observed after LPS stimulation. This is 
consistent with previous reports showing that Mtr inhibits the release of TNFα induced 
by KCs activation in cold ischaemia–reperfusion injury [200]. These data together 
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suggest that the inhibitory effect of Mtr on hepatic inflammation observed in Chapter 4 
is likely to be a result, at least in part due to its effects on macrophages including KCs. 
 
Several studies have suggested that upregulation of HSP72 is associated with the 
inhibition of inflammation [265, 266]. Earlier studies have indicated that upregulation 
of HSP72 by Mtr or other substances significantly protects against TNFα production, 
inhibiting inflammation [219, 267, 268]. Consistent with results from Chapters 3 and 4, 
the anti-TNFα effect of Mtr was associated with upregulation of HSP72 in J774A.1 
cells. Given that upregulation of HSP72 might play a role in the anti-inflammatory 
effects of Mtr, the upregulation of this protein may be a potential cellular mechanism 
leading to reduction of inflammation and fibrosis. In this Chapter, protection by Mtr 
was correlated with quercetin, an HSP72 inhibitor, to further investigate the cellular 
mechanism of the anti-inflammatory effects of Mtr. These data add support to the role 
of HSP72 in Mtr preventing inflammation. These findings together raise the possibility 
that Mtr might offer distinct therapeutic effects to manifestations of NASH. 
 
Another potential cellular target for the inhibitory effect of Mtr is mTOR. Inhibition of 
mTOR in experimental liver fibrosis significantly decreases fibrosis progression [164]. 
The results in this Chapter showed that Mtr also independently inhibited mTOR protein 
in J774A.1 macrophages, in agreement with the effect on mTOR in NASH mice. This 
is also consistent with recent clinical observations that Mtr inhibits mTOR expression 
in acute myelocytic leukaemia [252]. Further, the effects of Mtr on mTOR were evident 
even after treatment with the HSP72 blocker quercetin. 
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Consistent with the increased TNFα production following LPS stimulation, increased 
inflammatory markers including CD68, MCP-1 and NLRP3 were observed in activated 
J774A.1 cells. These findings are novel because there are no reports regarding the 
effect of Mtr on inflammation marker levels in LPS-stimulated macrophages. Further, 
the anti-inflammatory effects of Mtr could inhibit the inflammatory cytokines, 
consistent with the previous observations from Chapter 4. Quercetin however increased 
the expression of these proteins and exacerbated inflammation after stimulation with 
LPS. Blocking of HSP72 by quercetin can make cells more vulnerable to inflammatory 
and mTOR activity. Indeed, upregulation of HSP72 by Mtr was accompanied by 
inhibition of TNFα in LPS-stimulated inflammation. These results suggest that the 
induction of HSP72 by Mtr may confer protection against LPS-induced inflammation at 
least in part by inhibiting production of key inflammatory cytokines. 
 
Another protective effect of Mtr is the prevention of the increased expression of 
fibrogenic pathways induced by MCD diet in mice (Chapter 4). In this Chapter, Mtr 
inhibited TGFβ and collagen 1–associated LPS-induced stimulation of cellular 
fibrogenesis, whereas quercetin further increased both cytokines after stimulation with 
LPS. This is consistent with previous findings that Mtr inhibits TGFβ and prevents liver 
fibrosis in vitro and in vivo in other animal models [189]. These results provide further 
support for the idea that inhibition of fibrogenic pathways by Mtr might provide a 
possible mechanism for its antifibrotic effects. 
 
In summary, the results in this Chapter have revealed the possible mechanism—and 
promising novel anti-inflammatory and antifibrotic properties—of the beneficial effect 
of Mtr. Consistent with the previous Chapters, the major target of this mechanism 
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appears to be the mTOR-HSP72 axis. In addition, treatment with quercetin inhibited 
HSP72 and increased mTOR, supporting this explanation. It is likely that Mtr confers 
protection against LPS-induced inflammation and fibrosis at least in part by 
upregulating HSP72 and inhibiting mTOR. These findings suggest that the anti-
inflammatory and antifibrotic effects of Mtr in macrophages are important mechanisms 
for the therapeutic effects in NASH as discussed in previous Chapters. 
 
  
 
Chapter 6 General Discussion
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6.1 Introduction 
 
This Chapter will summarise the key findings from Chapters 3, 4 and 5 and discuss the 
potential implications and limitations of the study. It concludes by providing 
suggestions for further research based on the novel findings in this thesis. 
 
6.2 Major findings 
 
Chapter 1 reviewed literature reports on the research of NASH and current status of the 
treatments for NASH. Secondly, it elaborates the rationale for the selection of Mtr as a 
candidate for the study in this thesis to investigate its effects and mechanisms for the 
treatment of this disease with distinct properties different from others. 
 
In brief, NAFLD is an umbrella term for metabolic liver disease, with a global increase 
in prevalence accompanied by increased metabolic diseases such as obesity and T2D. It 
is the most common cause of chronic liver disease and regarded as a manifestation of 
the metabolic syndrome in the liver. NAFLD has different stages based on its natural 
history and the disease pathogenesis. It has been widely recognised that excessive lipid 
accumulation in the liver causes the first hit. This benign stage can progress to NASH 
(steatohepatitis) with additional inflammation, cell damage and/or fibrosis in the liver, 
and may further deteriorate to cirrhosis and liver failure. However, treatment of 
NAFLD is currently unsatisfactory. One challenge in the study of therapeutics for 
NASH is the lack of a single animal model that fully reflects the pathological 
characteristics as presented in humans. 
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Current drugs used for the treatment of NAFLD are inadequate because of various 
adverse effects or unreliable effects on inflammation and fibrosis. Indeed, it is 
important to identify a novel therapeutic for NAFLD, and drug repurposing may be an 
effective strategy. This approach has been increasingly used in recent years because of 
existing knowledge of bioavailability and more reliable safety. Using this approach, this 
thesis selected Mtr as a candidate drug to examine its therapeutic effects for the 
treatment of NAFLD. 
 
Chapter 3 investigated the potential of Mtr for the treatment of NAFLD in HFru-fed 
and HFD-STZ models in mice. Mtr treatment was able to attenuate hepatosteatosis and 
associated disorders in glucose homeostasis. Chapter 4 examined the therapeutic effects 
of Mtr in the treatment of hepatic inflammation and fibrosis, two other characteristics 
of NASH. Chapter 5 examined the therapeutic effects of Mtr on inflammation in a 
macrophage-like cell line and the cellular mechanism involved. These major findings 
are summarised in the following three sections. 
 
6.2.1 Reduction of hepatosteatosis and associated disorders in glucose 
homeostasis 
 
Chapter 3 evaluated the therapeutic effects of Mtr on hepatosteatosis and associated 
disorders in glucose homeostasis in HFru-fed mice. The most important finding from 
this study is that Mtr was effective for the treatment of hepatosteatosis and associated 
glucose intolerance. Several mechanisms for the antisteatotic effects of Mtr were 
examined. The results suggested that Mtr reduced TG accumulation in the liver, but not 
in muscle. This indicates that the liver is a major site for the action of Mtr and that 
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improved glucose tolerance is attributable to a reduction in hepatosteatosis. Further 
studies suggested that inhibition of hepatic DNL is likely the underlying mechanism 
responsible for the antisteatotic effect of Mtr in mice fed with HFru diet. Moreover, Mtr 
inhibited ER stress, which was associated with increased DNL, and upregulated hepatic 
protein expression of HSP72. Importantly, Mtr displayed a distinct mechanism in 
reducing hepatosteatosis associated with glucose intolerance via upregulation of 
HSP72. This Chapter further examined the efficacy of Mtr in hepatosteatosis-associated 
hyperglycaemia in a mouse model of T2D induced by HFD-STZ. The anti-
hyperglycaemic effects of Mtr observed in this study were also found closely associated 
with a reduction in hepatosteatosis (Figure 6.1). 
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Figure ‎6.1 Mtr ameliorated of hepatosteatosis and associated hyperglycaemia. (A) 
Excess carbohydrate causes increased hepatic ER stress-DNL pathways through 
downregulation of HSP72. (B) Mtr exerts its effects through upregulation of HSP72, 
preventing hepatic ER stress-DNL pathways and associated hyperglycaemia. 
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In summary, Mtr treatment improved hepatosteatosis and glucose tolerance in both 
models, suggesting that the liver is the major target of Mtr because lipid and glucose is 
mainly metabolised in the liver. Upregulation of HSP72 by Mtr may suppress ER stress 
to inhibit DNL, and therefore hepatosteatosis, hyperglycaemia and NAFLD. The 
findings of upregulation of HSP72 from our present study demonstrate, for the first 
time, a plausible mechanism for the antisteatotic therapeutic effect of Mtr on 
hepatosteatosis and hyperglycaemia in mouse models of HFru feeding. 
 
6.2.2 Amelioration of hepatic inflammation and fibrosis 
 
The third study (Chapter 4) investigated the hepatoprotective effect including anti-
inflammatory and antifibrotic effects in an MCD diet-induced mouse model of NASH. 
The first important finding of this study is that Mtr was able to inhibit inflammation 
without affecting caloric intake in MCD mice. However, Mtr treatment failed to reduce 
hepatosteatosis in MCD-fed mice as it does in HFD, HFru diet and T2D mice models. 
Because MCD diet-induced hepatosteatosis is due to the disruption of TG export, this 
finding suggests that Mtr does not promote TG export. 
 
The second important finding is that Mtr exerted its antifibrotic effects at the transition 
stage of NASH without fibrosis to severe NASH-related fibrosis. The anti-
inflammatory effect of Mtr in MCD diet-induced NASH was evidenced by marked 
decreases in the activation of TNFα secretion and CD68 and NLRP3 expression. This 
mouse model displayed mild fibrosis in the liver because of a short period of MCD diet 
feeding. In this short-term MCD model, Mtr reduced TGFβ and Smad3 expression and 
inhibited fibrosis. In addition, protein expression levels of TGFβ and caspase-1 (which 
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play a role in fibrosis), and Smad3 and collagen type 1 (which are associated with 
collagen deposition), were decreased. Overall, Mtr demonstrated therapeutic effects for 
the inhibition of inflammation and fibrosis in MCD diet-fed mice. Again, the anti-
inflammatory and antifibrotic effects of Mtr were accompanied by upregulation of 
HSP72 and downregulation of mTOR pathways (Figure 6.2). 
 
 
 
Figure ‎6.2 Mtr dysregulated of HSP72 and mTOR expression. (A) Hepatic 
inflammation and fibrosis are the major phenotypes of NASH. (B) Mtr exerts its effects 
through upregulation of HSP72 and downregulation of mTOR, preventing hepatic 
inflammation and fibrosis, and therefore protecting against the development of NASH. 
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6.2.3 Cellular mechanism involved in the effects of matrine 
 
Chapter 5 investigated the mechanism of the anti-inflammatory and antifibrotic effects 
in macrophages, a key cell type responsible for NASH, using a well characterised 
murine macrophage cell line. The findings obtained in this Chapter were similar to the 
markers measured in Chapter 4, as a further indication of the anti-inflammatory effects 
of Mtr at the cellular level. The major inflammation and fibrosis markers activated by 
LPS in J774A.1 macrophages were inhibited by Mtr despite the low concentration of 
Mtr used. Notably, Mtr markedly inhibited LPS-induced increases in mTOR in 
J774A.1, suggesting that the therapeutic effect of Mtr may involve the inhibition of 
mTOR-related autophagy and inflammation in NASH, similar to the results in the MCD 
diet model reported in this thesis. 
 
Overall, this thesis addressed the specific aims based on the gaps in knowledge 
identified by careful evaluation of the literature in Chapter 1. The relationship of the 
concluded studies to the specific aims are summarised in Figure 6.3. 
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Figure ‎6.3 A schematic view of the findings related to the research aims in Figure 
1.9. 
Mtr acts as a promising antisteatotic drug by blocking the ER stress-DNL axis required 
for the development of hepatosteatosis. Many of the markers in this pathway, such as 
eIF2α, CHOP, IRE1, SREBP1c, ChREBP, SCD1 and FAS, are downregulated after 
Mtr treatment. Moreover, Mtr improves hyperglycaemia associated with 
hepatosteatosis, and attenuates hepatic inflammation and fibrosis by inhibiting 
inflammatory and fibrogenic pathways in NASH. The anti-inflammatory and 
antifibrotic effects are evidenced by blocking TNFα, NLRP3, CD68, TGFβ and 
collagen 1 expression. These anti-NASH effects involve upregulation of HSP72 as well 
as reduction in the mTOR axis. Figure 6.4 illustrates the proposed mechanism linking 
the above-mentioned effects to Mtr’s therapeutic properties in NAFLD and associated 
disorders. 
 
Chapter six – General Discussion 
 
155 
 
 
 
Figure ‎6.4 Schematic illustration of the proposed mechanism for Mtr’s therapeutic 
effects. Mtr achieves these effects through ameliorating ER stress, DNL, and 
inflammatory and fibrotic signalling cascades via hepatic HSP72 upregulation and 
mTOR reduction. These findings suggest that Mtr may be repurposed for the treatment 
of NAFLD and associated diseases such as hyperglycaemia and NASH. Solid lines 
indicate hypothesised mechanistic links; dotted lines indicate pathways requiring future 
studies. 
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6.3 Limitations and future studies 
 
To achieve the ultimate goal of repurposing Mtr for the treatment of NAFLD/NASH, 
further studies are needed in three general aspects. 
6.3.1 Long-term safety for the new usage 
 
The results in Chapter 3 showed that the antisteatotic effects of Mtr are due to 
decreased DNL and associated disorders in glucose metabolism. First, further 
evaluation of the long-term safety at the dose designed for this new therapeutic 
application is required. This is important because the reported safety of Mtr has not 
been evaluated for the metabolic condition described in this thesis. Treatments for 
metabolic conditions including NAFLD/NASH require long-term administration. 
 
6.3.2 Clinical trials for the new usage 
 
Second, additional studies are needed to fully characterise the therapeutic effects of Mtr 
to provide more comprehensive evidence to guide the clinical trials for its new 
application. According to the basic science data from this Chapter, Mtr is able to target 
the major components of NAFLD pathogenesis. Randomised controlled trials are the 
most appropriate study design to confirm the effectiveness of Mtr treatment in humans 
with NAFLD/NASH. 
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6.3.3 Precise mechanism for the molecular mode of action 
 
6.3.3.1 Anti-hepatosteatosis 
 
Third, the molecular mode of action and pathways involved require more detailed 
studies. The specific proposals for the second and third aspects are suggested below. 
Mtr showed a reduction in lipid accumulation in HFru and HFD-STZ mice. However, 
signs of hepatosteatosis were not assessed by morphological studies. One feasible 
approach for the assessment of lipid droplets is the use of oil red O staining [269, 270]. 
In future studies, histological liver sections should be performed to further assess 
hepatosteatosis in these nutritional models. 
 
In addition, the mechanisms underlying the effect of Mtr on hepatosteatosis need 
further study. As reviewed in Chapter 3, dietary fructose has been shown to have a 
special tendency to induce NAFLD dependent on the activation of the ER stress 
pathway [44]. ER stress may be a novel mode of action for the inhibitory effect of Mtr 
on hepatosteatosis. Experiments using TUDCA, a classic inhibitor of ER stress, in HFru 
mice treated with Mtr are suggested. This will help to determine whether the 
amelioration of HFru-induced hepatosteatosis and associated disorders in glucose 
homeostasis by Mtr is due to decreased ER stress. Measuring ER stress markers 
including eIF2α, CHOP, IRE1 and XBP1 will help to confirm the role of ER stress in 
Mtr’s inhibitory effects. A similar animal study may be conducted with HSP72 
knockout mice to confirm the role of HSP72 in this model. The HSP72 knockdown 
approach may be used to provide definitive evidence to prove the hypothesised role of 
HSP72 in Mtr’s antisteatotic effects. 
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6.3.3.2 Anti-inflammation 
 
The data from Chapter 4 suggested that the anti-inflammatory effects of Mtr may be 
related to upregulation of hepatic HSP72 as a likely mechanism. Another possible 
mechanism is the inhibition of hepatic mTOR, which was downregulated in Mtr-treated 
MCD diet-fed mice—this will be discussed below. Using an animal model with HSP72 
knockdown or knockout may provide definitive evidence to prove the hypothesised role 
of HSP72 in Mtr’s anti-inflammatory effects. Importantly, mice with muscle-specific 
transgenic overexpression of HSP72 are protected against high fat-induced obesity and 
metabolic disorders [196]. Future studies are needed to examine the anti-inflammatory 
effect of Mtr by using an HSP72 knockout model. Further, the only mouse model in 
which mTOR is genetically altered is the ‘flat-top’ mutant, where incomplete and 
complete deletions cause failure of mTOR inhibition and shorter lifespan of mice, 
respectively [271]. 
 
Current data in this Chapter showed that Mtr can significantly inhibit the activation of 
inflammatory cytokines. This inhibition was proposed to be associated with HSP72-
mTOR pathways in the liver. However, NASH features were not assessed by 
histological abnormalities of steatohepatitis in the liver. In future studies, the NASH 
activity scores of hepatic steatosis, inflammation, hepatocyte ballooning and fibrosis 
should be performed to further assess Mtr’s efficiency for the treatment of NASH in 
this nutritional model [10]. This can be achieved by staining liver sections with H&E to 
examine macrovesicular and microvesicular steatosis, admixtures of inflammatory 
cells, collagen fibres and hepatocyte ballooning—features that are often observed in 
NASH [272]. 
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6.3.3.3 Anti-cell injury 
 
Hepatic cell injury has been proposed as another component of NASH features [6]. 
Therefore, further studies may be performed to examine the anti-cell injury of Mtr by 
using cell lines such as HepG2 cells, which mimic hepatocytes. First, hepatic injury 
may be assessed by measuring plasma ALT, a standard indication of liver injury. 
Hepatocyte ballooning is another indication of cell injury and a key feature required for 
the diagnosis of NASH. With H&E staining and microscopic examination, hepatocyte 
ballooning is seen as hepatocytes with fatty changes and groups of ballooned 
hepatocytes with enlarged, rounded, rarefied cytoplasm, some of which contain small 
Mallory-Denk bodies. Mtr’s effects on hepatocyte ballooning can be quantified by 
histological grading and staging systems of NASH [10]. 
 
6.3.3.4 Anti-fibrosis 
 
In light of these antisteatotic, anti-inflammatory and antifibrotic effects of Mtr, it may 
be worthwhile to investigate the cellular mechanism underlying the antifibrotic effects 
of Mtr in cell lines representative of HSCs. The antifibrotic effects of Mtr may be 
further studied using an appropriate cell line. For example, human HSCs (LX-2) can be 
pretreated with Mtr, and then exposed to a potent fibrotic inducer [273, 274]. 
Quantitative RT-PCR and western blotting can be used to measure mRNA and protein 
levels of fibrogenic genes. 
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6.4 Final conclusion and potential significance 
 
Overall, the studies in this thesis have laid a solid base for further investigation of the 
cellular mechanism of the therapeutic effects of Mtr attributed to its effects on HSP72-
mTOR pathways for the treatment of NASH and associated metabolic disorders. The 
results will serve the development of new treatments for NAFLD. 
 
The findings from this thesis have significant implications for evaluating the 
therapeutic effects of Mtr in the treatment of NAFLD/NASH. The novelty of Mtr is of 
potential great significance for the treatment of patients suffering NAFLD. 
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Repurposing matrine for the treatment of hepatosteatosis and
associated disorders in glucose homeostasis in mice
Ali Mazhari1, Xiao-Yi Zeng1, Xiu Zhou1, Songpei Li1, Jun Xu2, Wen Tan3, Ross Vlahos1, Stephen Robinson1 and Ji-Ming YE1
The present study investigated the efﬁcacy of the hepatoprotective drug matrine (Mtr) for its new application for hepatosteatosis
and associated disorders in glucose homeostasis. The study was performed in two nutritional models of hepatosteatosis in mice
with various abnormal glucose homeostasis: (1) high-fructose diet (HFru) induced hepatosteatosis and glucose intolerance from
hepatic, and (2) hepatosteatosis and hyperglycemia induced by high-fat (HF) diet in combination with low doses of streptozotocin
(STZ). Administration of Mtr (100 mg/kg every day in diet for 4 weeks) abolished HFru-induced hepatosteatosis and glucose
intolerance. These effects were associated with the inhibition of HFru-stimulated de novo lipogenesis (DNL) without altering
hepatic fatty acid oxidation. Further investigation revealed that HFru-induced endoplasmic reticulum (ER) stress was inhibited,
whereas heat-shock protein 72 (an inducible chaperon protein) was increased by Mtr. In a type 2 diabetic model induced by HF-STZ,
Mtr reduced hepatosteatosis and improved attenuated hyperglycemia. The hepatoprotective drug Mtr may be repurposed for the
treatment of hepatosteatosis and associated disorders in glucose homeostasis. The inhibition of ER stress associated DNL and fatty
acid inﬂux appears to play an important role in these metabolic effects.
Keywords: matrine; hepatosteatosis; glucose intolerance; hyperglycemic control
Acta Pharmacologica Sinica (2018) 39:1–7; https://doi.org/10.1038/s41401-018-0016-8
INTRODUCTION
The liver plays an important role in regulating whole-body lipid
metabolism and glucose homeostasis. Excess accumulation of
lipids (namely hepatosteatosis), either from endogenous de novo
lipogenesis (DNL) and/or inﬂux of exogenous fatty acids (FA), can
disturb glucose homeostasis, increasing the risk of type 2
diabetes (T2D) [1, 2]. Although the degree of hepatosteatosis
and T2D do not necessarily tightly coupled [3], inhibition of excess
hepatic DNL has been shown to ameliorate hepatosteatosis and
associated glucose intolerance [4]. Shulman and colleagues have
also demonstrated that correction of hepatosteatosis in patients
with T2D is important for hyperglycemia control [5]. In search for a
new therapeutic for the treatment of hepatic steatosis from DNL,
we have taken the approach of repurposing existing drugs for
these conditions [6, 7].
Matrine (Mtr) is a small molecule (MW: 248) found in
Sophora and it is structurally different from the drugs currently
used to treat T2D [8–10]. Mtr has been used clinically as a
hepatoprotective drug for the treatment of tumors and
viral hepatitis [8], where DNL is often increased [11]. A recent
study from our laboratory found that Mtr is able to reduce
hepatosteatosis, fasting blood glucose and glucose intolerance in
high fat (HF)-fed mice [9]. However, the HF model does not
exhibit the characteristics of DNL-induced hepatosteatosis and
glucose intolerance because the accumulation of triglyceride (TG)
in the liver is due to a direct inﬂux of lipids into the liver from the
HF diet [12, 13].
The liver is a major site of DNL production from carbohydrates
[12, 14] and interestingly the inhibition of hepatic DNL reduces
hepatosteatosis and hyperglycemia [4, 15]. It has been suggested
that an increase in DNL is the second major source of lipid
accumulation in the liver and contributes about 26% of patients
with hepatosteatosis [16]. In mice, a high-fructose (HFru) diet
induces hepatosteatosis as early as 1 day [17] prior to the
development of glucose intolerance [12, 18, 19]. Dietary fructose is
almost entirely metabolised in the liver in its ﬁrst pass, and serves
mainly as a substrate for DNL in both animals [13, 17, 20] and
humans [19, 21–23]. HFru diets increase the expression of
lipogenic transcription factors, sterol regulatory element binding
protein (SREBP1c) and carbohydrate response element binding
protein (ChREBP), which upregulate lipogenic genes. Upregulation
of these lipogenic transcription factors can result in hepatostea-
tosis and glucose intolerance via promoting DNL [24, 25]. Notably,
HFru-stimulated hepatic DNL via SREBP1c is dependent on the
activation of the ER stress pathway [12, 26].
The primary aim of the present study was to investigate
whether the hepatoprotective drug Mtr can limit the hepatostea-
tosis and the associated glucose intolerance that usually results
from increased DNL in HFru-fed mice. If so, the second aim was to
investigate whether the action of Mtr is via the ER stress pathway.
Finally, we also evaluated whether Mtr assists glycemic control in a
T2D mouse model generated by a combination of HF and
streptozotocin (STZ) where an increased DNL via SREBP1c is also
involved [27, 28].
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MATERIALS AND METHODS
Animals and diets
C57BL/6J mice aged 10–12 weeks and weighing 21–24 g were
obtained from the Animal Resource Centre Pty. Ltd. (Perth,
Australia). The animals were housed in a temperature-controlled
room (22 ± 1 °C) on a 12-h light/dark cycle with free access to food
and water. Mice were fed ad libitum for 1 week on a normal chow
diet (~70% calories from starch, ~10% calories from fat, and ~20%
calories from protein; Gordon’s Specialty Stock Feeds, Yanderra,
Australia). Mtr (≥ 98% by HPLC) was purchased from Sigma
Aldrich. The experiments described in this manuscript were
approved by the Animal Ethics Committee of RMIT University
(Application ID: 1012) and conducted in compliance with the
guidelines of the National Health and Medical Research Council of
Australia for Animal Experimentation.
Two sets of animal experiments were performed. In the ﬁrst set
of experiments, mice were fed a HFru diet (35% fructose, 35%
starch, ~10% fat and ~20% protein) to generate hepatosteatosis.
Mice were fed for 8 weeks with or without Mtr at a dose of 100
mg/kg every day as a food additive in the last 4 weeks as
described previously [9, 10]. Body weight gain and food intake
were measured twice a week. For blood glucose levels, blood
samples were collected from the tail tip and measured using a
glucometer (AccuCheck II; Roche, New South Wales, Castle Hill,
Australia) after 2 weeks of Mtr treatment. In the second set of
experiments, the effects of Mtr on hepatosteatosis and hypergly-
cemia were examined in a T2D model induced by HF feeding in
combination with low doses of STZ as previously reported [28–30].
Brieﬂy, mice were fed a HF diet (45% calorie from lard, 20%
calories from protein and 35% calories from carbohydrate) for
14 weeks to induce insulin resistance. After 8 weeks of HF feeding,
mice were injected with STZ at a low dose (40 mg/kg per day, ip)
for 5 consecutive days to reduce the level of plasma insulin by
~50% [28–30]. One week after the last injection of STZ, fasting
blood glucose was usually increased by 50%–100% (hyperglyce-
mia, deﬁned as T2D). The T2D mice were then divided into 2
groups: one group receiving Mtr added in the HF diet (100mg/
kg per day) for 4 weeks (T2D-Mtr) whereas the other group was
fed HF alone (T2D-Con) for the same period of time. During the
period of Mtr treatment, fasting blood glucose was monitored
once a week. A normal control group of mice (CH-Con) was
included for the same period. At the end of both sets of
experiments, mice were killed by cervical dislocation and liver
tissues were collected and freeze-clamped immediately for further
analysis.
Assessment of the effect on hepatosteatosis
Hepatosteatosis was assessed by measuring TG content in
the liver. Mice were fasted for 5–7 h before being killed; the
liver was collected and freeze-clamped immediately. As
described previously [13, 28] plasma and liver TG levels
were determined with a Peridochrom triglyceride GPO-PAP
biochemical kit (Roche diagnostics). The method of lipid extraction
from liver with chloroform/methanol has been described
previously [17].
Assessment of the effect on hepatic FA oxidation
FA oxidation was assessed in fresh liver tissue ex vivo as
described [12, 13]. Brieﬂy, fresh liver samples were homogenised
in an isolating medium which contained 100mM sucrose,
50mM Tris, 100mM KCl, 1 mM KH2PO4 and 0.1 mM EGTA, 0.2%
FA-free BSA at pH 7.0. The liver homogenate was incubated
with [14 C]-palmitate and [14 C]–CO2 produced from the incubation
was collected in 1 M sodium hydroxide. Palmitate oxidation
rates were determined by counting the 14 C radioactivity of
captured CO2 and acid-soluble metabolites and oxidation
rate were expressed as nanomoles of CO2 per gram of wet
weight per hour [12].
Assessment of the effects on DNL and ER stress
DNL and ER stress were assessed by immunoblotting with speciﬁc
anti-bodies for the key proteins in the DNL, ER stress and heat shock
protein (HSP) pathways based on our recent work [9, 10, 12, 13, 17].
Brieﬂy, freeze-clamped liver was homogenized in ice-cold lysis
buffer supplemented with fresh protease inhibitor and phosphatase
inhibitor (Sigma Aldrich). The key proteins in the DNL pathway
included SREBP-1 (Santa Cruz), ChREBP (Abcam), acetyl-CoA
carboxylase (ACC, Upstate), fatty acid synthase (FAS, Abcam) and
stearoyl-CoA desaturase 1 (SCD-1, Cell Signaling). The key proteins
measured in the ER stress pathway included inositol-requiring
kinase 1 (IRE1, Abcam), eukaryotic translation initiation factor 2α
(eIF2α, Cell Signaling) and CHOP (Santa Cruz). The effect on the HSP
pathway was assessed by heat shock protein 72 (HSP72, Abcam)
based on our recent work [9, 10]. Proteins were quantiﬁed using a
ChemiDoc and densitometry analysis was performed using Image
Lab software (Bio-Rad Laboratories, USA).
Statistical analysis
All results are presented as means ± s.e.m. One-way analysis of
variance was used to assess the statistical signiﬁcance across all
groups. When signiﬁcant differences were found, the Tukey-
Kramer multiple comparisons post hoc test was used to establish
differences between groups. Differences at P < 0.05 were con-
sidered to be statistically signiﬁcant and P < 0.01 were considered
to be highly signiﬁcant.
RESULTS
Effects on body weight, adiposity, hepatosteatosis and glucose
tolerance in HFru-fed mice
HFru feeding is a well-deﬁned model of hepatosteatosis, visceral
adiposity and glucose intolerance resulting from increased DNL in
the liver [12]. As expected, HFru feeding moderately increased the
mass of epididymal fat (by 40%, P < 0.01) without altering body
weight or food intake (P > 0.05; Fig. 1a–c). The TG content
(indicative of hepatosteatosis) was increased dramatically in
the liver (by threefold) but only moderately in muscle (~35%)
(both P < 0.01; Fig. 1d). As shown in Fig. 1e, HFru-fed mice also
showed moderate glucose intolerance.
Administration of Mtr prevented the moderate body weight
gain (8%–10%) in HFru-fed mice during this period of time
(Fig. 1a). It corrected HFru-induced increases in epididymal fat,
liver TG content and glucose intolerance (all, P < 0.01 vs untreated
HFru-fed mice) to the levels similar to CH-fed normal mice
(Fig. 1b–e). Although not signiﬁcantly reduced, muscle TG content
in Mtr-treated HFru-fed mice was no longer different from the
value of CH-fed normal mice (Fig. 1d).
Effects on FA oxidation and DNL in the liver of HFru-fed mice
We ﬁrst examined whether Mtr treatment may promote FA
oxidation in the liver of HFru-fed mice. As shown in Fig. 2a,
palmitate oxidation by the liver homogenates was not affected by
the treatment with Mtr, suggesting that the reduced hepatostea-
tosis by Mtr is not likely to be due to an increased FA oxidation in
the liver. We next examined the DNL pathway because
HFru-induced hepatosteatosis is believed to result from the
stimulation to this pathway in the liver [13, 17, 20]. As expected,
HFru-fed mice exhibited dramatic increases in DNL proteins in the
liver (Fig. 2b–e), including SREBP-1c (by 2-fold), ChREBP (by 33%)
ACC (by 3-fold), FAS (by 3.4-fold) and SCD-1 (by 4-fold; all P < 0.05).
Interestingly, these lipogenic proteins except for ACC were
signiﬁcantly reduced by the treatment with Mtr, including
SREBP-1c (by 45%, P < 0.01), ChREBP (by 33%, P < 0.05), SCD-1
(by 32%, P < 0.01) and FAS (by 24%, P < 0.05). These results
suggest that the reduced TG content in the liver by Mtr can be
attributed to its inhibitory effect on HFru-induced increase in
hepatic DNL.
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Effects on ER stress and HSP72 in the liver of HFru-fed mice
By promoting DNL in the liver, the activation of ER stress represents
a key step in the pathogenesis of hepatosteatosis [12, 31, 32].
As shown in Fig. 3a, HFru-fed mice exhibited marked increases of
the mature form of eIF2α (by 2-fold), CHOP (by 2.3-fold) and
IRE1 (by 2-fold) along with the upregulation of the DNL pathway
in the liver. Treatment with Mtr markedly reduced the protein
levels of these hepatic ER markers towards the levels seen in CH
fed mice. These results indicate that Mtr induced-suppression of ER
markers may be associated with the improvement in lipogenesis,
which could account for its beneﬁcial effects on hepatosteatosis.
Recent studies indicate that HSP72 is likely to mediate the effect of
Mtr on hepatosteatosis and glucose intolerance [9, 33, 34]. As
shown in Fig. 3b, there was ~50% suppression of HSP72 (P < 0.05
vs CH fed mice) in the liver of HFru-fed mice and this reduction was
reversed following treatment with Mtr (P < 0.05 vs untreated HFru-
fed mice).
Effects on hyperglycemia in T2D mice
To investigate the relationship of the effect on hepatosteatosis
with glycemic control, we examined the metabolic effects of Mtr
in T2D mice generated by a HF diet in combination with low doses
of STZ [9, 27, 28]. The body weight were reduced in HF-STZ
induced T2D mice (by ~15%) and treatment with Mtr had no
effect on the body weight (Fig. 4a), while visceral adiposity
remained unchanged in T2D-Con mice compared to CH-fed mice
Mtr signiﬁcantly reduced epididymal fat in T2D mice (P < 0.05,
Fig. 4b). T2D-Con mice displayed typical fasting hyperglycemia
and Mtr treatment signiﬁcantly reduced the degree of the
hyperglycemia over the period of 4 weeks (by 20%–30%, Fig. 4c).
As expected, HF-STZ-induced T2D showed severe glucose
intolerance but this was not attenuated by the treatment with
Mtr (Fig. 4b).
Effect on TG levels in T2D mice
Recent studies indicate that hepatosteatosis can contribute to
hyperglycemia and hepatic insulin resistance [12, 35]. To
determine whether the reduced hepatosteatosis by resulting from
Mtr treatment is associated with the control of hyperglycemia in
T2D mice, we measured the TG content in the liver. As shown in
Fig. 5a, b, T2D mice exhibited hypertriglyceridemia and hepatos-
teatosis, however Mtr signiﬁcantly reduced these conditions (P <
0.05). Together, these results clearly indicate that Mtr reduces the
T2D-induced hepatosteatosis that is associated with hyperglyce-
mia and this could account for its beneﬁcial effects on the
regulation of lipid metabolism.
DISCUSSION
The present study investigated whether the hepatoprotective
drug Mtr can treat the hepatosteatosis and associated
glucose intolerance in HFru-fed mice resulting from increased
DNL. Consistent with our previous studies [13, 17, 36], HFru-fed
mice developed hepatosteatosis and glucose intolerance
by promoting ER stress associated DNL. Treatment of these
mice with Mtr ameliorated hepatosteatosis and glucose intoler-
ance. Within the liver, Mtr decreased the protein expression
of DNL enzymes concomitant with reduced ER stress. We
further examined the effects of Mtr on hepatosteatosis in
relation to glycemic control in T2D mice, which display a
phenotype of hyperglycemia and hepatosteatosis associated
with increased DNL [27, 28]. The results showed that Mtr
treatment reduced hepatosteatosis and improved hyperglycemia.
Collectively, these ﬁndings suggest that Mtr has the potential
to be repurposed for the treatment of hepatosteatosis resulting
from increased DNL and associated disorders in glucose
metabolism.
Fig. 1 Effects of Mtr on body weight gain, visceral adiposity, hepatosteatosis and glucose tolerance in HFru-fed mice. Mice were fed a high-
fructose (HFru) diet for 8 weeks and matrine (Mtr, 100mg/kg per day in diet) was administered in the last 4 weeks. A glucose tolerance
test (GTT at 3 g glucose/kg BW, ip) was conducted after 2 weeks of treatment with Mtr. Epididymal (Epi) fat weight and liver TG content were
determined at the end of the study. (a) Body weight gain, (b) Epididymal fat weight as a percentage of body weight, (c) Caloric intake, (d) TG
content in liver and muscle. (e) Glucose tolerance. **P < 0.01 vs CH; #P < 0.05, ##P < 0.01 vs HFru (n= 7–8 mice/group)
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Overconsumption of dietary fructose can lead to DNL and
hepatosteatosis [12, 37], which in turn can result in glucose
intolerance and contribute to hyperglycemia [19, 38]. Therefore,
correction of hepatosteatosis is beneﬁcial for improving glucose
homeostasis in metabolic syndrome. For example, in obese
patients with T2D, a reversal of hepatosteatosis can improve
hepatic insulin action and glycemic control [5]. We have
investigated drugs that have previously been used for the
treatment of liver conditions, in order to determine whether they
can be repurposed to treat hepatosteatosis [7]. One such
candidate we have identiﬁed by this approach is Mtr because
liver has been shown to be the major target site of Mtr [39, 40].
Indeed, our recent work has demonstrated that Mtr is able to
attenuate the increased fasting blood glucose and improve
glucose tolerance in insulin resistant mice induced by a HF diet
[9]. The same study found that these anti-diabetic effects of Mtr
appears to result from its effect in reducing hepatosteatosis
without affecting HF diet induced lipid accumulation in muscle.
Mtr is clinically used for treatment of chronic liver conditions
including hepatocellular carcinoma and viral hepatitis with
minimal adverse effects [7–9]. Interestingly, both hepatocellular
carcinoma and viral hepatitis are associated with an increase in
DNL [10, 41, 42]. Indeed, our studies in 3T3L1 adipocytes have
found that Mtr can reduce DNL and lipid accumulation within the
cells [43]. Although our recent studies have demonstrated that Mtr
is able to reduce hepatosteatosis and glucose intolerance in mice
that have been fed a HF diet [9], the source of hepatosteatosis in
this mouse model is from the exogenous FA due to the intake of
dietary fat rather than endogenous FA from an increased DNL.
Therefore, it is not clear yet whether Mtr is effective for metabolic
disorders by that involve an increased hepatic DNL [12].
Several studies have demonstrated that DNL enzymes are over-
expressed during the development of hepatosteatosis [24, 44].
HFru-fed mice are a well-deﬁned animal model of DNL-induced
hepatosteatosis and insulin resistance [12, 13], and DNL-induced
hepatosteatosis can be observed as early as 1 day after HFru
feeding [36]. Indeed, the present study showed that chronic HFru
feeding resulted in hepatosteatosis (increased TG level) by
promoting DNL (indicated by SREBP1c, ChREBP, acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS) and stearoyl-
CoA desaturase-1 (SCD-1)) without affecting FA oxidation, as
indicated by unchanged level of [14C]–palmitate. However,
reduced hepatic FA oxidation and mitochondrial enzyme activity
has been demonstrated to occur prior to the appearance of
hepatosteatosis, it has been shown that DNL is a primary cause of
the development of hepatosteatosis [12, 45]. As expected,
treatment with Mtr signiﬁcantly reduced steatosis in the liver
(not muscle because high distribution of Mtr in the liver after and
oral administration [40]) and the associated glucose intolerance in
these mice. We then examined the key lipogenic enzymes and
found that SREBP1c, ChREBP, SCD-1 and FAS in the liver were all
reduced in HFru-fed mice treated with Mtr. These results suggest
that Mtr is likely to reduce hepatosteatosis via inhibition of the
DNL pathway.
As an increase in FA oxidation can also attenuate hepatos-
teatosis [46], we next investigated whether the reduction of
hepatosteatosis caused by Mtr in HFru-fed mice results from
an increase in liver FA oxidation. However, Mtr did not increase
the oxidation of 14C-palmitate in the liver, indicating FA
oxidation pathway was not activated in HFru-fed mice. This
ﬁnding adds further support to our interpretation that Mtr
reduces hepatosteatosis and glucose intolerance in HFru-fed
mice by inhibiting DNL rather than by stimulating FA oxidation
in the liver.
It has been shown that the ER stress pathway plays a critical role
in HFru-induced DNL and hepatosteatosis [32, 36]. For example, an
ob/ob mice hepatosteatosis is largely due to increased DNL as a
result of hyperphagia in an ER stress-dependent manner [47]. The
same study also showed that alleviation of hepatic ER stress by
overexpression of GRP78 reduces hepatosteatosis and insulin
resistance by inhibiting DNL. Similarly, in HFru-fed mice, inhibition
of ER stress by TUDCA and Betulin suppress DNL and improve
Fig. 2 Effects of Mtr on FA oxidation and DNL pathways in the liver of HFru-fed mice. FA oxidation was detected by incubating fresh liver
homogenates with [14 C]–palmitate and DNL was assessed by the protein expression of palmitate in this pathway. (a) Liver lyzates from mice
were immunoblotted with the mature form of SREBP-1c and ChREBP (b), SCD-1 (c), FAS (d) and ACC (e) and then quantiﬁed for statistical
analysis. *P < 0.05, **P < 0.01 versus CH-Con; #P < 0.05, ##P < 0.01 versus HFru-Con, n= 7–8 mice per group
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insulin signaling in the liver [13, 17, 20]. To investigate whether the
inhibition of hepatic DNL by Mtr involves the ER stress pathway,
we examined the major ER stress markers in response to HFru-
induced DNL. Interestingly, the results showed that HFru-induced
ER stress (indicated by eIF2α, CHOP and IRE1) were all inhibited by
Mtr. These ﬁndings suggest that attenuation of ER stress may be a
novel mode of action for the inhibitory effect of Mtr on DNL and
the resultant hepatosteatosis.
Fig. 3 Effects on ER stress and HSP72 in the liver of HFru-fed mice. Liver lyzates from mice were immunoblotted for (a) eIF2α, CHOP and IRE1
and (b) HSP72 and quantiﬁed for statistical analysis. *P < 0.05, **P < 0.01 versus CH-Con; #P < 0.05, ##P < 0.01 versus HFru-Con, n= 7–8 mice per
group
Fig. 4 Effects of Mtr on body weight, visceral adiposity, blood glucose and glucose tolerance in T2D mice. T2D was generated by a high-fat
(HF) diet plus low-dose of STZ injections. After the development of hyperglycemia, Mtr (100mg/kg per day in diet) was administered to
diabetic mice for 4 weeks. Body weight at the end of the study (a). Epididymal (Epi) fat weight (b). Blood glucose levels (after 5–7 h of fasting)
(c) were monitored once a week. An ipGTT (1.0 g glucose/g body weight) was performed after 2 weeks of treatment with Mtr (d). **P < 0.01 vs
CH-Con; ##P < 0.01 vs T2D-Con (n= 7–8 mice/group)
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In terms of the possible cellular target of Mtr, our previous work
suggested that a downregulation of HSP72 may contribute to lipid
accumulation in vivo [9], and in vitro [43]. We showed that Mtr is
able to increase HSP72 expression and protect against lipid
accumulation and glucose intolerance in the liver [9]. Consistent
with this observation, the present study found that liver tissue
from HFru-fed mice had signiﬁcantly lower concentrations of
HSP72 protein, and this reduction was prevented by Mtr
treatment. HSPs have been implicated in the regulation of diverse
metabolic disorders including hepatosteatosis (the major meta-
bolic defect of non-alcoholic fatty liver disease) and insulin
resistance (the major metabolic defect of T2D) [33, 48, 49]. It has
been reported that an enhanced expression of HSP72 can inhibit
ER stress to protect cell survival [50]. Collectively, our ﬁndings
suggest that Mtr may inhibit the ER-DNL axis by up-regulating
HSP72 to reduce hepatosteatosis and the associated glucose
intolerance.
Hepatic DNL and hepatosteatosis also occur in transgenic
diabetic mice such as db/db [24]. Therefore, in the present study
we explored whether Mtr is able to reduce hepatosteatosis in a
mouse model of T2D induced by HF-STZ [27, 28]. Our results
showed that Mtr reduced epididymal fat and lowered hypergly-
cemia, indicating that Mtr may have the potential to control
hyperglycemia in T2D. Because Mtr showed no effect on normal
fasting blood glucose, glucose tolerance or liver TG content in
chow-fed mice [9], the anti-diabetic effects of Mtr could be
attributed to its effect in reducing hepatosteatosis.
In summary, we report here a potential novel application of the
hepatoprotective drug Mtr for the treatment of hepatosteatosis
and associated abnormal glucose homeostasis. This study is the
ﬁrst to evaluate the effect of Mtr on hepatosteatosis induced by
the ER stress-DNL signaling pathway in HFru-fed mice. As
suppression of ER stress can reduce hepatosteatosis by inhibiting
DNL [16, 36], it is likely that Mtr may exert these beneﬁcial effects
by suppressing ER stress-induced increase in hepatic DNL. We
speculate that the upregulation of the chaperon protein HSP72
may play a critical role in suppressing ER stress (as illustrated in
Fig. 6) but this hypothesis requires validation by further studies
using HSP72 knock-down animal model. Together with our recent
ﬁndings in HF-fed mice [9], our results suggest that Mtr may be
repurposed for the treatment of hepatosteatosis and associated
disorders in glucose homeostasis including T2D.
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Abstract 
Ethnopharmacological relevance: Matrine has been isolated from Sophora flavscens, and 
used as a prescribed for treatment of inflammation, cancer, and liver diseases. 
Aim of this study: The present study investigated the effects of matrine (Mtr) on a methionine 
choline-deficient (MCD) diet-induced NASH.  
Materials and methods: C57B/6J mice were fed a MCD diet for 6 weeks to induce NASH 
with or without the treatment of Mtr or metformin as a comparator.  
Results: The results showed that Mtr treatment suppressed plasma ALT, TNFα, and hepatic 
fibrosis markers (TGFβ and Smad3) induced by MCD diet. Along with these effects, Mtr 
reversed the reduced level of HSP72 induced by MCD diet, suggesting a likely role of HSP72 
in coordinating the therapeutic effects of Mtr for NASH. Metformin did not improve 
inflammation and had no effect on collagen 1 and caspase-1. Notably, Mtr treatment 
simultaneously decreased mTOR which is frequently activated in NASH.  
Conclusions: These findings suggest Mtr may be able to upregulate HSP72 and inhibit 
mTOR against NASH induced by MCD diet in a mechanism different from metformin.  
Key words: Matrine; NASH; inflammation; fibrosis; HSP72; mTOR; methionine choline-
deficient diet 
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1. Introduction 
Non-alcoholic steatohepatitis (NASH) is a severe condition of non-alcoholic fatty liver 
disease (NAFLD), the most common chronic liver disease. It is characterized with liver 
steatosis, damage, inflammation and variable degrees of fibrosis by the American Association 
for the Study of Liver Diseases (AASL) [1]. Although the exact mechanism (s) that mediate 
the transition from steatosis to steatohepatitis remain unknown, hepatic inflammation is 
believed to play a key role in NASH pathogenesis [2]. Furthermore, it may induce hepatic 
fibrosis that aggravates the progression of this disease [1]. Untreated NASH with advanced 
fibrosis may increase the incidence rate of liver cirrhosis, hepatocellular carcinoma and liver 
transplantation [1]. Therefore, the major treatment of NAFLD has been focused on NASH 
because effective control of NASH can prevent or delay the progression to these conditions. 
To date, there is still no approved drug specifically for NASH [1]. 
Matrine (Mtr) is a small molecule (MW: 248), a natural product derived from a plant named 
Sophora Flavescens (Kushen alkaloids) [3]. The active compound Mtr has been widely 
prescribed as a hepatoprotective drug in China with very minimum adverse effects [4]. In 
addition, Mtr has several well-recognized pharmacological effects targeting the liver 
including anti-inflammatory, antitumor and anti-viral activities [3, 4]. One of the well-
characterized anti-inflammatory effects of Mtr is inhibition of pro-inflammatory cytokines 
TNFα, the golden key in the pathogenesis of NASH [5]. Moreover, Mtr treatment 
significantly inhibits inflammation upon challenge with LPS in vivo and in vitro and liver 
damage in reperfusion injury of rat liver [6]. Our previous study reported the therapeutic 
effects of Mtr on hepatosteatosis and glucose intolerance induced by a high-fat diet in mice, 
with a mechanism different from metformin [7]. Given the close relationship between 
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metabolic syndrome and NAFLD, we are going to further investigate the effect of Mtr 
contained the active compound that suppress NASH with a focus on hepatic damage, 
inflammation and fibrosis, which are three hallmarks of NASH [1].  
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2. Materials and Methods 
 
2.1. Animal care, diets and experimental design  
Male C57BL/6J mice (10-week old) were purchased from the Animal Resources Centre 
(Perth, Australia) and acclimatized in the animal facility at RMIT University with a standard 
chow diet (CH diet, Specialty Feeds, Australia) for at least one week. Mice were assigned to 
four groups randomly: 1) fed ad libitum with a standard chow diet (CH-Con), 2) MCD alone 
(MCD-Con), 3) MCD treated with matrine (MCD-Mtr; Mtr: 100 mg/kg/day), and 4) MCD 
treated with metformin (MCD-Met; Met: 250 mg/kg/day) as a food additive for 6 weeks. 
Body weight and food intake were monitored daily throughout the experiment. 5-7 hours 
after food removal, tail vein blood was collected for glucose measurement using a glucometer 
(AccuCheck II; Roche, Australia). At the end of the study, plasma was also collected from 
the tail vein and stored at -80°C for biochemical test. A ketamine/xylazine mixture (up to 100 
mg/kg body weight ketamine and 20 mg/kg body weight xylazine) is administered via 
intraperitoneal injection. Mice fixation was performed via transcardial perfusion with 
heparinized PBS (10-20 ml/mice) then perfused with 4% paraformaldehyde (PFA; 10-20 
ml/mice, ProsciTech; # C007). At the completion of the paraformaldehyde perfusion, liver 
right lobe was dissected and immersed in 4% PFA-filled glass scintillation vials for further 
experiments. All experiments were approved by the Animal Ethics Committee of RMIT 
University (#1415) in accordance with the guidelines of the National Health and Medical 
Research Council of Australia.  
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2.2. Preparation of Matrine 
Mtr (Purity > 99.5%) was a gift from Professor Li-Hong Hu 
from the Shanghai Institute of Materia Medica; metformin 
was purchased from Sigma-Aldrich. The powders were 
stored at -20 °C then weighted and carefully mixed with 
diet at a dose of 100 mg/kg every day.  Fig. 1 shows the 
molecular structure of matrine. 
 
 
 
2.3. In vivo Evaluation of Total Body Fat Content 
After four weeks of treatment, the total body fat content in mice was evaluated using the 
EchoMRI™-100H Body Composition Analyzer (Echo Medical Systems, Houston, TX, 
USA). 
2.4. Assessment of the effect on hepatic steatosis 
Hepatosteatosis was assessed by measuring hepatic TG content, which was extracted by the 
method of Folch and determined using a colorimetric assay kit (Triglyceride GPO-PAP; 
Roche Diagnostics, Australia), as described previously [8]. 
2.5. Assessment of the effect on liver damage  
To examine the effects of Mtr on liver damage, the second component of NASH, plasma 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in 
week five using commercial kits (ALT/SGPT and AST/SGOT both Liqui-UV Kit, Boerne, 
USA) [9]. 5-7 hours after food removal, blood plasma was collected from the tail vein and 
Fig. 1 Molecular structure of matrine. 
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prepared according to the manufacturer’s instructions. The absorbance was measured at 340 
nm using a FlexStation (Molecular Devices, Sunnyvale, CA, USA).  
2.6. Quantification of total and non-heme iron  
The total iron and non-heme iron contents of liver samples were determined calorimetrically 
[10], because iron deposition is also regarded as a characteristic of NASH [11, 12]. As 
described previously [13], a fixative liver tissue was homogenized with 50 mM NaOH  and 
incubated overnight at 75-80 degrees. To quantify the amount of total iron and non-heme 
iron, either reagent A (a freshly mixed solution of equal volumes of 1.4 M HCl, 4.5% [w/v] 
KMnO4 and 40% TCA in H2O) or reagent B (same as reagent A without KMnO4) was added 
to samples [10].  
The iron content of the sample was calculated by comparing its absorbance to that of a range 
of standard concentrations of equal volume. Standards (5x diluted standards) were prepared 
as a mixture of FeCl3 in 10 mM HCl, 50 mM NaOH. Standard value was measured using 
lysis reagent that either contained or lacked permanganate [13]. The mixture was transferred 
into 96 well plate and its absorbance was measured at 550 nm. 
2.7. Real-time polymerase chain reaction of liver RNA 
Total RNA was isolated from mouse livers using TRIzol reagent (Invitrogen, #15596026) as 
previously described [14]. Real-time PCR was carried out using the IQ SYBR Green 
Supermix (Bio-Rad Laboratories Inc, USA) for genes of interest. Target gene expression was 
normalized to the housekeeping gene (18S). The primer sequence (5′ to 3′) of 18S is 
CGCCGCTAGAGGTGAAATTCT (sense) and CGAACCTCCG ACTTTCGTTCT 
(antisense); TNFα: CACAAGATGCTGGGA- CAGTGA (sense) and 
TCCTTGATGGTGGTGCATGA (antisense); IL-1β: 
CAACCAACAAGTGATATTCTCCATG (sense) and GATCCACACTCTCCAGCTGCA 
(antisense); CD68: TGACCTGCTCTCTCTAAGGCTACA (sense) and 
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TCACGGTTGCAAGAGAAACATG (antisense); Collagen 1: 
CTGCTGGTGAGAGAGGTGAAC (sense) and ACCAAGGTCTCCAGGAACAC 
(antisense). 
2.8. Western Blotting 
Liver lysates were resolved by SDS-PAGE and immunoblotted with specific antibodies [15]. 
Antibodies were diluted 1:1000 with a TBST buffer containing 1% BSA, 0.02% sodium 
azide (Sigma-Aldrich, #71289) and 0.0025% phenol red (Sigma-Aldrich, #32661). 
Antibodies for HSP72 (Catalogue No. C92F3A-5, 1:1000 dilution) and HSP90 (ADI-SPA-
840HRP, 1:1000) were purchased from Enzo Life Sciences, Farmingdale, NY, USA; MCP-1 
(#2027, 1:1000), HSF1 (#4356, 1:1000), TGFβ (#3709, 1:1000), Smad3 (#9523, 1:1000), 
mammalian target of rapamycin (mTOR), phospho
Ser2448
 mTOR (#2983, 1:1000), α-Tubulin 
(#3873, 1:1000) and GAPDH (#2118, 1:1000) were purchased from Cell Signaling, Danvers, 
MA, USA. A nod-like receptor pyrin containing 3 (NLPR3, #20B-0006-C100, 1:1000) was 
purchased from AdipoGen San Diego, USA. Goat Anti Mouse (#sc-2005), Goat Anti Rabbit 
(#sc-2004) and Goat Anti-Rat (#sc-2065) from Santa Cruz (USA). Proteins were quantified 
using a ChemiDoc, and densitometry analysis was performed using Image Lab software (Bio-
Rad Laboratories, Australia). 
2.9. Histological evaluation of liver sections 
The liver samples perfused using PFA were sliced to 5 μm sections. Free-floating sections 
were used and stained with picrosirius red for liver fibrosis. Slides were quantified in five 
non-overlapping fields of view per animal using an Olympus BX41 microscope with a 20X 
objective lens and an Olympus DP72 digital camera (Olympus, Australia) [9, 16]. The mean 
of value was calculated for each experimental group using the threshold function in the 
ImageJ software package (NIH Image, Bethesda, MD, United States). Data are represented as 
percentage (%) of positive area per field.  
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2.10. Statistical analysis 
All results are presented as means ± SEM. One-way analysis of variance was used to assess 
the statistical significance across all groups. When significant differences were found, the 
Tukey-Kramer multiple comparisons post-hoc test was used to establish differences between 
groups. Differences at p ≤ 0.05 were considered statistically significant and p ≤ 0.01 were 
considered highly significant. 
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3. Results 
3.1. Effects on adiposity, hepatosteatosis and plasma glucose  
MCD diet feeding is a common dietary model of NASH despite the absence of several 
metabolic phenotype on body weight gain and calorie intake [17, 18]. As expected, MCD 
diet-fed mice showed a reduced body weight, body weight gain fasting and blood glucose 
level despite a significant increase in calorie intake. As shown in Table 1, the excess TG 
accumulation, indicative of hepatosteatosis, was increased dramatically in the liver of MCD-
Con mice compared with CH-Con (by 2 fold, p < 0.01). The difference in weight gain 
between chow, MCD alone and MCD with treatments was maintained throughout the 6-week 
treatment period.  
Mtr had no effect on body weight gain and calorie intake in MCD diet-fed mice. Consistent 
with previous studies [18, 19], MCD diet-fed mice showed increased adiposity and 
hepatosteatosis but no glucose intolerance or mild hypoglycemia. There was no change in 
fasting blood glucose level in Mtr-treated MCD diet-fed mice compared to MCD diet-fed 
group. Associated with these effects, Mtr also was had no effect in reducing hepatic TG in 
MCD diet-fed mice (Table 1). Similarly, metformin did not show any effect on any of these 
parameters in MCD diet-fed mice. 
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Table 1. Effects of matrine and metformin on body weight, total food intake and liver 
triglyceride 
 CH-Con MCD-Con MCD-Mtr MCD-Met 
Body weight (g) 24.3±0.2 23.5±0.2
**
 22.6±0.1
††
 22.7±0.1
††
 
Body weight gain (g) 2.0±0.2 0.4±0.2
**
 0.3±0.2 
 
0.7±0.1 
Caloric intake (kcal/kg.day) 268.2±7.5 313.7±9.0 319.7±10.0 
 
334.8±18.4 
Fasting blood glucose (mM) 8.0±0.5 7.4±0.4 6.3±0.4 
 
6.4±0.5 
Liver triglyceride (mol/g) 13.8±4.2 31.6±3.3** 28.2±2.5 
 
31.2±3.1 
 
Mice were fed a chow (CH-Con), or MCD alone (MCD-Con), MCD-treated with matrine 
(MCD-Mtr; 100mg/kg/day) or MCD-treated with metformin (MCD-Met; 250mg/kg/day). 
Body weight and food intake were measured twice a week. Blood glucose was performed at 
week 5. Plasma was collected before tissue collection at week 6 for the subsequent analysis 
for ALT and AST. **p < 0.01 vs. CH-Con; ††p < 0.01 vs. MCD-Con (n = 8 mice/group). 
 
3.2. Effects on body composition using MRI 
MCD diet feeding resulted in a lack of metabolic phenotype possibly due to signiﬁcantly 
decreased body weight (Fig. 2A). As illustrated in Fig. 2B, in spite of the reduced body 
weight as a result of MCD diet feeding, there was a significant increase in fat mass in MCD 
diet-fed mice compared to the CH-Con group. MRI also revealed that MCD diet-fed mice 
with or without treatment of Mtr or metformin had significant decreases in lean mas 
compared to the CH-Con group (Fig. 2C). However, Mtr and metformin had no effect on the 
fat mass of MCD diet-fed mice.  
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Fig. 2. Effects of Mtr on body composition in MCD mice 
The body composition of CH-Con, MCD-Con, MCD-Mtr and MCD-Met was determined by 
EchoMRI analyzer at week 4 (A) Lean+fat mass; (B) Fat mass; (C) Lean mass. *p < 0.05, 
**p < 0.01 vs. CH-Con; †p < 0.05 vs. MCD-Con; ns: no significant vs. CH-Con or MCD-
Con (n = 8 mice/group). 
 
3.3. Effects on hepatic inflammation  
Hepatic inflammation is critical in the progression of NASH, in which secreted pro-
inflammatory cytokines produced by the Kupffer cells promote cell injury and fibrogenesis in 
the liver [1]. Key inflammatory cytokines, including TNFα, IL1β, MCP-1 and NLRP3, are 
particularly associated with liver inflammation, ultimately NASH [1, 20]. To examine the 
role of inflammation in MCD diet-fed mice, the protein activity or expression of these 
inflammatory markers were measured. As expected, MCD-diet resulted in a marked pro-
inflammatory response in the liver as evidenced by increased gene expression of TNFα (2-
fold increase), as well as increased protein levels of MCP1 (1.5-fold) and NLRP3 (1.5-fold). 
The increased expression of MCP1 coincided with an increased gene expression of CD68, 
suggesting recruitment and activation of the Kupffer cells, confirming the presence of hepatic 
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inflammation. Administration of Mtr, but not metformin, significantly decreased the 
expression of TNFα, CD68 (both p < 0.05 vs. MCD-Con mice) and MCP-1 (p < 0.01 vs. 
MCD-Con mice) (Fig. 3 A, C and D). However, no significant differences were detected in 
the expression of IL-1β amongst the experimental groups (Fig. 3 B). It has been suggested 
that NLRP3 blockade reverses advanced stage liver inflammation and fibrosis in MCD diet-
induced NASH [2]. Consistent with results on the inhibition of inflammatory markers, Mtr 
significantly decreased the inflammasome activation in MCD diet-fed mice (Fig. 3 E). In 
contrast to Mtr, metformin had no effect on the activities or expression of these markers (Fig. 
3 A-E). 
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Fig. 3. Effects of Mtr on inflammation in MCD-fed mice. (A) TNFα mRNA, (B) IL1β 
mRNA and (C) CD68 mRNA. Protein expression of MCP-1 (D) and NCLP3 (E), and the 
corresponding representative blots (F). *p < 0.05 vs. CH-Con; †p < 0.01, ††p < 0.01 vs. 
MCD-Con; ns: no significant vs. CH-Con or MCD-Con (n = 7-8 mice/group). 
 
3.4. Effects on the hepatic fibrogenesis 
The effect of Mtr on hepatic fibrosis was examined, as liver fibrosis is another hallmark of 
advanced NASH [21, 22]. As shown in Fig. 4 A-C, MCD diet-fed mice exhibited marked 
increases in the hepatic expression of key fibrogenic proteins , namely TGFβ, collagen1 and 
Smad3 (p < 0.05 vs. CH-Con). Mtr treatment completely normalized the protein abundance 
of these fibrotic markers to the corresponding levels in CH-Con mice. Meanwhile, metformin 
treatment decreased these markers but less effective compared to Mtr treatment. There was 
no significant change in caspase-1 protein expression between groups (Fig. 4 D).  
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Fig. 4. Effects of Mtr on fibrosis in MCD diet-fed mice. Liver lysates from mice were 
immunoblotted for (A) TGFβ, (C) Smad3 and (D) Caspase-1 or RT-PCR for (B) collagen 1.  
*p < 0.05 vs. CH-Con; †p < 0.01, ††p < 0.01 vs. MCD-Con; ns: no significant vs. CH-Con or 
MCD-Con (n = 7-8 mice/group).  
 
To further evaluate the effect of Mtr on hepatic fibrogenesis, liver sections were stained with 
picrosirius red to quantify the extent of liver fibrosis. As shown in Fig. 5, there was ~83% 
increase of liver fibrosis (p < 0.01 vs. CH-Con fed mice) in the liver of MCD-fed mice and 
this increase was reversed following treatment with Mtr (~66% reduction, p < 0.01 vs. MCD-
Con mice). In comparison, no significant reduction of liver fibrosis was observed following 
metformin treatment.  
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Fig. 5. Effects of Mtr on fibrosis in MCD diet-fed mice. (A) Representative images 
showing collagen staining with picrosirius red in liver sections from control and treated 
groups. Scale bar = 200 µm, 10, 40x magnification. (B) Mtr treated mice had significantly 
reduced fibrosis area compare to MCD-Con group. **p < 0.01 vs. CH-Con; ††p < 0.01 vs. 
MCD-Con (n = 7-8 mice/group).  
3.5. Effects on plasma level of liver enzymes and iron deposition 
Liver damage has been suggested to be an important factor that distinguishes NASH from 
hepatosteatosis [23]. We next examined whether Mtr treatment may alleviate liver damage in 
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MCD diet-fed mice. As shown in Fig. 6 A, MCD diet-fed mice exhibited marked increases in 
ALT (by 2-fold) and AST (by 1-fold) levels along with the increase of hepatosteatosis in the 
liver (Table 1). Mtr treatment markedly decreased both plasma ALT and AST levels, 
indicating Mtr may reduce liver damage. In contrast, metformin reduced the level plasma 
ALT, but not AST, in MCD diet-fed mice (Fig. 6 B). Iron overload plays an important role in 
the development of NASH [11]. It has been demonstrated that iron overload exacerbates 
inflammation and fibrosis-induced steatohepatitis in humans [24] and rodents [12, 25, 26]. 
We further examined the effects of Mtr on iron levels in the liver of MCD diet-fed mice. 
Consistent with previous reports, the hepatic level of heme or non-heme iron was elevated in 
mice fed a MCD diet (Fig. 6 C and D). However, Mtr or metformin treatment had no effect 
on the increased level of heme or non-heme iron in the liver of MCD diet-fed mice (Fig. 6 C 
and D).  
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Fig. 6. Effects of Mtr on liver damage and iron level. After six weeks of feeding and drug 
treatment, blood sample was collected for the measurement of plasma levels of (A) ALT and 
(B) AST. Liver tissue was collected for the measurement of(C) heme and (D) non-heme iron. 
*p < 0.05, **p < 0.05 vs. CH-Con; †p < 0.01, ††p < 0.01 vs. MCD-Con (n = 7-8 mice/group). 
 
3.6. Effects on hepatic mTOR and HSPs expression  
Elevated protein expression of mTOR has been observed in NASH patients [27]. It has been 
reported that activation mTOR enhance hepatic inflammatory and fibrotic pathways, mTOR 
inhibitors decrease these pathways in HepG2 cells and rodents [27, 28]. Inhibition of mTOR 
has been shown to alleviate liver damage and fibrosis in a mouse model of NASH induced by 
MCD diet [29]. To explore whether the effect of Mtr on NASH involved the inhibition of 
mTOR pathway, the hepatic protein level of mTOR was assessed. Consistent with the 
observation in human NASH patient, MCD-Con mice had increased protein level of mTOR 
in the liver. Interestingly, treatment with Mtr normalized the protein level of mTOR (p < 0.01 
vs. MCD-Con) towards the levels seen in CH-Con mice (Fig. 7 A). Our results suggested that 
Mtr treatment inhibited MCD diet-induced hepatic mTOR expression. In comparison, 
metformin had no effect on the hepatic mTOR level in MCD diet-fed mice. 
Previous work from our laboratory has showed that the antisteatotic effects of Mtr involve the 
activation of HSP72 in the liver of HFD-fed mice [7]. The dissociation of HSP90 from HSF1 
triggers the trimerization and activation of HSF1, which in turn initiates the expression of 
HSP72 [30]. To determine whether Mtr-induced improvement on NASH was associated with 
the upregulation of HSP72, we measured the HSP90, HSF1 and HSP72 protein expression in 
the liver. As shown in Fig. 7 B-D, HSP90 and HSP72 expression were blunted (50% 
reduction compared to CH-Con mice, p < 0.05) by MCD diet feeding, but had no significant 
change on the protein level of HSF1. In addition to the upregulation of hepatic HSP72 and 
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unchanged level of HSP90, which is consistent with our previous report [7], Mtr treatment 
significantly increased the hepatic HSF1 level. In comparison, metformin treatment had no 
effect on the expression of HSP72 and HSP90, despite of the normalization of HSF1 level. 
These results indicate that the therapeutic effect of Mtr on NASH is associated with inhibition 
of mTOR and upregulation of HSPs and, in particular, HSP72.  
 
 
Fig. 7. Effects of Mtr on HSF1, HSP90, HSP72 and mTOR in MCD diet-fed mice. Liver 
lysates from mice were immunoblotted for (A) mTOR (B) HSP90, (C) HSF1 and (D) HSP72 
and quantified for statistical analysis.  *p < 0.05 vs. CH-Con; †p < 0.01, ††p < 0.01 vs. MCD 
-Con (n = 7-8 mice/group). 
 
4. Discussion 
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Our previous studies, which focused on the metabolic effect of Mtr, have demonstrate that 
Mtr treatment was effective in reducing hepatosteatosis, adiposity and glucose intolerance in 
various diet-induced mouse models [7]. Current study further investigates the effect of Mtr on 
NASH, a hepatic manifestation of the metabolic syndrome [1]. This study demonstrated that 
Mtr markedly ameliorated hepatic damage, inflammation and fibrosis, with inhibition of 
mTOR and upregulation of HSP72, in a mouse model of NASH induced by MCD diet 
feeding. In comparison, metformin had no effect on inflammation, collagen deposition, 
HSP72 or mTOR. 
While high-fat or high-fructose feeding results in several prominent features of metabolic 
syndrome (including obesity, hepatosteatosis, glucose intolerance etc.), they do not induce 
apparent and severe hepatic damage or fibrosis in the liver [31]. In contrast, MCD diet 
feeding is a well-recognized model of NASH that rapidly induces hepatic steatosis, damage, 
inflammation and fibrosis in mice, despite of the absence of insulin resistance and 
hyperglycemia [17, 18, 31]. Therefore, we evaluated the protective effects of Mtr on NASH 
in mice fed a MCD diet.  
Consistent with previous studies, mice fed a MCD diet developed hepatic inflammation and 
fibrosis that reflected the natural course of NASH in human [18, 19, 32]. Mtr prevented MCD 
diet-induced inflammation and fibrosis in the liver after 6 weeks of treatment, as 
demonstrated by a Mtr-induced suppression of the increases in TNFα, CD68, MCP-1 and 
NLRP3, and hepatic fibrosis markers (TGFβ, Smad3 and collagen1) induced by MCD diet.  
Several studies indicated that activation of inflammatory cytokines has a vital role in the 
progression of NASH [1, 22].The increase of pro-inflammatory cytokines production via the 
activation of Kupffer cells, in particular TNFα, was suggested to be the key mediator of 
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NASH progression [33].  Alternatively, inhibition of TNFα activity using anti-inflammatory 
drugs improved liver damage, inflammation and NASH [34, 35]. Furthermore, in line with 
increased TNFα production, the increased presence of CD68 and MCP-1 are associated with 
the severity of NASH [1, 9]. The results of the current study proved that Mtr significantly 
reduced these inflammatory targets-induced by MCD diet feeding. Another central 
participator in the development of NASH is the activation of the NLRP3 inflammasome [20, 
36]. It has been recently reported that blockage NLRP3 activation reduced liver inflammation 
and fibrosis in MCD diet-fed mice [2]. It generally believes that the anti-inflammatory 
activities of Mtr are largely due to its ability to scavenge airway inflammation and hepatic 
inflammation [6]. The result of Mtr-induced attenuation of hepatic inflammation, through 
inhibiting the activity of TNFα and suppressing several inflammatory proteins and 
chemokines (including CD68, MCP-1 and NLRP3) in the MCD diet-fed mice, supported the 
notion that Mtr is likely to reduce NASH via inhibition of the inflammation pathway.  
Consistent with elevated levels of pro-inflammation cytokines and exacerbated fibrosis, 
MCD-diet feeding resulted in hepatic fibrosis, is also known as another hallmark of NASH 
[1, 18], and it is considered as a result of repetitive inflammation events [22]. In NASH, 
fibrosis closely correlates with the degree of inflammation and severity of the disease [21, 
22]. While Mtr prevents liver fibrosis (TGFβ and collagen production) induced by carbon 
tetrachloride (CCl4) in rats [37], whether Mtr inhibit fibrosis in a NASH model without the 
involvement of chemical toxicity remains unclear. To investigate whether the inhibition of 
hepatic inflammation by Mtr involves the inhibition of fibrosis signaling and collagen 
production [20, 38]; we examined the effect of Mtr on fibrosis in a mouse NASH model 
induced by MCD diet. Consistent with the reduction in inflammation, our data indicated that 
Mtr inhibited the activation of fibrosis by suppression of TGFβ, Smad3 and collagen 1 
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synthesis in the liver of MCD diet-fed mice. The effect of Mtr in alleviating fibrosis was 
further support by the histological data revealing a significant reduction in the number of 
collagen proportionate area in MCD diet-fed mice after Mtr treatment.  
Consistent with elevated levels of pro-inflammation cytokines and exacerbated fibrosis, 
MCD-diet feeding resulted in severe liver damage as indicated by the elevated plasma level 
of liver enzymes, particularly ALT, which has been considered as a requisite in the diagnosis 
of NASH [1, 39]. Treatment with Mtr significantly decreased the elevated plasma levels of 
ALT and AST, indicating a less extent of liver damage, which is in line with the effect of Mtr 
on hepatic inflammation and fibrosis.  
After demonstrating the effect of Mtr in improving inflammation, fibrosis and liver damage 
in MCD diet-induced NASH, we next investigated the possible molecular mechanism 
involved. Our previous work suggested that upregulation of HSP72 may contribute to 
hepatosteatosis induced by HFD or HFru feeding in mice [7]. Another study from our lab 
showed that Mtr could reduce glucose intolerance in mice caused by an increase in de novo 
lipogenesis (DNL) in HFru diet-fed mice (accepted data). Consistent with this observation, 
the present study found that liver tissue mice fed with MCD diet had significantly lower 
concentrations of HSP72 and HSP90 protein, and this reduction was rescued by Mtr 
treatment. Heat shock protein 72 (HSP72) is the major inducible heat shock protein, exerts 
cytoprotective effects by assisting in protein folding, protein degradation, signal transduction 
and translocation of client proteins across membranes [40]. It is been suggested that HSP72 
expression is progressively suppressed in the liver and muscle of obese and NAFLD patients 
[41], and in skeletal muscle of T2D patients [42]. An elevation in HSP72 is associated with 
the reduction in JNK phosphorylation and attenuation of insulin resistance [43]. These results 
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suggest the anti-inflammatory effects of Mtr, at least in part, involving the activation of 
HSP72 in the liver.  
It is worthwhile noting that Mtr also inhibited MCD-induced increase in mTOR. This is 
interesting because overexpression of mTOR contributes to NAFLD progression [27]. It has 
been suggested to play an important role in the development of NASH by activating 
inflammation and fibrosis in mice fed with choline-deficient diet-induced steatohepatitis [29]. 
In comparison, metformin showed no effect on MCD-induced increase in mTOR or NASH 
phenotype. These data suggest that the suppressed mTOR by Mtr may also contribute to its 
therapeutic effects for NASH. However, studies are required to determine the molecular 
mechanism involved and how the HSP pathway may interact with the mTOR pathway to 
medicate the therapeutic effects of Mtr for NASH. 
In conclusion, the present study suggests that Mtr, a hepatoprotective drug, might offer 
protective effects against NASH via suppression of hepatic inflammation, fibrosis and 
damage, possibly via the upregulation of HSP72 and the reduction of mTOR (Fig. 8). Future 
work involving the use of HSP72 and/or mTOR liver-specific knock-out model is required to 
further confirm the exact molecular regulator of the effect of Mtr. 
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Fig. 8. A Schematic diagram illustrating the proposed mechanism underlying the effects 
of Mtr against MCD diet-induced NASH 
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